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Abstract 
Acute liver failure confers a high risk of death, with liver transplantation offering the only 
effective therapy for life-threatening cases. Hepatic macrophages are crucial for innate 
immune integrity and effective hepatocyte proliferation. The macrophage may therefore 
present a novel therapeutic target to enhance regeneration following acute liver injury. 
 
In this thesis I describe the development and use of mouse models of liver injury 
including partial hepatectomy, partial hepatectomy plus chronic liver injury and 
paracetamol intoxication. I show the development of liver function assays in these 
models including quantification of hepatic clearance of indocyanine green by fluorescent 
imaging and assessment of hepatic phagocytic capacity using fluorescent microbeads.  I 
then describe macrophage based therapeutic interventions in mouse models of liver 
injury. Firstly the direct administration of bone marrow derived macrophages in partial 
hepatectomy plus chronic liver injury. I then tested the administration of macrophage 
colony stimulating factor in mouse models of partial hepatectomy, partial hepatectomy 
plus chronic liver injury and paracetamol intoxication, describing the phenotype and 
exploring mechanisms of action.  
 
Collaborating with others I assessed serum CSF1 levels in humans with liver injury due 
to partial hepatectomy or paracetamol intoxication. I show that in acute liver failure a 
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Hypotheses 
1. Macrophages have a central role in liver regeneration 
 




1. Develop preclinical models of liver regeneration 
 
2. Develop functional assays with translational potential to assess liver regeneration in 
vivo 
 
3. Trial macrophage based therapies to enhance liver regeneration 
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1.1 The clinical setting 
Liver disease is a major cause of morbidity and mortality. Since the 1970’s the death rate 
attributed to liver disease has increased exponentially, especially in the under 65 age 
group. This change is particularly concerning given gradual reduction in other leading 
causes of mortality (Figure 1.1). A wide range of conditions have been attributed to this 
increase, including viral hepatitis (B and C), alcohol, fatty liver disease and cancer. Liver 
transplantation currently offers the only effective therapy for life threatening liver 
failure. However the demand for donor organs does not meet the requirement and many 
patient die whilst awaiting liver transplantation. There are currently no therapies 
proven to enhance regeneration of the injured liver.  
 
Regenerative demand is placed on the liver in a wide range of clinical settings, including 
partial hepatectomy to remove liver cancer and viral or toxin induced liver injury. In this 
section I review the clinical context in more detail, review the biology underpinning the 
regenerating liver, explore the consequences of a failing liver and then examine potential 
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Figure 1.1: Change in death rate in the UK for various diseases between 1970 and 20061 
 
  
Manipulating macrophages to enhance liver regeneration 
3 
Introduction 
Partial hepatectomy for liver cancer 
Liver cancer can arise either following metastasis of an extrahepatic cancer or arise as a 
primary liver cancer, typically on a background of chronic liver disease (Figure 1.2). 
Colorectal liver metastasis is the commonest cause of hepatic malignancy leading to 
surgical resection2. However given the increase in chronic liver disease primary hepatic 
cancers, including hepatocellular carcinoma and cholangiocarcinoma, are also on the 
increase (Figure 1.3)3.  
 
A potentially curative treatment option for liver cancer is surgical removal of the cancer 
and the portion of the liver containing the cancer. Depending on the location, number 
and extent of the cancer up to around 75% of liver volume can be resected and the liver 
remnant will predictably regenerate over a period of weeks to months2.  However, due 
to the rapid rise in liver cirrhosis and resulting hepatocellular carcinoma, it is now 
common for even relatively small tumours to be unresectable due to concerns over 
insufficient projected postoperative liver regeneration4,5. Multiple cancer foci’s even in a 
normal liver may necessitate a radical resection (>75% volume to be resected), which 
may risk leaving an inadequate liver remnant and the development of liver failure. 
Preoperative chemotherapy may impair hepatic function6, even in the absence of 
underlying chronic liver disease, so impairing regeneration and risking development of 
failure 
  
One approach to the concern over the regenerative capacity of the liver remnant is to 
perform portal vein branch ligation or embolisation. This results in partial atrophy of the 
cancer bearing lobe and stimulates compensatory regeneration in the remaining lobe, 
thereby increasing future liver remnant volume preoperatively. However, in the 
common scenario of background liver fibrosis this may not be successful as underlying 
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liver disease can impair the regenerative response. If postoperative liver failure does 
ensue there is currently no available rescue therapy to enhance the regenerative 
response. Concern over regenerative capacity of the liver remnant means many patients 
are deemed unsuitable for surgery and are denied the option of a potentially curative 
intervention.  
  




Figure 1.2: Schematic illustrating the occurrence of hepatic malignancy either via 
colorectal liver metastasis or on a background of chronic liver disease 
 
Figure 1.3: Incidence of primary liver cancer in the UK between 1975 and 20103 
Age standardised incidence rates per 100,000 population in the United Kingdom 
Chronic liver disease 
Primary liver cancer 
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Acute liver injury 
Aetiology of acute liver injury varies across the world, with viral causes predominant in 
the developing world and drug induced liver injury most prominent in Western Europe 
and the USA (Figure 1.4)7. The main viral causes worldwide include hepatitis A, B and E. 
Hepatitis A and E are spread mainly through the faecal-oral route and are typically self-
limiting infections with low mortality, resolving over a period of weeks. Hepatitis A 
vaccination programmes have dramatically reduced its incidence. Hepatitis B is 
transmitted via exposure to body fluids of an infected individual. Mortality rate with 
hepatitis B is higher than A and E infections, but vaccination programmes and other 
public health measures have resulted in a substantial decrease in incidence and 
subsequent fall in the development of acute liver failure and mortality8,9.  
 
Drug induced liver failure in the USA and Western Europe is most commonly due to 
paracetamol intoxicationi where the drug may be ingested with suicidal intent. In the UK 
the availability of paracetamol as an over-the-counter medication was thought to be a 
key factor in its selection by suicidal individuals. Legislation was introduced in 1998 to 
restrict the quantity of paracetamol that could be purchased at any one time. This change 
was associated with a 40% fall in admission to specialist liver units with paracetamol 
intoxication associated liver failure (up to 2004)10. However, this reduction has not 
necessarily been maintained and  considerable regional variation exists. For example in 
Scotland there seems to have been little effect of the change in legislation on proportion 
of patients presenting with acute liver failure due to paracetamol intoxication11 (Figure 
1.5).  
 
                                                             
i Paracet a mol  is  known also known a s ace ta minophe n in t he USA, C a na da a nd Ja pa n.  I t  ma y also be 
referred t o a s APAP in re fere nce  t o it s che mical  na me  N -acet yl -p-a minophe nol .  It  is  a  widely 
a va ila ble a nd use d over -t he -counte r a nalge sic .  
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A wide spectrum of other drugs can cause acute liver failure, including non-steroidal 
anti-inflammatories, statins, antibiotics, antiepileptics, anti-tuberculosis drugs and 
toxins, e.g. amanita phalloides (mushroom). Ischemic injury can occur in cardiac failure 
or sepsis as a result of hypotension, metabolic liver disease (such as Wilson’s disease ii), 
autoimmune hepatitis or Budd-Chiari syndromeiii 12,. Partial hepatectomy to remove liver 
cancer can also induced acute liver failure as discussed in the previous section (“Partial 
hepatectomy for liver cancer”).  
 
In life threatening liver failure liver transplantation is currently the only effective 
therapy, although donor organ availability is limited and life-long immunosuppression 
is required in the majority of cases. 
 
                                                             
ii Wilson’s  disea se  is  a  aut osomal  rece ssive  condit ion which is  charact er ise d by accumulat ion of 
copper  in t issue s.  This ca n lea d t o a ra nge of  manife st at ions, including ne urologica l disorders a nd 
chronic l iver  disea se .  
iii Budd-C hiar i syndrome involve s a tr ia d of  signs a nd sympt oms including abdomina l  pa in, asc ite s 
a nd he pat omegaly. It  is ca use d by occ lusion of t he  he pat ic ve in e it he r by t hrombosis wit hin t he vein 
(pr ima ry) or e xternal  occlusion of  t he  ve in (seconda ry,  e .g . due  t o a  t umour).  




Figure 1.4: Aetiology of acute liver failure according to geographical location.  
(adapted from Berry et al., 20107) 
 
 
Figure 1.5: Proportion of yearly admissions attributed to paracetamol overdose in 
Scotland. 
POD: paracetamol overdose; Non-POD: aetiology of acute liver failure other than POD. 
(adapted from Bretherick et al., 201111)  
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Acute on chronic liver failure 
Acute liver failure may arise on a background of chronic liver disease, where an 
additional insult, such as infection, further toxic insult, or surgery tips the balance from 
compensated liver disease towards decompensation and liver failure. The patient with 
chronic liver disease may already be functioning on reserve capacity and it may not take 
much to tip this balance. Outcomes are particularly poor in this group of patients given 
the marked impairment in the liver’s regenerative capacity. 
 
Hepatic cirrhosis is the manifestation of end stage chronic liver disease. Cirrhosis has 
traditionally been regarded as an irreversible condition characterised by dense hepatic 
fibrosis, which surrounds regenerative nodules, induced by long term iterative liver 
injury. Common causes of chronic liver disease include hepatitis C and alcohol 
dependency. Non-alcoholic steatohepatitis is becoming an increasingly common cause of 
chronic liver disease, associated with rising levels of obesity13. Hepatitis C has long been 
regarded an incurable condition, however recent breakthroughs indicate that curative 
treatments are now becoming a reality14 iv. Given reports indicating the potential 
reversibility of the fibrotic process in humans15, it will be interesting to see how removal 
of the underlying viral cause influences established fibrosis.  
 
  
                                                             
iv Ear ly c l inica l  t rial  re sult s  indicat e  t hat  100% cle ara nce  of  he pat itis  C  virus ca n be  a chie ve d using 
NS5A inhibit ors which t arget  ste ps in t he  vira l repl icat ion cycle .  
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1.2 The biology of liver regeneration following acute injury 
Liver regeneration is a complex process, involving multiple growth factors, cytokines 
and cell types. In experimental models acute liver injury is either induced by partial 
hepatectomy, toxic liver insult, or occurs on a background of chronic liver injury. In 
experimental models of partial hepatectomy liver lobes are removed, leaving an 
uninjured liver remnant which then regenerates rapidly. Acute toxic liver injury induces 
hepatocellular necrosis and apoptosis, with regeneration comprising both clearance of 
dead tissue, remodelling of liver architecture and restoration of hepatocyte mass. 
Chronic liver injury can lead to progressive hepatic fibrosis with acute injury in this 
context caused either by partial hepatectomy or toxins. The biology of regeneration in 
each of these contexts is discussed below.  
 
Regeneration following partial hepatectomy 
Liver regeneration following partial hepatectomy reflects a compensatory hyperplasia 
of the liver remnant. The term ‘regeneration’ in this context is something of a misnomer. 
Liver regeneration in this context does not reflect a restoration of both form and 
function, as occurs in the out-budding of the salamander limb following limb removal for 
example16, rather a process of liver remnant hypertrophy and hyperplasia characterised 
by rapid hepatocyte proliferation.  
 
The majority of the mechanistic understanding of liver regeneration has come from 
partial hepatectomy in rodent models. Here the lobulated liver facilitates surgical 
resection, with the standard model being resection of 2/3 liver mass by the removal of 
the left and median liver lobes. Direct assessment of liver regeneration in humans is 
limited by the technical challenge and safety concerns of obtaining liver biopsies in the 
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postoperative period. Directly relating liver regeneration in rodents to that in humans 
may be difficult but it does allow identification of factors that may be beneficial or 
harmful in the clinical setting. 
 
Liver regeneration in rodents is highly effective with liver weight returning to its 
preoperative weight by around day 7-10 following 2/3 PH. The ratio of liver weight to 
body weight is remarkably consistent, at around 5%. Factors governing liver size are 
unclear, but the change in flow dynamics through the liver remnant are thought to be 
central to this. There is no evidence that the liver can intrinsically “sense” its final size 
and final size does not appear to relate to metabolic demand17.  
 
Liver regeneration can be divided into four phases: Intiation, hepatocyte priming, 
hepatocyte proliferation and termination. 
 
Initiation  
Alterations in cytokine expression are noted within 5 minutes following partial 
hepatectomy in mice, with an upregulation in urokinase plasminogen activator (uPa) 
across the whole liver18. There is evidence to suggest that the mechanical stress caused 
by changes in flow dynamics following loss of liver volume may induce this uPA 
activity19,20. The source of this uPA activity in the liver has not been characterised but by 
examining other systems it is likely that this is macrophage mediated. Sokabe et al. 
showed that shear stress can increase uPA gene expression in the vascular endothelium 
of carotid vessels, however this was related to turbulent flow and not laminar stress, 
which would be seen in the liver following PH19. However Yeh et al. showed that under 
sheer stress macrophages can upregulate uPA expression in coculture with 
chondrocytes21. uPAR is certainly highly expressed by macrophages22 and macrophages 
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are abundant in the liver. Urokinase activity is known to induce matrix remodelling 
which fits with an early upregulation of MMP9 (from 30 minutes) gene expression 
following PH in mice23. Remodelling of hepatic matrix is required for the release and 
activation of hepatocyte growth factor (HGF, the main hepatocyte mitogen), which is 
bound to matrix via glycosaminoglycans18. TGFβ is well recognised as a mito-inhibitor 
and is bound to matrix decorin in the steady state, exerting a competing effect to HGF. 
Matrix remodelling releases TGFβ into the circulation where it binds to alpha-2-
macroglobulin and is inactivated24. Figure 1.6 illustrates these early matrix remodelling 
events following partial hepatectomy. 
  





Figure 1.6: Matrix remodelling events and release of growth factors following partial 
hepatectomy.  
Matrix remodelling is an early event following partial hepatectomy and is required for 
hepatocyte proliferation. The hepatocyte mitogen, HGF, and mito-inhibitor TGFβ are 
released from their matrix components (glycosaminoglycans and decorin respectively) 
by matrix metalloproteinases (MMPs) and urokinase activity. While HGF acts directly on 
hepatocytes to induce proliferation, TGFβ binds to alpha-2 macroglobulin limiting its 
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Hepatocyte priming and proliferation 
Tissue necrosis factor (TNF), Il6, serotonin and bile acids also increase in the circulation 
following partial hepatectomy and are required for effective regeneration through their 
priming effects on hepatocytes and effects on the hepatic environment25-27. Macrophage 
depletion studies in mice have demonstrated that TNF and Il6 are derived from 
macrophages, the depletion of which markedly impairs regeneration28,29. Indeed 
supplementary Il6 can both induce hepatocyte proliferation and promote liver 
regeneration following PH in rats with cirrhotic liver injury30. Platelet derived serotonin 
mediates vascular flow in mice following partial hepatectomy and its supplementation 
can facilitate regeneration in mouse models of maximal partial hepatectomy31. Bile acids 
accumulate in the circulation following partial hepatectomy and signal to the nuclear bile 
acid receptor on hepatocytes (FXR)27. Blockade of this receptor or a reduction of 
circulating bile acids in mice impairs regeneration32.  
 
Depletion of either natural killer t cells or eosinophils impairs regeneration and this is 
thought to be due to the direct effects of Il4 signalling on hepatocytes via Il4Rα33,34. 
Hepatic stellate cells can contribute to regeneration through the production of HGF and 
may have a role in catecholamine production which can promote hepatocyte 
proliferation35. Bone marrow derived liver sinusoidal progenitor cells are released from 
the bone marrow in response to rising granulocyte colony stimulating factor (GCSF) 
levels and contribute to regeneration in mice as they are a rich source of hepatocyte 
growth factor36. 
 
As well as HGF, the other main growth factor involved in liver regeneration is epidermal 
growth factor (EGF) which is produced by Brunner’s glands in the duodenum37. These 
two growth factors (HGF and EGF) are known as direct hepatocyte mitogens as injection 
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of these growth factors alone can induce hepatocyte proliferation and hepatic 
enlargement. Figure 1.7 illustrates the phases required for effective liver regeneration. 
While these events are ongoing,  beta catenin and Notch-1 intracellular domain appear 
in the hepatocyte nuclei,  NFκB and Stat 3 activity is enhanced and hepatocytes enter the 
cell cycle20. Developmental morphogens, such as Hedgehog have also been related to 
liver regeneration, highlighting the link between development and regeneration. In the 
case of hedgehog signalling, blockade of this pathway markedly impaired liver 
regeneration in mice, related to reduced matrix deposition and the non-parenchymal cell 
proliferation which is required for hepatic remnant enlargement38.  
  




Figure 1.7: Summary of the initiation, priming and hepatocyte proliferation phases 
following partial hepatectomy.  
Immediately following partial hepatecytomy portal flow increases to liver remnant with 
an increase in availability of gut derived substances, such as lipopolysaccharides, as a 
result of this increased flow. Combined with proinflammatory events, such as the release 
of TNF and Il-6 hepatocytes are primed to enter the cell cycle and proliferate. 
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Termination of liver regeneration 
While the initiation of liver regeneration has been studied in detail, mechanisms leading 
to its proper termination are poorly characterised. Dong et al. report the Hippo/YAP 
signalling pathway as a mechanism of universal size control in both drosphila and 
mammalsv. The mouse experiments showed that transgenic induced YAP overexpression 
lead to liver growth characterised by widespread hepatocyte proliferation39. However as 
Yap is known to induce cellular proliferation to conclude that that the YAP/Hippo 
pathway regulates liver size may be erroneous especially as the proliferative stimulation 
also resulted in liver cancer. Rather, this experiment shows that overexpression of YAP 
can induce hepatocyte proliferation, which is essentially no different from the 
administration of a direct mitogen such as HGF.  
 
There is often an overshoot in hepatocyte proliferation, which activates a small wave of 
apoptosis in hepatocytes when a similar liver size to that preoperatively is achieved40. 
The role of TGFβ1 in this setting has been considered. As mentioned earlier, TGFβ1 is a 
known inhibitor of hepatocyte proliferation, however the expression of TGFβ1 rises 
early following partial hepatectomy and remains elevated throughout the regenerative 
process41. In addition overexpression of TGFβ1 does not lead to widespread apoptosis, 
rather proliferating hepatocytes are scattered throughout the parenchyma42 vi. Given the 
role of extracellular matrix (ECM) remodelling in the initiating events of liver 
regeneration, reconstitution of the ECM and associated signalling molecules may play an 
important role in the termination of liver regeneration17. As well as a source for growth 
                                                             
v The Hippo signa ll ing pat hwa y is highly conserve d pat hwa y pre se nt  in drosphil ia t hrough to 
ma mmals.  It  ha s a  ke y role  in de te rmining cel lula r a popt osis a nd prol i fe rat ion.  In drosphila  it  has 
bee n shown t o be a  regulat or  of orga n size .  YAP is  a n oncoge ne  39. Dong,  J . ,  et al .  Elucidat ion of  a 
universa l  size -cont rol  me cha nism in Drosophila and ma mma ls. Cell  130 ,  1120-1133 (2007).  
 
vi This  pa per  a lso showe d t hat  TGFβ induce d marke d he pat ic  fibrosis (TGFβ is  wel l recognise d a s a 
profibrot ic  a ge nt ).  The overwhelming phe not ype  wa s t hat  of TGFβ induce d glomerulone phritis 
lea ding t o re nal  fa i lure .  
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factors the ECM contains signalling molecules which communicate with surrounding 
cells. Integrins mediate much of these signalling pathways. The role of integrins in 
mediating hepatocyte proliferation is illustrated by mice lacking integrin linked kinase. 
Here, in the steady state liver size was increased by nearly 60%43. The signals that 
facilitate appropriate remodelling however are unknown. Changes in flow dynamics and 
potentially vascular stress are likely to have a role to play given there is a reduction in 
these signals with increasing liver size. However conclusively demonstrating the series 
of events responsible for, rather than just associated with, termination of liver 
regeneration remains elusive.  
 
Regeneration following acute toxic liver injury 
As with partial hepatectomy, much of our understanding of liver regeneration following 
acute toxic liver injury has come from the manipulation of rodent models. Common toxic 
agents to induce acute liver failure in rodents include paracetamol, carbon tetrachloride, 
and thioacetamide44.  
 
Paracetamol 
Paracetamol intoxication is one of the most clinically relevant of the injury models given 
this is one of the commonest causes of acute liver failure in the UK, USA and most of 
Europe45. There are three main pathways by which administered paracetamol is 
eventually metabolised. Over 90% undergoes either glucuronidation (addition of 
glucuronic acid) or sulfation (sulphate conjugation)46. These metabolites are then 
excreted via the kidneys. However a small percentage can form the toxic reactive 
intermediate N-acetyl-p-benzoquinone imine (NAPQI). This is detoxified by conjugation 
with glutathione. At high doses the glucuronidation and sulfation pathways can become 
saturated, forming excess NAPQI, depleting glutathione stores and binding to liver 
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proteins. This can lead to mitochondrial dysfunction, oxidative stress and activation of 
necrotic and apoptotic pathways. Glutathione concentrations are lowest in the 
centrilobular regions where tissue destruction is evident47. Following fasting the effects 
of paracetamol at toxic doses are considerably worse. This leads to a marked neutrophil 
infiltrate and increased severity of injury in mouse models of paracetamol intoxication48. 
Antoine et al., showed that fasting does not deplete glutathione levels or alter 
paracetamol metabolism, rather fasting depletes basal ATP which inhibits caspase-
driven apoptosis resulting in predominant necrotic injury48. Following injury 
regeneration then relies upon CCR2 dependent monocyte and macrophage recruitment 
to clear necrotic debris49,50. In humans, monocytopenia is associated with the most 
severe injury51,52.  Figure 1.8 summarises the process.  
 
Carbon tetrachloride 
Carbon tetrachloride has been widely used as an agent to induce hepatic fibrosis 
following a chronic injury regimen. However a single high dose can be used to induce 
acute liver injury. Liver injury is induced by the formation of reactive intermediates via 
the cytochrome P-450 pathway and also alterations in calcium homeostasis53,54. Carbon 
tetrachloride induces a centrilobular injury.  
 
Thioacetamide 
Thioacetamide forms the active metabolite TAA-S-oxide after biotransformation via the 
flavine adenine dinucleotide pathway55. At lower doses this can induce hepatocyte 
apoptosis but at high doses oxidative stress results in lipid peroxidation and 
centrilobular necrosis in mouse and rat liver36. 
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Given the direct clinical relevance of paracetamol intoxication this model of liver injury 
has received the most research attention, particularly in recent years.  
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Regeneration following acute on chronic liver injury 
Induction of chronic liver injury in mice and rats is typically performed by long term 
administration of carbon tetrachloride or thioacetamide. One of the earliest changes in 
the development of fibrosis is the loss of fenestrations in the liver sinusoidal endothelial 
cells and the formation of a basement membrane56. Hepatic stellate cells (the liver’s 
fibroblasts) are the typical scar forming cells of the liver which then act with infiltrating 
monocyte populations to generate fibrotic scars57. Stellate cells interact with other 
mediators, such as platelet derived serotonin, which can enhance the fibrotic response58. 
The remodelling process is constantly active however with cellular populations having 
contrasting roles in both injury and resolution phases. For example depletion of 
monocyte/macrophage populations during injury reduces scar formation but depletion 
during recovery impairs scar resolution 59.  
 
Acute liver injury can be applied to a background of chronic liver injury either by a high 
dose of toxin, such as carbon tetrachloride, or by partial hepatectomy. Following acute 
on chronic toxic liver injury the background hepatic fibrosis does exert a degree of 
protection from further acute injury, demonstrating the functional role of this process60. 
The mechanism underlying this protective effect was attributed to collagen mediated 
extracellular signalling such as ERK-1 (extracellular regulated kinase 1). Following 
partial hepatectomy on a background of chronic liver injury in rats, matrix remodelling 
is accelerated leading to a rapid reduction in fibrosis in the liver remnant61. This effect 
was attributed to increased expression of matrix metalloproteinases 9, 12 and 13.  
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1.3 The consequences of a failing liver 
Why do patients die from liver failure? 
The failing liver can trigger a cascade of events, characterised by multiorgan dysfunction 
and sepsis, which can result in eventual death. Multi organ involvement markedly 
increases the risk of death, such that with three or more organs involved the chance of 
death approaches 80% versus less than 4% in patients with no extrahepatic 
involvement62. Typical manifestations include the development of bacterial infection, 
encephalopathy, gastrointestinal haemorrhage and ascites62.  
 
In chronic end stage liver disease the induction of acute liver failure by bacterial infection 
is the commonest cause of death63. Infection rates are increased following extended 
partial hepatectomy and sepsis complicates acute liver failure in over 30% of cases2,64.  
 
Hepatic encephalopathy, due to circulating ammonia and other neurotoxins, is often 
precipitated by infection and is associated with a profound inflammatory mediator 
response65,66. This can lead to cerebral oedema and intracranial hypertension 
manifesting with varying degrees of neuropsychiatric disturbances, from mild confusion 
to coma and subsequent death. Cerebral oedema accounts for around 20-25% of deaths 
from acute liver failure67. Gastrointestinal haemorrhage may relate to pre-existing 
vascular abnormalities, such as the development of oesophageal varicesvii, in 
combination with coagulopathy due to impaired hepatic synthetic function. Patient 
comorbidities may contribute to other causes of death relating to renal, respiratory and 
cardiac failure.  
                                                             
vii Oe sopha ge al var ice s are  dila te d ve ins forming in t he  lowe r t hird of  t he oe sophagus a s a 
conseque nce  of porta l hype rte nsion (increa se d pre ssure in t he  port al  va scula ture  due t o the  
c irculat ory a bnorma lit ie s of  chronic l iver  disea se)  




Clinical deterioration and death in liver failure is clearly a multifactorial process, with 
the development of sepsis and the inflammatory response major mediators. Given its 
position, directly downstream from the gut, the liver is an organ which exhibits 
predominant innate immunity68. The disruption of both liver architecture and function 
that occurs in liver injury can impair this immune barrier. 
 
The liver and innate immunity 
The liver receives approximately 80% of its blood supply via the portal vein, with the 
remaining 20% supplied by the hepatic artery68. The liver therefore represents the last 
line of defence against gut derived pathogenic material arriving via the portal vein. The 
innate immune system is designed for rapid defence against pathogenic material. It is 
multi-layered, involving physical barriers, such as mucous membranes and skin, 
chemical barriers, such as stomach acid secretions, humoral factors, such as complement 
and interferons, lymphocytic cells, including natural killer cells and phagocytic cells, 
including neutrophils and macrophages.  
 
The innate immune response relies on recognition of pathogens via “pathogen-
recognition receptors” (PRRs) which detect “pathogen-associated molecular patterns” 
(PAMPs)69.  Lipopolysaccharide is perhaps the best defined PAMP and relates to gram 
negative bacteria which predominate the gut flora.  PRRs include membrane bound 
receptors (toll-like receptors and c-lectin receptors) and cytoplasmic PRRs (NOD-like 
receptors and RIG-1-like receptors)69. Gut-derived PAMPs first come into contact with 
the hepatic macrophage population, which filter the portal blood from their location 
extending into the hepatic sinusoids. The liver contains the body’s largest populations of 
macrophages in direct contact with the blood and their location directly downstream of 
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the gut highlights the importance of this barrier (Figure 1.9)68, viii. As well as phagocytic 
functions, hepatic macrophages can endocytose smaller soluble macromolecules, such as 
lipopolysaccharide (LPS). Liver sinusoidal endothelial cells (LSECs) are also capable of 
eliminating soluble macromolecules and colloidal waste through endocytosis (such as 
LPS), but do not have phagocytic functionality. Other innate immune cells within the liver 
include natural killer (NK) cells and natural killer T cells (NKT). NK cells interact with 
other immune cells, in particular T cells, to regulate the immune response to pathogens 
involving cytokine release, priming other immune cells and subsequently influencing the 
adaptive immune response70, ix. Eosinophils and neutrophils are found in low numbers in 
the steady state liver but increase in number markedly following tissue injury. 
 
There is mounting evidence that the impairment in hepatic innate immune function 
following injury is a major factor influencing the subsequent clinical outcome. In the 
context of experimental models of liver injury, hepatic bacterial clearance capacity is 
impaired, leading to increased systemic exposure to gut commensals71. Translocation of 
gut bacteria is a major cause of sepsis in chronic liver disease, which is thought to be 
linked to both a change in gut flora and also an alteration in gut integrity72-74. In 
experimental models of maximal partial hepatectomy (90%), marked bacterial 
translocation occurs 2 hours following surgery, associated with an overgrowth of  
Escheria coli in the distal intestine and dramatically reduced reticuloendothelial system 
function75. Hepatic phagocytic capacity in the clinical setting can be tested by measuring 
the rate of clearance of radiolabelled albumin microspheres from the circulation. Here 
clearance of these particles is markedly impaired in severe acute toxic liver injury, partial 
                                                             
viii Overal l  t he  gut  host s t he  body’s  large st  populat ion of  ma crophage s,  howe ver  t he se  macrophage s 
serve a barr ier funct ion re la ting t o t he int e st ina l lume n a nd are not posit ione d t o serve  a s blood 
f i l ters .   
ix Ada pt ive immunit y (a lso known a s acquire d immunit y) re fers t o immune protect ion t hat develops 
in re sponse  t o a n a nt ige n.  It  t ypica lly  involve s t he  de ve lopme nt  of a nt ibodie s,  is  me dia te d by T ce lls 
a nd B ce lls  a nd ca n acquire  “me mory” such t hat  subseque nt insult s wi t h the sa me a nt ige n lea d t o a 
more robust  re sponse .   
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hepatectomy and in chronic liver injury76,77. The importance of maintaining innate 
immune capacity following liver injury is clear and suggests an important link between 









Figure 1.9: Relationship between the gut, portal blood, hepatic sinusoid and hepatic 
macrophage with illustrations of liver disease. 
Central figure adapted from Stutchfield and Forbes, 201378.  
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Linking hepatic regeneration and innate immunity 
Innate immune cells have a central role in liver regeneration. During regeneration 
hepatic macrophages are important for hepatocyte priming and subsequent hepatocyte 
proliferation, while NK cells and eosinophils enable effective hepatocyte proliferation via 
Il-4 related signalling pathways (as discussed in “1.2 The biology of liver regeneration 
following acute injury”) 28,33,34.  
 
In the steady state it is the hepatic macrophage that is the predominant innate immune 
cell in the liver68. There is direct link between the number of mature hepatic 
macrophages and gut bacterial load, demonstrating the dynamic nature of this system79. 
Maintenance of hepatic macrophages is influenced by macrophage colony stimulating 
factor (CSF1)80,81. CSF1 is ubiquitously produced by many tissues82,83, but hepatic 
macrophages serve as the major clearance site of CSF1 via receptor mediated 
endocytosis84. Hepatic regeneration following PH is stunted in CSF1 deficient mice 
(op/op) and reduction in hepatic macrophage number by blockade of macrophage 
colony stimulating factor significantly reduces hepatic size85.  
 
Hepatic macrophages have a protective effect following ischemia reperfusion injury of 
the liver involving a heme oxygenase-1 dependent mechanism86. In chronic liver injury 
macrophages have distinct roles during both injury and repair, important in the 
fibrogenesis phase after injury and equally important to facilitate remodelling and 
fibrosis resolution during recovery59. Indeed transplantation of ex vivo differentiated 
macrophages in a mouse model of fibrosis can reduce hepatic fibrosis by upregulating 
matrix remodelling87. 
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NK cells can induce antifibrotic pathways following liver injury via effects on stellate 
cells, but may also mediate hepatocyte cytotoxicity dependent on the disease context88,89. 
In patients eosinophilia indicated a favourable outcome in drug induced liver injury 
although in experimental models eosinophils have a role in mediating the pathogenesis 
of drug induced liver injury although the mechanism was unclear90,91. 
 
Ultimately, maintaining an effective immune response in the presence of injury is a 
highly evolved process. The relationship between cells of innate immunity and liver 
regeneration is certainly complex, with evidence to suggest distinct roles in the 
pathogenesis, repair and resolution phases following liver injury. Rather than simply the 
presence of cells within the tissue being pathological, the context in which these cells 
find themselves appears to be the key determinant. Directing the immune response by 
targeting specific cells of the innate immune system could provide an effective 
therapeutic strategy to enhance recovery from liver injury. 
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1.4 Therapeutic strategies to facilitate liver regeneration 
There is currently no therapy proven to enhance regeneration of the liver in clinical 
practice. Strategies to improve outcomes in liver failure currently focus on intensive care 
support as multiorgan failure and sepsis ensues. In life threatening liver failure, liver 
transplantation is currently the only therapy proven to improve survival in acute and 
acute-on-chronic liver failure92,93. The decision to undergo transplantation for acute liver 
failure in the UK is currently based on a series of clinical criteria which identifies those 
patients at greatest risk of death- the King’s College Criteria94 (Figure 1.10). While these 
criteria are designed to identify the sickest patients, active sepsis should be treated prior 
to transplantation95. The King’s College Criteria are widely accepted as a prognostic 
algorithm reflecting marked clinical deterioration, although its sensitivity has been 
questioned96.  
 
The ability to accurately identify those patients who are likely to require transplantation 
prior to clinical deterioration would be highly desirable. Recent work has identified a 
range of biomarkers related to hepatic injury which show promise in predicting patients 
most likely to die or require liver transplantation, the most promising of these is acetyl-
HMGB1which serves an indicator of necrosis97,98. If patients most likely to deteriorate 
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Liver specific therapies to improve outcomes following liver injury have included 
directly targeting hepatocytes to proliferate using mitogens, supporting liver function 
using an extracorporeal device, administering hepatocytes or hepatocyte like cells 
directly or targeting the non-parenchymal cells of the liver to facilitate recovery of the 
hepatic environment (Figure 1.11).  




Figure 1.10: Simplified King’s college criteria 
The King’s college criteria serves as a prognostic algorithm to identify those patients who 
are likely to die from acute liver failure. The criteria are divided into patacetamol and 
non-paracetamol induced acute liver failure, reflecting differences in progression of 
acute liver failure in these cohorts. 
  




Figure 1.11: Cell therapy based strategies to support the injured liver 
Cell therapies to support the injured liver can be broadly grouped into those that 
contribute to the hepatocyte proliferation, either directly (e.g. allogeneic hepatocytes or 
stem cell derived hepatocytes) or cell therapies that aim to enhance endogenous 








Administration of hepatocyte mitogens (such as HGF) may boost hepatocyte 
proliferation in preclinical models and safety has been demonstrated in a recent phase I 
clinical trial99-101. However in the context of cancer surgery, growth factor administration 
could increase risk of recurrence or promote metastasis. In addition the short half-life of 
these agents, in animal models which have shown benefit, rely upon viral vector gene 
therapy to upregulate growth factor expression, which is not a translatable model. A 
range of hormone strategies have been trialled in the clinic including insulin / glucagon 
infusion and human growth hormone in the settings of acute liver failure and partial 
hepatectomy with chronic liver injury respectively102,103. However neither of these 
interventions resulted in demonstrable clinical benefit.  
 
Extracorporeal liver support 
Extracorporeal liver support systems have been trialled in settings of acute and acute-
on-chronic liver failure with limited success. These systems can either involve an 
albumin dialysis circuit and charcoal filtration (artificial liver support), or contain 
functional hepatocyte-like cells, intended to perform both detoxification and synthetic 
functions (bioartificial liver support). I undertook a meta-analysis of randomised 
controlled trials involving extracorporeal liver support systems prior to my PhD. This 
indicated a small survival benefit in acute liver failure, but there was no evidence of 
survival benefit in acute-on-chronic liver failure104. 
 
Cellular therapies 
Direct administration of stem cells or even allogeneic or differentiated hepatocytes has 
had limited success105. This is likely due to the unfavourable environment which these 
cells encounter within the injured liver. Bone marrow derived cells are thought to 
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contribute to regeneration by promoting endogenous processes and their 
supplementation (by adoptive transfer) or mobilisation may further promote 
regeneration of the liver following PH106. Beneficial effects of various BM derived cells 
administered in rodent models of liver regeneration have been reported and this cell 
source also offers the opportunity to use autologous cells105. Favourable effects are likely 
due to paracrine action, although the mechanisms underlying this are poorly 
understood107,108. It was previously thought that bone marrow derived cells could 
transdifferentiate into hepatocytes109-111. However this has subsequently not been 
repeatable, with hepatocytes either erroneously identified, likely the result of cell fusion 
events, or  involve animal models with unique selection pressures not directly relevant 
to clinical practice107. 
 
Clinical studies administering BM derived cell populations (eg mononuclear cells) 
mainly in liver cirrhosis have begun with potentially promising results112. However these 
small, generally uncontrolled trials tend to administer mixed cell populations, limiting 
the understanding of mechanism and risking administration of profibrotic cell 
populations106,112. In the context of liver surgery, evidence from small (poorly controlled) 
clinical studies suggests that administering enriched bone marrow progenitor cell 
populations (CD133+ and/or CD34+) to patients at the time of portal vein embolization 
may further boost future liver remnant volume113-116. 
 
In chronic liver injury, bone marrow derived macrophages are pivotal to remodelling 
fibrosis, which is a key requirement for the hepatic progenitor cell (HPC) response.59,117 
With this in mind, preclinical studies have recently demonstrated a therapeutic role for 
macrophage administration in promoting remodelling of fibrotic liver matrix87. There is 
mounting evidence that the macrophage is a key cell in the control of liver regeneration 
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following partial hepatectomy also118-120. Mechanisms of macrophage action in this 
context include the production of cytokines and growth factors, regulation of vascular 
tone, minimising endotoxin mediated systemic inflammation and hepatocyte 
damage29,121-123. With the macrophage functioning as a major mediator of both 
regeneration and the innate immune system, this cell represents a potential therapeutic 
target.  
 
Colony stimulating factors 
There are three colony stimulating factors- macrophage colony stimulating factor (MCSF, 
CSF 1), granulocyte macrophage colony stimulating factor (GMCSF, CSF2) and 
granulocyte colony stimulating factor (GCSF, CSF3). MCSF has a role in the maintenance 
of cells of the monocyte macrophage lineage from bone marrow precursor to tissue 
resident macrophage. GMCSF is involved in both neutrophil and macrophage 
maintenance and is predominantly produced by inflammatory cells. GCSF is involved 
maintenance of bone marrow stem cell populations and their release into the blood, as 
well as neutrophil production and function. 
 
While the importance of CSF1 in liver regeneration was discussed earlier, its therapeutic 
potential has not been explored in liver disease. However CSF1 supplementation 
following kidney and neurological injury has shown regenerative benefit 124,125. In the 
clinical setting higher CSF1 level has been associated with more rapid liver regrowth 
following living donor PH126. GMCSF (CSF2) has a role in stimulating remodelling of the 
liver, likely through effects on neutrophils during regeneration and supplementation can 
facilitate regeneration in normal and cirrhotic rats127-129. However, there is evidence that 
overstimulation of GMCSF can have cytotoxic effects in the presence of 
lipopolysaccharide, inducing widespread hepatocyte apoptosis130.  





GCSF (CSF3) can mobilise liver sinusoidal progenitor cells (LSECs), which are a rich 
source of hepatocyte growth factor. GCSF therapy can promote regeneration in rat 
models of acute liver injury and recent evidence suggests that in patients with acute-on-
chronic liver failure, GCSF therapy can improve survival36,114.  
 
In summary, therapeutic strategies to enhance liver regeneration either focus on 
enhancing the hepatocyte pool (cell administration or mitogens) or facilitating non 
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1.5 Targeting macrophages  
Experimental strategies to enhance liver regeneration have typically focussed on the 
hepatocellular compartment, neglecting the importance of hepatic immune function. In 
considering an appropriate strategy to enhance liver regeneration it seems both the 
effects on hepatocellular regeneration and on innate immunity should be considered. 
 
Given the macrophage predominates in the liver during the steady state, the critical role 
of the liver macrophage in maintaining homeostasis through innate immune functions 
and the role of the macrophage in regeneration, the macrophage appears to offer a 
suitable therapeutic target. To understand the best methods in which to target 
macrophages, an understanding of tissue macrophage dynamics in the steady state, 
injury and repair is necessary. 
 
The origin of liver macrophages 
There has been considerable attention on the origin of tissue macrophages over the past 
40 years. Liver macrophage origin remains controversial with options including 
proliferation of mature macrophages, replenishment by circulating monocytes or 
derivation from a progenitor / stem cell originating from within the liver.  
 
Historical perspective of liver macrophage origin 
Using radiolabelled thymidinex to identify cells undergoing mitosis, Crofton et al showed 
back in the 1970s that tissue resident macrophages in the liver are capable of 
proliferation in the steady state131. However the percentage was low, with just 1% of 
                                                             
x The  ra dioact ive  nucle oside ,  3H -t hymidine ,  inte grate s wit h ne w chromosoma l  DNA during  mit osis.  
DNA is  re pl ica te d during  S -pha se of t he ce ll  cycle a nd t his  where  t he  incorporat ion occurs.  
Manipulating macrophages to enhance liver regeneration 
39 
Introduction 
liver macrophages incorporating 3H-thymidine at 1 hour following injection 
(approximately 1.4%). To assess whether replenishment of hepatic macrophages was 
principally due to resident cell proliferation of a long lived population or replenishment 
of macrophages by bone marrow derived monocytes, this group explored the dynamics 
of monocytes in the bone marrow and peripheral blood in comparison to labelled cells 
in the liver. 48 hours following a single injection the authors found that liver macrophage 
labelling had increased to 10.4% of the population and thereafter this percentage 
reduced slowly. Monocyte labelling in the blood was much higher however, at up to 60% 
48 hours following injection. The authors concluded that the increase in labelled Kupffer 
cells could not be attributed to proliferation of resident liver macrophages alone and 
therefore that monocytes must be contributing to the liver macrophage pool. Following 
this the authors irradiated mouse livers, but protected bone marrow finding that liver 
macrophages returned rapidly. Crofton concluded that tissue resident macrophage 
replenishment was not due to proliferation but derived from circulating monocytes.  
 
The results of Crofton et al. contrasted with an earlier parabiosisxi experiment (1976) 
where 3H-thymidine was repeatedly given to one rat in the pair following vascular 
coupling132. The liver of the second rat was then examined at later time points for 3H-
thymidine positive macrophagesxii. While monocytes were labelled in the non-injected 
rat, hepatic macrophages labelling was minimal suggesting that crossover of labelled 
monocytes was not contributing to the second rat’s liver macrophage populations.  
 
These two early studies have a number of limitations, given they both rely on indirect 
measures and summations for identification of macrophages (phagocytic ability), cell 
                                                             
xi Para biosis  is  t his conte xt  re fers t o the surgical  joining  of  two a nimals which the n share  a 
c irculat ory syste m. 
xii Label le d monocyte s crosse d be twee n rat s such that  labe l le d monocyte pe rce nta ge wa s similar in 
bot h a nimals 
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labelling (3H-thymidine incorporation) and assessment with a single technique (non-
parenchymal liver cell smear and cell count). The use of radiation to deplete tissue 
macrophages can result in general tissue injury and this undoubtedly influences the 
monocyte / macrophage response.  
 
In the intervening years there were isolated reports indicating the proliferative capacity 
of macrophages or “macrophage-like” cells. Such as the depletion experiment by 
Yamamoto et al.133. Here clodronate encapsulated liposomesxiii were administered to 
deplete tissue macrophages. Liver macrophage number returned to normal by day 14 
following injection. There appeared to be a population of small, highly proliferative 
“macrophage-like cells” that the authors suggested could represent a liver macrophage 
progenitor cell population. Equally, however, these cells may have represented 
immature monocyte populations induced by the widespread depletion of phagocytic 
cells. 
 
Overall, given the low proliferation of macrophages in the steady state, it became the 
widely accepted belief that tissue resident macrophages and inflammatory macrophages 
are terminally differentiated cells arising from blood monocytes135. 
 
Contemporary analysis of liver macrophage origin 
30 years on from the experiments of Crofton131 and Volkman132 developments in genetic 
manipulation and cell labelling techniques have enabled the question of macrophage 
origin to be readdressed. Bouwens et al, labelled liver macrophages with a single 
                                                             
xiii C lodrona te  is  a  bisphosphonate  which,  whe n in solut ion,  doe s not  cross l iposomal  or  ce llular 
phosphol ipid me mbra ne s.  Howe ver  whe n it  is e nca psula te d in l iposome s,  t he  l iposome  is ta ke n up 
by pha gocyt ic ce lls  a nd re lea se d int racel lular ly , impa ir ing  mit ochondria l function a nd lea ding to 
a popt osis  of the  pha gocyt ic cel l 134. Le he nkari ,  P .P . ,  et  al .  Furt her  insight  int o mechanism of  
a ct ion of  c lodronat e: inhibit ion of  mit ochondria l ADP/ATP t ra nsloca se  by a  nonhydrolyza ble , 
a de nine -conta ining  met abol ite .  Molecular pharmacology  61 ,  1255-1262 (2002).  
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injection of latex beadsxiv. They found that the mean number of labelled liver 
macrophages did not change over a period of 3 months. These results indicate the 
longevity of the liver macrophage population and could account for the low proliferation 
rate if this macrophage population was indeed self-renewing. It has subsequently 
become accepted that macrophages are capable physiologically relevant proliferation 
under certain stimuli. Jenkins et al recently demonstrated that accumulation of 
macrophages at inflammatory foci occurs independently of blood monocytes, via a 
process of self-renewal involving interleukin-4 and CSF1136. Subsequently both bone 
marrow derived and tissue resident macrophages have been shown to be capable of 
proliferation during inflammation137. 
 
With regards to the liver resident macrophage in the steady state, Klein et al., exploited 
the two different alleles of the CD45 gene (CD45.1 and CD45.2) to create chimeric mice. 
In their experiments CD45.2 mice received CD45.1 bone marrow following irradiation to 
the hind limbs while shielding the liver119. Mice were then examined in the steady state 
and following liver transplantation. By extracting macrophages and assessing 
populations by flow cytometry they showed that 4 weeks following bone marrow 
transplantation 99% of hepatic macrophages were derived from the donated bone 
marrow. However when assessed by immunohistochemistry, only 54% of hepatic 
macrophages were found to be derived from the transplanted bone marrow. The reason 
for this discrepancy was unclear. Klein et al trialled multiple macrophage extraction 
strategies to try to get at this population by flow cytometry but these were unsuccessful. 
The group termed this population “sessile macrophages”, in view of the fact that they 
could not be extracted. They commented that they were unsure where this population of 
macrophages arose from, but that there was no evidence they were derived from a 
                                                             
xiv Lat e x bea ds are ra pidly phagocyt ose d by macropha ge s  
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progenitor cell population. This discrepancy highlights the problems with relying on a 
single technique for cell identification and in particular the limitations of cell extraction.  
 
Schulz et al. opted for a genetic strategy whereby haematopoietic stem cells could be 
ablated without the requirement for radiation via the conditional knock out of the 
transcription factor Myb138. This approach meant that tissue macrophages dynamics 
could be explored without the requirement for radiation, so avoiding the effects of tissue 
injury on macrophage phenotype, This group found that a population of macrophages 
arose in the yolk sac, prior to the development of haematopoietic stem cells and that 
there was evidence that these yolk sac derived macrophages persisted into adulthood as 
the predominant liver macrophage.  Experiments by Yona et al. have since confirmed 
these findings of a liver macrophage population independent of the bone marrow using 
a different strategy. Yona et al., exploited the dynamics of the Cx3Cr1 gene which is 
expressed by monocytes but not tissue liver macrophages in the adult139. Using mice with 
either conditional or constitutively active Cre recombinase genes in the Cx3Cr1 they 
showed that fetal liver macrophages were Cx3Cr1 positive but adult liver macrophages 
were not. By labelling fetal liver macrophages with the conditional Cx3Cr1 reporter (red 
fluorescent protein) in mice with constitutively expressed Cx3Cr1 (green fluorescent 
protein) it was shown that the majority of the liver macrophages were derived from the 
embryonically labelled macrophages (red fluorescent protein).  
 
These contemporary findings contrast with the historical perspective of replenishment 
of macrophages in the steady state and demonstrate the importance of adopting different 
strategies and multiple methods of assessment to address a specific question. The 
genetic labelling techniques of Schulz138 and Yona appear the most robust although these 
groups did not disrupt normal homeostasis by testing macrophage replenishment in 
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injury or following macrophage loss. In the peritoneal cavity resident macrophages are 
under the transcriptional control of Gata6, which controls their proliferative renewal 
both during homeostasis and during inflammation140. Recognition of hepatic 
macrophages as a distinct self-renewing macrophage population is likely to identify 
specific genes regulating their homeostasis and response to injury and inflammation.  
 
Applying these genetic strategies to models of liver injury and macrophage depletion will 
be interesting and no doubt demonstrate the plasticity of the system.  
 
Regulation of cells of the monocyte macrophage lineage 
There are two key haemopoetic growth factors which can influence monocyte and 
macrophage production and phenotype. These are macrophage colony stimulating factor 
(MCSF or CSF1) and granulocyte-macrophage colony stimulating factor (GMCSF, CSF2).  
 
CSF1 is produced by a wide range of tissues and in the liver can be produced by both 
parenchymal and non-parenchymal cells141,142. Colony stimulating factor 1 is an essential 
regulator of optimal monocyte- macrophage function, necessary for the generation of 
monocytes from bone marrow progenitor cells and the maintenance of tissue 
macrophages143. GMCSF has negligible circulating levels, but this can rise in response to 
an inflammatory stimulus, in particular in response to infection. GMCSF is produced by 
inflammatory cells rather than epithelial tissue144.  While GMCSF can influence 
macrophage phenotype it lacks the capacity to generate mature human monocyte or 
tissue macrophage populations145. 
 
There is thought to be competition between CSF1 and GMCSF when both are present at 
high concentrations, such that macrophage phenotype can be influenced146. With tissue 
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macrophages exposed to CSF1 under normal conditions in the steady state it has been 
regarded a more anti-inflammatory, “pro-regenerative” macrophage phenotype, 
whereas GMCSF, which is only present during inflammatory reactions is regarded as 
inducing a “pro-inflammatory” macrophage phenotype144. In vitro classification of 
macrophages has led to the categories of M1 (more “pro-inflammatory”, characterised 
by TNF alpha and Il6 production) and M2 (more “anti-inflammatory”, characterised by 
high Il10 production) macrophages147.  However, in vivo the situation is more complex 
with macrophages displaying a range of activation states and a phenotypic spectrum 
dependent on the specific microclimate of the individual cell.  
 
CSF1 has a central role in mediating repair following organ damage. In mouse models of 
injury in both the brain and kidney CSF1 blockade impairs the regenerative response and 
supplementation of CSF1 can facilitate recovery148-150. GMCSF elicits a more 
proinflammatory, “M1” response to facilitate destruction of invading pathogens144. This 
pro-inflammatory state induced by GMCSF can have negative consequences, with 
overexpression of GMCSF in the context of lipopolysaccharide administration leading to 
widespread hepatocyte apoptosis130. 
 
The biology of macrophage colony stimulating factor 
The macrophage colony stimulating factor (CSF1) deficient mouse (op/op mouse) shows 
an extremely low number of mononuclear phagocytes, general growth retardation, 
impaired regenerative capacity and poor fertility, although it is still viable82,83. Mice with 
genetic ablation of the CSF1 receptor (CSF1R) express a more severe phenotype 
however, and rarely survive to adulthood151. Recently a second ligand for the CSF1R was 
identified which could account for the discrepancy between the ligand and receptor 
deficiency models.  Following a functional screen of a comprehensive set of recombinant 
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proteins against a range of cell types Lin et al. identified a novel cytokine which 
interacted specifically with the CSF1 receptor152. The authors named this novel cytokine 
Il-34. Further analysis by other groups has shown that while there is functional overlap 
between Il34 and CSF1 their tissue expression is more diverse. For example while Il34 
mRNA is expressed in the liver, Il34 deficiency had no effect on liver resident 
macrophage numbers153. However Il34 deficiency did result in a marked depletion of 
Langerhans cells (dendritic cellsxv of the skin) and microglia (the resident macrophage 
of the brain and central nervous system).  
 
Antibody blockade of the CSF1 receptor in the steady state markedly reduces 
macrophage numbers in the liver and also reduces liver size in mice, demonstrating the 
importance of CSF1R signalling in maintaining homeostasis80. Using radiolabelled CSF1 
it was shown in the 1980s that liver resident macrophages are the principle regulators 
of serum CSF1 concentration84. This group showed that macrophages selectively cleared 
CSF1 by receptor mediated endocytosis and subsequent intracellular degradation.  The 
effect of removal of liver tissue on circulating CSF1 level has not previously been 
established in mouse models. However it was recently shown in humans that patients 
undergoing living donor partial hepatectomyxvi, a higher serum CSF1 level was associated 
with increased rate of liver remnant growth126. In chronic liver disease, serum CSF1 
levels are elevated but the functional consequences of this are unclear156.  
 
                                                             
xv De ndrit ic  cel ls  a nd ma crophage s are  morphological ly  simila r a nd t here ha s be e n some  cont roversy 
a s t o whet he r t he se  t wo ce l ls  act ua l ly re pre se nt  subt ype s of  the  sa me  ce l l  rat he r  t ha n dist inct ce lls 
a lt oget he r . Trea te d as se pa rat e cel ls , ma cropha ges perform a pre domina nt ly innate  immune re ponse , 
where a s de ndrit ic  ce lls  int er face  wit h the  a da ptive  immune  syste m through a nt ige n pre se nta t ion.  
154.  Fe re nbach, D.  & Hughe s, J . Macropha ge s a nd de ndrit ic ce l ls:  what is the dif fere nce?  Kidney 
Int  74 ,  5-7 (2008),  155. Hume ,  D.A. Macrophage s a s APC  a nd t he  de ndrit ic cel l  myt h. J  Immunol  
181 ,  5829-5835 (2008).   
xvi Living donor part ia l he pate ct omy is  t he  f irst pa rt of  a  l iver  t ra nspla nt  proce dure whereby a n 
individual  (usua lly a  relat ive  of t he  pat ie nt  requiring  liver  tra nspla ntat ion) unde rgoe s pa rt ial  
he pa tect omy t o donat e part  o f t he ir l iver  t o a patie nt  wit h l iver  fa ilure .  
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Macrophages during liver injury and repair 
Macrophage dynamics have been explored in models of liver injury although techniques 
to define origins have not been as rigorous as that shown in the steady state. Efforts have 
centred around ablation of specific cells using genetic and toxin based approaches. These 
have centred around the CD11b-DTR mousexvii, clodronate encapsulated liposomes (see 
Footnote xiii, p40) and limitation of cellular trafficking by chemokine inhibition.  
 
 Following chronic liver injury Prakash et al., used adoptive transfer experiments and 
depletions using the CD11b-DTR mouse to show that monocytes are recruited from the 
circulation and become macrophages necessary for effective remodelling of hepatic 
fibrosis158. The CD11bDTR mouse depletes cells expressing the CD11b cell surface 
receptor. While this model is regarded as a model to deplete monocytes and 
macrophages, a number of other cell types also express this receptor, including 
neutrophils and eosinophils. However, in a model of lung injury induced by 
lipopolysaccharide, infiltrating neutrophil numbers did not seem to be affected by 
CD11b-DTR, despite neutrophil upregulation of CD11b expression in association with 
injury159. In a lung model of sterile inflammation, numbers of eosinophils in the 
circulation were not affected by CD11b-DTR depletion but there was reduced 
recruitment of eosinophils to the lung160. It seems likely that administration of diphtheria 
toxin will influence the phenotype of these CD11b expressing cells. Interestingly, 
although monocytes and some tissue resident macrophages (kidney, peritoneum, lung) 
are depleted by the administration diphtheria toxin in the CD11b-DTR mouse, liver 
                                                             
xvii The  C D11b -DTR construct  ta rge t s ce lls  e xpre ssing  the  C D11b rece pt or  where by a dministrat ion of 
dipht her ia  t oxin (DTR) lea ds t o de plet ion of  t hese  cel ls .  Mice  do not  ot herwise  e xpre ss a  rece ptor  
for  t he  diphther ia  t oxin.  I t  is  re porte d t hat  t his  model  pre fere nt ial ly target ing monocyte s  a nd 
ma cropha ge s, alt hough ot he r cel ls  do e xpre ss the C D11b rece ptor . 157. Duff ie ld,  J .S . ,  et al .  
C ondit ional  a bla t ion of macrophage s hal t s progression of  cresce nt ic glomerulone phrit is . A m J  Pathol  
167 ,  1207-1219 (2005).  
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resident macrophages are not86.  This is likely to be due to the low CD11b expression of 
these cells161.  
 
 Thomas et al, showed that adoptive transfer of macrophages during the fibrotic process 
can enhance the remodelling effects87. Following acute liver injury characterised by 
necrosis (paracetamol intoxication), monocyte macrophage infiltration via the 
chemokine CCR2, is required for effective clearance of necrotic debris49,52. In models of 
liver regeneration in the absence of liver remnant injury (partial hepatectomy), 
circulating monocytes are recruited via ICAM-1 and mediate hepatocyte proliferation via 
the production of tumour necrosis factor and interleukin (IL)-628. Depletion of 
macrophages in liver regeneration either using the CSF1 deficient mouse or by ablation 
with clodronate encapsulated liposomes impairs the hepatocyte proliferative 
response162 
 
An understanding of the origin of macrophages and their potential manipulation allows 
consideration of therapeutic possibilities. Both administration of bone marrow derived 
macrophages and stimulation of macrophages in vivo via macrophage colony stimulating 
factor (CSF1) appear to be suitable strategies to explore the effects of macrophage 
manipulation on liver regeneration. A macrophage based therapy could address a rapidly 
increasing clinical need by promoting safe resection of liver cancers and facilitate 
regeneration following acute liver injury. 
 
 I therefore aimed to determine whether the positive effects of macrophage therapy seen 
in mouse models of liver fibrosis can be extended to liver resection and define the 
mechanisms underpinning this action. In this thesis I go on to explore the effects of 
macrophage stimulation in vivo using a CSF1 based therapy in surgical models of liver 
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regeneration and a model of acute toxic liver injury. Finally I explore the dynamics of 
serum macrophage colony stimulating factor in humans following both partial 
hepatectomy and acute toxic liver injury. 
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2.1 Animal experiments 
All experiments adhered to the Animals (Scientific Procedures) Act 1986. I obtained 
ethical approval from the University of Edinburgh ethics committee for partial 
hepatectomy and partial hepatectomy plus chronic liver injury experiments. The licence 
to operate was granted by the Home Office. I obtained wild type C57BL/6 mice from 
Charles River for the liver regeneration, macrophage administration and CSF1-Fc 
experiments. Mice were randomly distributed to ensure weight and age distribution 
across groups. Mice were maintained on 12-hr light-dark cycle and had free access to 
water and food. 8 -12 week old male mice were used for all experiments. Mice from the 
same batch were used in each experiment. 
 
I obtained MacGreen mice (Tg(Csf1R-GFP)Hume163 for imaging experiments from the 
Roslin Institute, University of Edinburgh. I collaborated with Professor Allan Mowat and 
Calum Bain (Post-doctoral scientist) from the University of Glasgow to undertake 
experiments using the CCR2-/- mouse. I collaborated with Professor Steve Anderton to 
obtain Il6-/- mice.  
 
I collaborated with Professor Jeff Pollard who had previously performed lineage tracing 
experiments using an inducible CSF1R-Cre system to identify CSF1R expressing cells in 
the liver. These experiments had been performed at the Albert Einstein College of 
Medicine, USA following ethical approval and according to NIH guidelines for the care of 
laboratory animals. 
 
Chapter 2. Materials and Methods 
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In this experiment which had previously been performed, Tg(Csf1r-Mer2iCre)jwp were 
crossed to Rosa floxed stop tomato red (obtained from the Jackson labs) at the Albert 
Einstein College of Medicine and lineage tracing experiments performed138. To induce 
the cre recombinase mice were fed for two weeks with F6370 Rodent Diet formulated 
with Tamoxifen at 750 mg/k (Bio-Serv). This method had previously been have found to 
give optimal induction of the cre recombinase, with greater than 90% of monocytes 
labelled138.  All mice were bred and maintained under specific pathogen-free conditions. 
 
2.2 Reagents 
Chronic liver injury was induced by intraperitoneal injection of carbon tetrachloride 
(Sigma-Aldrich; 99.9%) in solution with olive oil (Sigma-Aldrich; highly refined, low 
acidity). CSF1-Fc is a conjugate of porcine CSF1 with the Fc region of porcine IgG1A 
(43.82kD total) produced by Zoetis for D. Hume (UK patent application GB1303537.1). 
Porcine CSF1 is equally active in mice164 and the conjugate was formed for increased in 
vivo stability. CSF1-Fc does not exhibit any endotoxin like activity in murine BM-derived 
macrophages and phosphate buffered saline (PBS) was used as the control165. CSF1 
receptor blockade was induced by the CSF1R tyrosine kinase inhibitor, GW2580 
(160mg/kg suspended in 0.5% hydroxypropylmethylcellulose and 0.1% Tween 80165, LC 
laboratories), or using the antibody AFS98 (produced from hybridoma by BioServ UK). 
The GW2580 vehicle and rat IgG2a (provided by BioServ UK) were used as control. CSF1-
Fc, GW2580 and AFS98 were administered immediately following 2/3 partial 
hepatectomy or 12 hours following acetaminophen intoxication (point of maximal 
injury166). 5,Bromo-2-deoxyuridine (50mg/kg, Sigma-Aldrich) was administered 1 hour 
prior to cull by intraperitoneal injection.  
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2.3 Models of liver regeneration 
Partial hepatectomy 
I performed 2/3 partial hepatectomy under isofluorane anaesthesia by ligating the left 
lobe and left and right median lobes as previously described167. I performed surgery 
between 9am and 12pm to minimise the effect of diurnal variation on liver regeneration. 
I strictly adhered to aseptic technique and conducted animal husbandry according to 
veterinary advice.  
 
Partial hepatectomy and chronic liver injury 
I induced hepatic fibrosis in mice by intraperitoneal injection of carbon tetrachloride 
(CCl4) at doses from 0.5mcl/g to 2 mcl/g made up in olive oil in a 1:3 (CCl4:olive oil) 
solution (see section 3.2 Partial hepatectomy and chronic liver injury, p67 for discussion 
of dosage choice). I performed partial hepatectomy as per details above at day 3 




I performed paracetamol intoxication by intraperitoneal administration of 350mg/kg 
acetaminophen (Sigma Aldrich) dissolved in PBS following an overnight fast as 
previously described168. PBS was warmed to 60 degrees Celsius to facilitate solution and 
then kept warm until intraperitoneal injection. See section 3.3 Acute toxic liver injury, 
p81 for explanation of dosage choice.  
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2.4 Therapeutic interventions 
Macrophage generation for direct administration 
I extracted bone marrow from syngeneic mouse femurs and cultured in Teflon pots in 
DMEM/F12 medium conditioned with CSF-1 derived from L929 cells. This method 
follows protocols well established within this laboratory87. Following 7 days culture cells 
I characterised a sample of these cells according to surface marker expression based on 
flow cytometry (F4/80; CD209; Ly6C; CD11b) and immunohistochemistry (CD68; MR; 
INOS).  
 
I initially selected the portal vein as the optimal route of administration of macrophages, 
following on from previous work within this laboratory87. However following partial 
hepatectomy, portal vein injection resulted in an unacceptably high complication rate.  
Therefore the route of administration was changed to intrasplenic injection (see section 
“5.2 Optimising route of cellular injection“, p   
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5.2 Optimising route of cellular injection” page 104).  
 
CSF1 receptor stimulation with CSF1-Fc 
The treatment group received 0.75mcg/g CSF1-Fc165 administered subcutaneously 
either in the steady state without injury, immediately following partial hepatectomy or 
12 hours following paracetamol intoxication and subsequently every 24 hours for three 
further doses. 0.75mcg/g dose choice was based on unpublished data by collaborators 
(D. Hume and D Gow) who had performed dose escalation studies. Control mice received 
subcutaneous PBS of appropriate volume. I considered whether administering a pure Fc 
fragment for control was appropriate but after discussion with collaborators and 
supervisors this was not deemed necessary due to the relatively small number of Fc 
fragments administered in conjugation  and the fact that a true control would require a 
Fc-conjugation with an inactive protein and this was not available.  
 
CSF1 receptor inhibition 
The antibody against the CSF1 receptor (AFS98) and the small molecule inhibitor 
(GW2580) were administered immediately following partial hepatectomy or at 12 hours 
following paracetamol intoxication. Administration was continued until post-operative 
day 2 with daily administration following partial hepatectomy (peak proliferative time 
point). In the case of paracetamol intoxication inhibition was commenced 12 hours 
following injury until day 3. 
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2.5 Terminal procedures 
Mice were culled via CO2 inhalation at various time points from the point of injury 
according to Home Office guidelines and weighed. Following a midline laparotomy blood 
was aspirated from the inferior vena cava for serum analysis.  Mice were perfused slowly 
through the inferior vena cava with 5mls of PBS and viscera excised and weighed. Liver 
and other viscera were either fixed in 4% formalin for immunohistochemistry, placed in 
RNA later® (Life Technologies), or placed in PBS for flow cytometry.  
 
2.6 Assessment of hepatic function 
Indocyanine green assay 
I developed an assay to assess indocyanine green clearance non-invasively. The 
development of this assay is discussed in “Functional assessment of liver regeneration”, 
p84. Mice were anaesthetised with isofluorane anaesthesia and placed in the IVIS 
scanner (Fluorescent imaging camera). Indocyanine green [Sigma] diluted in sterile 
water was then administered via a peripheral vein. 30 seconds following this serial 
fluorescent images were taken at 1 minute intervals for up to 30 minutes. Regions of 
interest were drawn over the left and right hind paws, the liver region and also lower 
abdomen (control compensation for liver region). Efficiency of fluorescence (ratio of 
absorbed to emitted photons) was then used to quantify the fluorescent signal. 
 
Phagocytosis assay  
I developed an assay to assess phagocytosis in vivo. The development of this assay is 
discussed in “Functional assessment of liver regeneration”, p84. Mice were anaesthetised 
with 2% isolfluorane and the inferior vena cava was cannulated. 0.1mls of 5000IU/ml 
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heparin solution was infused to prevent blockage of the catheter. 100μl of red 
fluorescent bead solution (1:5 Latex beads 1.0μm, fluorescent red, SIGMA-ALDRICH®) 
was infused through the cannula (1:2 solution for assay following paracetamol injuryxviii).  
 
Ex vivo fluorescent quantification was performed at one minute following bead injection 
and 15mls 0.9% NaCl flush (see Supplementary Figure 5a). For assessment of bead 
clearance from the circulation 20mcl of blood was removed from the cannula every two 
minutes starting from 1 minute post injection for 15 minutes. Blood was immediately 
fixed with 300μl FACS-Lysing solution (BD Biosciences). The cannula was flushed after 
sample removal and subsequently, dead space aspirated prior to sampling. After the 15 
minute timepoint mice were perfused with 15mls 0.9% saline through the IVC cannula 
after dividing the portal vein enabling outflow. Organs were then removed (Liver, spleen, 
lungs, kidney, brain) and images captured using a Kodak In-Vivo Multispectral FX image 
station (Excitation: 550nm; Emission: 600nm; Exposure 1 sec; f-stop 2.8). Subsequently 
blood samples were analysed using a LSR-Fortessa™ flow cytometer (BD Biosciences) 
with fluorescent beads detected on the blue channel (B695/40) by a 1 minute sample 
collection on low flow rate setting. Multiphoton imaging was performed using a Zeiss 
LSM7 MP with Coherent Chameleon Ti:Sa laser.  
 
2.7 Immunohistochemistry 
Three µm sections of formalin-fixed tissue were used for immunostains. Ki67, BRDU, pan 
cytokeratin and CYPD2 required heat mediated antigen retrieval with 0.01M sodium 
                                                             
xviii Give n t he degree  of  t issue  loss wa s much le ss that  t ha t following pa rt ia l he pate ct omy (a pprox. 
70% fol lowing pa rt ia l he pate ct omy versus 10 -20% following paraceta mol  int oxicat ion) I  increa sed 
dose  of f luore sce nt be a ds a dminist ere d  in t he  parace ta mol  mode l .  
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citrate pH 6.0 for 10 minutes. Primary antibodies were used at the following dilutions: 
Ki67 (Leica) 1:500, BRDU (Abcam) 1:100, F4/80 (clone CI:A3-I, Biolegend) 1:100, CYPD2 
(Abcam) 1:100. Appropriate secondary antibody was applied at a 1:250 dilution. Dual 
immunohistochemistry with F4/80 and BRDU or Ki67 was performed by first developing 
F4/80 using the Tyramide signal amplification system (PerkinElmer®) with subsequent 
heat mediated antigen retrieval followed by BRDU or Ki67 staining. Ki67 and F4/80 dual 
immunohistochemistry was also performed by developing F4/80 with an alkaline 
phosphatase substrate kit (red, Vector) and following heat mediated antigen retrieval 
Ki67 was developed with 3,30-diaminobenzidine (Dako) then counterstained with 
Harris’ hematoxylin. Stained slides were blinded and images taken on the Nikon Eclipse 
E600. For image quantification of F4/80 staining 20 non overlapping images were 
photographed at x200. The extent of DAB staining quantified using image analysis 
software (Adobe Photoshop CS6). For CYPD2 quantification images were quantified 
using image analysis software (Adobe Photoshop CS6). For Ki67 quantification 20 serial 
non overlapping images were photographed at x400 then hepatocytes identified by 
assessment of morphology. 
 
2.8 Flow cytometry 
Liver was digested in 2mg/ml collagenase D (Sigma Aldrich) at 37degC for 30minutes 
then passed through a 100μm filter. 7 minute 50G spin to remove hepatocytes. Further 
purification of nonparenchyaml cells using 30% percoll® (Sigma) gradient. Cell stained 
with fixable viability dye eFluor 780® then incubated with Fc block (TrustainfcX™, 
Biolegend) prior to staining with CD45 (clone:30F11, AF700, Biolegend), F4/80 
(clone:BM8, PECy7, Biolegend), CD11b (clone:RM208, FITC, Invitrogen), Ly6C 
(clone:HK1.4, PerCP/Cy5.5, Biolegend), dump gate (PE: CD3 (clone:17A2, PE, Biolegend, 
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CD19 (clone:6D5, PE, Biolegend), Siglec F (clone:E502440, PE, BD Biosciences), Ly6G 
(clone:IA8,PE, BD Biosciences). For proliferation assay cells were fixed and permeablised 
using BD Pharminogen BRDU flow kit then stained with antiBRDU (FITC, BD 
Pharminogen) and Ki67 (eF660, eBioscience). Flow cytometry performed using the LSR 
Fortessa. Gating strategies for cellular populations are shown in Appendix 2, (p233) and 
Appendix 3, (p233). 
 
2.9 Quantification of Messenger RNA (mRNA) Levels by 
Real-Time Reverse-Transcription Polymerase Chain 
Reaction 
RNA extraction kits (Qiagen) were used to extract RNA from whole tissue. cDNA was 
generated from 1 µg of RNA using the Quantitect reverse transcription kit. Predesigned 
validated primer sets for MARCO (macrophage receptor with collagenous structure), 
MSR1 (macrophage scavenging receptor 1), MR (mannose receptor), Il6, OSM 
(oncostatin M), TNF (tumour necrosis factor), IFNg (interferon gamma), Il10 and GAPDH 
were purchased from Qiagen (Qiagen Quantitect Primers). Quantitative real-time PCR 
was performed using Express SYBR Green (Qiagen, UK). Gene expression was calculated 
relative to GAPDH for each sample. Values are shown relative to the mean of the control 
group, which served as the comparator. Gene array at 6 hours following CSF1-Fc 
administration was performed using Cytokine and Chemokine array RT2 Profiler PCR 
arrays and analysed using the online RT2 profiler PCR Array Data Analysis (Version 3.5, 
Qiagen, UK) and presented by Volcano plot. Affymetrix Mouse gene 1.1 ST Array data 
were accessed from the Gene Expression Omnibus website and analysed using GEO2R.  
To take into account the false discovery rate due to multiple comparisons, the Benjamini 
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& Hochberg (False discovery rate) correction was applied to gene data series.  The gene 
array data is provided in Appendix 1, (p231). 
 
2.10 Serum Analyses 
Serum biochemistry assays were performed using commercially available kits by a 
biochemist, including alanine aminotransferase (ALT; Alpha Laboratories), alkaline 
phosphatase (Alk phos; Roche Diagnostics), total bilirubin (bili; Alpha Laboratories Ltd), 
albumin (Alb; Alpha Laboratories). Serum cytokines and chemokines were analysed 
using MILLIPLEX® mouse cytokine/chemokine array (Merck-Millipore). All 
cytokine/chemokine assays were completed in collaboration with a Merck-Millipore 
biomarker specialist. Results are presented relative to the mean of the control group. 
Cytokines/chemokines above background signal are shown in the histograms. 
Cytokines/chemokines below background signal are listed below histograms. 
 
2.11 Human Work 
Ethical approval was obtained from the South East Scotland Research Ethics Committee 
(2) for examination of patient records and for collection of patient serum pre and post 
partial hepatectomy undertaken at the Hepatobililary Unit, Royal Infirmary of Edinburgh 
between December 2012 and October 2013. Serum samples were blinded and cytokine 
analysis completed in a random order. In the partial hepatectomy cohort liver failure was 
defined according to Schindl et al.2. For the acute liver failure cohort ethical approval was 
granted by the local human research ethics committee and informed consent was 
obtained from all patients, or the patient’s next of kin, before entry into the study. This 
study builds on previous analysis of this patient cohort by Antoine et al.97 and represents 
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84 adult patients admitted to the Royal Infirmary Edinburgh, UK or the University of 
Kansas Medical Centre, USA with acute liver injury. Serial patient samples were based on 
a second patient cohort where samples were collected from admission to hospital (as 
opposed to admission to the specialist liver centre with acute liver failure) some of these 
patients have been included in analyses previously but again serum CSF1 level had not 
previously been assessed97. Patients were grouped according to outcome, into those with 
acute liver failure who survived and those who required liver transplantation or died. 
Serum CSF1 was analysed using the Meso Scale Discovery® CSF1 immunoassay and 
analysed on a Meso QuickPlex SQ120. Serum acetyl-HMGB1 was previously analysed by 
mass spectrometry and this was not repeated97. 
 
2.12 Statistics 
Statistical analysis was performed on Graphpad Prism V6.0, except logistic regression 
analyses which were conducted in R169 by a qualified statistician. All data are presented 
as mean +/- standard error of the mean unless otherwise stated. Two tailed Student’s t 
test are used where appropriate to analyse parametric data. Mann-Whitney test was 
used for non-parametric data. One-way and Two way ANOVA with Bonferroni 
adjustment for multiple hypothesis testing are stated when used.  Kruskal-Wallis test 
was used to test non-parametric data involving greater than two groups. 
 
Benjamini & Hochberg (False discovery rate) correction was used in analysis of array 
data. Biomarker analysis and development of the logistic regression models was 
completed by a qualified statistician. All data were blinded prior to analysis. Data were 
first plotted irrespective of outcome. While CSF1 showed an appropriate range, many of 
the acetyl-HMGB1 values were grouped around zero, which leads to difficulty in creating 
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a combined model. Therefore a logarithmic transformation was performed on the acetyl-
HMGB1 variable. Preceding with the logarithmic transformation, a high correlation 
between CSF1 and acetyl-HMGB1 was seen. Using logistic regression to build a model, 
the individual models for CSF1 and acetyl-HMGB1 were first calculated. The models were 
then combined (glm(formula=outcome~log(acetyl-HMGB1)+CSF1, family = “binomial”, 
data=data). Comparison of the combined model and the CSF1 model alone was 
performed by analysis of deviance of the dual model versus the singular model. Level of 
significance was set at p<0.05 for all analyses. 
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The human liver is a solid organ which can be divided into right, left, quadrate and 
caudate lobes. However a more clinically relevant segmentation is based on the portal 
blood supply to the liver originally described by Couinaud in 1957 (Figure 3.1a). Liver 
surgery is planned according to this segmentation to facilitate tumour removal and 
minimise damage to remaining tissue.  
 
The murine liver is lobulated, including the left, median, right and caudate lobe (Figure 
3.1b) which facilitates surgical removal of liver segments, and subsequent study of the 
regenerative process. The availability of genetically manipulated mice means this species 
offers an ideal model to study regenerative processes.   
 
This sections describes the development of the techniques and procedures that I have 
used for this project. 
 
  
Chapter 3. Developing mouse models of liver 
regeneration 
Manipulating macrophages to enhance liver regeneration 
62 




Figure 3.1: Schematic demonstrating the human and mouse liver divided into segments 
and lobes respectively 
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3.1 Partial hepatectomy 
Aims   
1. Become proficient with 2/3 hepatectomy in mice and optimise operative procedures  
2. Characterise baseline regenerative parameters following 2/3 hepatectomy  




I performed 2/3 PH on C57Bl6 mice at time points from 1 day to 7 days to assess change 
in liver weight to body weight ratio change and hepatocyte proliferation (n=8 per time 
point). The procedure was well tolerated with no mortality. As has previously been well 
described I found that liver regeneration following 2/3 hepatectomy in mice is rapid. 
Figure 3.2 shows the regenerative response to 2/3 hepatectomy with liver weight to 
body weight ratio approaching that of a normal mouse by day 7. Hepatocyte proliferation 
peaked at day 2 as assessed by Ki67(a nuclear protein associated with proliferation) 
immunohistochemistry. 
 
I then analysed hepatic macrophage number and following partial hepatectomy, as 
identified by F4/80 positive cells, at time points from 1 hour to 7 days following surgery 
(n=4 per group). Figure 3.3 shows an increase in hepatic macrophage numbers following 
partial hepatectomy. There is also evidence of macrophage proliferation based on dual 
Ki67 and F4/80 immunohistochemistry which is reduced as a percentage during the 
early stages following partial hepatectomy.  
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Figure 3.2: Hepatic dynamics following partial hepatectomy.  
a) Schematic showing resected lobes in PH. b) Liver weight to body weight ratio 
following PH (n=8 per timepoint). c) Hepatocyte proliferation following PH based on 
number of Ki67 positive hepatocytes per high powered field (n=8 per timepoint). One 
way ANOVA shows Day 2 significantly elevated hepatocyte Ki67 expression compared to 
other time points (no signif diff between Day 1, 2, 7 and no surg). d) Indicative Ki67 
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Figure 3.3: Hepatic macrophage numbers following partial hepatectomy.  
a) Number of F4/80 positive macrophages per high powered field following PH (n=4 per 
timepoint; Kruskal-Wallis test; Dunn’s test for multiple comparisons; *p<0.05 . b) 
Percentage Ki67 positive macrophages per HPF following PH (n=4 per timepoint; 
Kruskal-Wallis test; Dunn’s test for multiple comparisons; *p<0.05). c) Indicative 
immunohistochemistry for F4/80 (pink) and Ki67 (brown) following PH. Arrows 
indicate dual positive cells.  
 
  
a b c 
Pre PH 
Day 7 post PH 
F4/80 Ki67 
Manipulating macrophages to enhance liver regeneration 
66 
Developing mouse models of liver regeneration 
Discussion 
The main non-parenchymal cells of the liver include tissue resident macropahges, 
stellate cells and sinusoidal endothelial cells. A range of other cells including T cells, 
natural killer cells and neutrophils have also been identified in the regenerating liver. 
Hepatic macrophages, neutrophils and stellate cells are thought to have a role in the 
matrix remodelling process through the production of matrix metalloproteinases. In 
addition to hepatocyte proliferation macrophages were also seen to proliferate following 
PH. Evidence of mitotic bodies in macrophages post-PH has previously been reported 
and this is confirmed here by the coexpression of F4/80 and Ki67. It was previously 
thought that in situ macrophage proliferation accounted for the increase in number of 
macrophages noted within the liver following PH but this has been questioned by more 
recent studies suggesting that infiltration of macrophages are important for effective 
hepatocyte proliferation28,131. However, these have been indirect assessments and the 
existence or role of these two populations remains uncertain. The importance of 
infiltrating macrophages in liver regeneration would support the idea of therapeutic 
macrophage administration in the context of PH.  
 
Conclusion 
Consistent with the literature I have shown that partial hepatectomy results in a rapid 
restoration of volume through hepatocyte proliferation and there is evidence to support 
an early infiltration of macrophages.  
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3.2 Partial hepatectomy and chronic liver injury 
Aims    
1. Establish a model of 2/3 hepatectomy on a background of hepatic fibrosis caused by 
chronic liver injury 
2. Develop a model that demonstrates maximal fibrosis, feasibility and low mortality 
 
Rationale for approach to fibrosis induction 
Carbon tetrachloride (CCl4) was selected to induce chronic liver injury. The resulting 
fibrosis shows a similar pattern to that seen in human disease and this model of chronic 
liver injury has previously been well characterised170. The use of CCl4 to induce injury 
plus partial hepatectomy in rodents has previously been reported61,99,171 . These other 
groups have used the enteral route, which avoids issues with adhesions caused by 
intraperitoneal injection (scar tissue forming within the intra-abdominal cavity)172. 
However this route was not sanctioned by the regional Home Office Inspector. The 
intraperitoneal route was therefore the only available option (subcutaneous 
administration leads to variable results). In reviewing the literature, the greatest fibrotic 
response was in a mouse model of CCl4 gavage 3 times per week. However this frequency 
of IP injection was thought to risk greater potential adhesion formation and increase risk 
of complications from IP injection. Therefore the strategy of twice weekly injections was 
decided upon. A time period of 8 weeks was chosen as the length of fibrosis induction 
based on previous studies, balancing consistency of fibrosis with financial cost of a 
lengthier model. To modulate degree of fibrosis and achieve a workable model of 
hepatectomy, three different doses of carbon tetrachloride were selected following 
literature review and discussion with this and other groups working in the liver fibrosis 
field. These doses were 2mcl/g, 1mcl/g and 0.5mcl/g of CCl4 per gram mouse weight in 
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a 1:3 mixture CCl4: low acidity olive oil [supplied Sigma-Aldrich]). These doses were 
based on literature review and discussion with researchers who have experience of this 
model.  
 
Assessment of fibrosis induction regimen 
C57Bl/6 mice were weighed prior to each injection and trends in weight loss monitored. 
If weight loss of over 20% occurred, mice were closely monitored and if weight regain 
did not occur or the condition of the mouse was deemed to have reached the severity 
limits of the experiment, the mouse was removed from the protocol and culled. Sirius red 
stain was used to indicate collagen deposition in the fibrotic liver. Image quantification 
was then performed using Adobe Photoshop (CS5).  
 
Partial hepatectomy following carbon tetrachloride 
I performed partial hepatectomy 72 hours following the last IP injection of carbon 
tetrachloride as this is the time point of maximal fibrosis following CCl4 injection158. In 
addition, at this time point the acute effects of carbon tetrachloride administration are 
limited, potentially increasing the clinical relevance of this model of fibrosis. Age-
matched control mice also underwent PH as previously described (termed 
“Hepatectomy control”). Further control mice underwent the fibrosis induction regimen 
but did not undergo PH (termed “Fibrosis control”). 
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Results 
I selected three doses of carbon tetrachloride to induce fibrosis 0.5mcl/g, 1mcl/g and 
2mcl/g. 2mcl/g CCl4 resulted in rapid weight loss and deterioration in mouse condition 
such that nearly 20% of mice were either removed from the protocol and were culled or 
died early on in the protocol. This dosing regimen was therefore terminated. 1mcl/g was 
generally well tolerated and resulted in a greater degree of fibrosis in comparison with 
the lower dose of 0.5mcl/g. Mouse body weight, Kaplein Meir plot of survival and fibrosis 
quantification are shown in Figure 3.4. 
 
I performed partial hepatectomy 3 days following the final dose of carbon tetrachloride.  
Level of fibrosis reduced rapidly following partial hepatectomy. Interestingly there was 
no significant difference in level of fibrosis at Day 4 between the higher and lower dose 
of CCl4 (M-W U 150.0 p=0.12) despite the significantly greater fibrosis at Day 0 (M-W U= 
5.0 p=<0.0001) (Figure 3.5).  Rate of fibrosis resolution was more rapid following partial 
hepatectomy than sham surgery (Figure 3.6). Similar increased rate of fibrosis resolution 
has previously been shown in rats61. 
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Figure 3.4: Fibrosis induction regimen.  
Mouse body weight and Kaplein Meir plot of survival during the 8 week fibrosis 
induction regime with twice weekly intraperitoneal injection of carbontetrachloride at 
three doses (0.5mcl/g, n=8; 1mcl/g, n=22; 2mcl/g, n=24). Mouse body weight was taken 
prior to each injection and the weights expressed relative to the body weight prior to 
starting the experiment (normalised weight). 
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Figure 3.5: CCl4 dose comparison following partial hepatectomy.  
Fibrosis quantification via sirius red analysis with representative siruis red staining. 2-
way ANOVA showing significant difference between high dose and low dose CC4 at Day 
0 and no significant difference between Day 4 values.  
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Figure 3.6: Comparison in fibrosis resolution between mice undergoing partial 
hepatectomy and mice undergoing sham surgery.  
Fibrosis quantification via sirius red analysis with representative siruis red staining 
(n>/=4 per timepoint). Two-way ANOVA with Bonferroni post hoc showing significant 
difference between PH + fibrosis (solid line) and sham surgery + fibrosis (dotted line) at 
day 4 and day 7 postoperatively.  
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I found that liver weight to body weight ratio was higher in CCl4 treated mice compared 
to uninjured mice at time 0 (i.e. immediately following partial hepatectomy) (Figure 3.7).  
Rate of liver growth following partial hepatectomy was greater in the uninjured mice 
compared to those with previous CCl4 induced chronic liver injury (Figure 3.7). 
Hepatocyte proliferation was significantly reduced following hepatectomy in fibrotic 
mice compared to age matched controls who did not undergo the fibrosis induction 
regimen at time points from day 2 to day 7 (p<0.001) (Figure 3.8).  
 
Liver progenitor cells were identified by morphological assessment following 
immunohistochemistry for pan cytokeratin (pan CK) (Figure 3.9). Previously termed 
oval cells, liver progenitor cells show potential for differentiation into either biliary cells 
or hepatocytes and stain positive for panCK. As biliary cells also stain positive for panCK 
morphological assessment was necessary to exclude ductular structures.  Following 8 
weeks CCl4 injury hepatic progenitor cells (PanCK positive) were evident. The number 
of these cells fell following partial hepatectomy at a similar rate to that following sham 
surgery (Figure 3.10). 
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Figure 3.7: Liver weight to body weight ratio following partial hepatectomy with or 
without CCl4 pretreatment 
a) Liver weight to body weight ratio following partial hepatectomy preceded by 8 weeks 
1mcl/g carbon tetrachloride via intraperitoneal injection versus no CCl4 pretreatment 
age matched controls (n>/=4 per group; two-way ANOVA with Bonferroni test). b) Liver 
weight to body weight ratio relative to liver remnant weight at day 0 comparing CCl4 
pretreated and age matched controls (n>/=4 per group; two-way ANOVA with 
Bonferroni test). (*p<0.05; ***p<0.001, ****p<0.0001) 
  
a b 
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Figure 3.8 Hepatocyte proliferation following partial hepatectomy with or without 
carbon tetrachloride pretreatment  
a) Comparison between hepatocyte Ki67 expression following PH with CCl4 
pretreatment and PH hepatectomy only in age matched controls (n=4 per group; 
comparison with 2-way ANOVA). b) Number of Ki67 positive hepatocytes per 200x field 
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Figure 3.9 Hepatic progenitor cells following chronic liver injury.  
a) Pan CK immunohistochemistry (biliary and progenitor cell marker) in the normal age 
matched control liver and following 8 weeks 1mcl/g CCl4 twice weekly intraperitoneal 
injection. b) High powered view of haematoxylin and eosin stain showing oval cells 
(equivalent to hepatic progenitor cells) and pan CK staining 
a 
b 
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Figure 3.10 Hepatic progenitor cells following partial hepatectomy.  
Comparison of hepatic progenitor cell numbers (defined as PanCK positive cells outwith 
a ductular structure) per high powered field in mice undergoing partial hepatectomy 
following CCl4 injury and mice who underwent CCl4 injury and sham surgery (two way 
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Discussion 
It is well recognised that regeneration of the fibrotic liver is impaired following partial 
hepatectomy, and this was demonstrated here in this mouse model of intra-peritoneal 
carbon tetrachloride and partial hepatectomy.  Interestingly the pattern of hepatocyte 
proliferation was similar to that of normal liver regeneration (i.e. peak proliferation at 
day 2 following partial hepatectomy). I had anticipated that the requirement for greater 
hepatocyte proliferation following chronic injury would have resulted in increased 
hepatocyte proliferation at later time points. However this was not the case and rate of 
proliferation fell in line with partial hepatectomy of the uninjured liver. 
 
The fibrotic livers were larger than uninjured livers relative to body weight ratio which 
may then have affected requirement for hepatocyte proliferation. In the human the 
cirrhotic liver is typically densely fibrotic and shrunken. While the carbon tetrachloride 
model was able to induce marked fibrosis, it did not result in the shrunken liver seen in 
humans. Modelling the lengthy fibrosis seen in humans, which occurs following decades 
of chronic injury, is clearly difficult to replicate in young mice over a limited period of 
time.  
 
I found that fibrosis resolution was more rapid following partial hepatectomy than 
following sham surgery. This supports work by Suarez-Cuenca et al., who demonstrated 
that following partial hepatectomy with chronic liver injury matrix remodelling is 
markedly upregulated associated with increased collagenase activity61 
 
I considered whether hepatic progenitor cells might contribute to regeneration following 
partial hepatectomy and chronic liver injury. Espanol-Suner et al. recently showed that 
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following chronic liver injury induced by a dietary liver injury model (choline-deficient 
diet) liver progenitor cells were able to differentiate into hepatocytes173. In this model, 
following injury induction, 0.78% of hepatocytes were shown to be derived from 
progenitor cells.  Two weeks following cessation of injury this had increased to 2.45% of 
the hepatocyte population. Following a 4 week carbon tetrachloride model there was no 
contribution to regeneration from progenitor cells and this was also the case following 
partial hepatectomy. In my model of partial hepatectomy and chronic liver injury I found 
that chronic liver injury induced a progenitor cell response. At time points up to 7 days 
following partial hepatectomy on a background of chronic liver injury and sham surgery 
there was a reduction in number of progenitor cells. Lineage tracing experiments would 
be required to test if these cells are differentiating into hepatocytes.  
 
The fact that chronic injury appeared to elicit a progenitor response, which was not seen 
following partial hepatectomy, it might be speculated that progenitor cell activation does 
not provide a significant contribution to regeneration in this setting. However, my work 
contrasts with that of others. Kuramitsu et al., found that liver progenitor cell number 
increased following partial hepatectomy on a background of chronic liver injury174. This 
group then tested the effects of blockade of progenitor cell proliferation via blockade of 
the progenitor mitogen TWEAK (tumour necrosis factor-like weak inducer of apoptosis) 
using a neutralising antibody. Rather than impair regeneration, this progenitor cell 
targeted intervention actually augmented liver regeneration in their modelxix. There is 
evidence that liver progenitor cells can differentiate into hepatocytes and these cells 
could contribute to hepatic regeneration following liver regeneration, although further 
work is required to assess how best this system can be manipulated. 
                                                             
xix The  model  of  l iver  f ibrosis  a nd partial  he pate ctomy use d by Kura mit su et  a l .  (2013),  involve d 6 
wee ks of  t hree t ime s we ekly ga va ge  of  ca rbon tet rachlor ide .   
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Given the limitations of the carbon tetrachloride model I trialled thioacetamidexx in the 
drinking water as an alternative form of chronic injury (see section “Thioacetamide”, 
p19). I trialled lengths of administration of up to 18 weeks. A small number of mice did 
display marked macroscopic fibrosis and a shrunken liver at 18 weeks however this was 
not consistent. On the basis of this pilot study I decided not to attempt to optimise this 
further given both time and cost limitations. I decided to focus instead on the carbon 
tetrachloride method of chronic injury and accept its limitations.  
 
Conclusion 
Partial hepatectomy with chronic injury is feasible. However it is limited by the 
requirement for repeated intraperitoneal injection, which can cause adhesions, and the 







                                                             
xx Thioacetamide is a organosulphur compoung which is known to induce hepatotoxicity 
in mice and has been used in chronic model of liver injury by addition to drinking water. 
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3.3 Acute toxic liver injury 
Aims 
1. Use a reliable model acute liver injury in mice directly relevant to humans. 
 
Selecting the appropriate model 
Paracetamol to induce acute liver injury in mice has been used widely as a model of acute 
toxic liver injury. This has direct clinical relevance as paracetamol intoxication is the 
leading cause of acute liver failure in UK (see Acute liver injury, p6). The response to 
paracetamol is dependent on a range of factors, including strain of mouse or rat, length 
of time fasting and dose of paracetamol48. After review of the literature I opted for a 
fasted mouse model with a dose of 350mg/kg of paracetamol48,168. This model resulted 
in a considerable degree of liver injury with minimal mortality. At higher doses mortality 
rates can reach 50% and death occurs rapidly168. 
 
Results 
In characterising this model I found that 350mg/kg paracetamol resulted in a 
considerable degree of injury and no mortality. Figure 3.11 provides an overview of 
serum alanine transaminase (ALT)xxi rise following paracetamol intoxication and also 
representative histology of liver sections at corresponding time points. Based on these 
initial sections I developed a method for analysing areas of necrosis in the H&E sections, 
which is shown in Figure 3.12. 
                                                             
xxi Alanine transaminase (ALT) is an enzyme found in hepatocyte, but also other cells 
such as muscle. It is released following hepatocellular injury and is a clinically accepted 
marker of liver injury.   
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Figure 3.11: Overview of paracetamol intoxication model.  
a) Serum ALT following paracetamol intoxication (n>4/group). b) Indicative 
haematoxylin and eosin histology at time points corresponding with serum ALT level in 
A. Figure shows x200 image 24 hours following intoxication (right side) and then close 
up image centred on the hepatic veins (zone 3) at 24 hours, 48 hours and 96hours 
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Figure 3.12: Quantification of necrotic area in mice following paracetamol intoxication 
Black= perimeter of necrosis; red= hepatic vein; green=portal tracts; blue = total area 
Formula for % necrosis=  
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In considering translation of a proposed therapy to the clinic, assessing translational 
measures of regeneration is important. Assessment of regeneration following PH can 
involve functional, proliferative, and volumetric parameters. In the preclinical setting, 
liver weight provides a measure analogous to liver volume assessed by CT scanning in 
the clinical setting. However size does not necessarily relate to function especially with 
background chronic liver injury. Effective functional assays are highly desirable. 
 
4.1 Hepatocyte function 
Background 
Two main techniques have been used to measure dynamic hepatic function, centred on 
compounds which are eliminated exclusively by hepatocytes. These include mebrofenin, 
a radio isotope detected by hepatobiliary scintigraphy, and indocyanine green, a 
fluorescent cyanine dye175.  
 
Both mebrofenin and ICG rely on similar transporter systems for uptake into 
hepatocytes. Mebrofenin uptake utilises the organic anion transporter polypeptide 
(OATP) family (OATP1B1and OATP1B3) while ICG utilises OATP1B3 and the Na+-
taurocholate cotransporting polypeptide (NTCP) transporter for uptake into hepatocyte 
and passage into the bile176. 
 
 
Chapter 4. Functional assessment of liver 
regeneration 
Manipulating macrophages to enhance liver regeneration 
85 
Functional assessment of liver regeneration 
Hepatobiliary scintigraphy (HBS) involves the administration of radioisotopes which are 
taken up by hepatocytes and excreted in the bile enabling imaging of the hepatobiliary 
system using gamma cameras to create two-dimensional images. Given the tissue 
penetrance of this technique it is possible to image uptake by the liver in vivo. HBS can 
provide both a volumetric and functional assessment of regeneration noninvasively, 
which has been validated in rodent models, showing promise for clinical 
investigation177,178.  
 
Indocyanine green has already been used extensively in clinical practice for a range of 
applications including as an indicator of hepatic function and for assessment of blood 
flow. The tissue penetrance of fluorescence is far inferior to gamma imaging and so 
assessment of ICG clearance in humans relies upon fluorescent quantification of blood 
samples or quantification in the peripheral circulation via pulse spectrophotometry 
following ICG injection. In some centres ICG clearance is routinely performed to assess 
patient’s suitability for surgery based on liver function179. ICG has been criticised for this 
application based on its dependency on hepatic blood flow. However as liver dysfunction 
increases, functional hepatocyte mass can become a major limiting factor, with ICG 
retention rate directly related to postoperative outcome180. 
 
 
While HBS can provide an effective non-invasive measure of liver regeneration the 
involvement of radioisotopes limits its application. Indocyanine green clearance can be 
performed in the clinical setting by repeat blood sampling (and subsequent near infrared 
spectroscopy) or by a noninvasive digital pulse densitometry device181. However in the 
preclinical setting repeat blood sampling can significantly deplete intravascular volume 
of small rodents and noninvasive digital pulse densitometry devices are too large for use 
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in these small animals. Recent advances in imaging technology have enabled fluorescent 
imaging of whole animals under anaesthesia to be undertaken. ICG is excited and emitted 
in the far-red part of the spectrum (absorbance: 600nm-900nm; emittance: 750-950) 
which shows much better tissue penetrance than lower wavelengths, so enabling in vivo 
imaging applications182.  
 
In vivo fluorescent imaging could provide a novel method to assess ICG clearance in 






Manipulating macrophages to enhance liver regeneration 
87 
Functional assessment of liver regeneration 
Results 
Following injection of indocyanine green, the liver region is clearly identified using the 
fluorescent imaging system and ICG can be seen to pass into the gut (Figure 4.1).  
 
I selected regions of interest over the hind paws to enable assessment of indocyanine 
green clearance over time. 1mg/kg ICG administered intravenously is rapidly cleared in 
both the normal mouse and following partial hepatectomy (Figure 4.2). Dose 
optimisation showed that with increasing concentration of ICG, clearance rate varies 
considerably, such that at 10mg/kg no clearance phase is seen (Figure 4.3). Following 
this dose optimisation 2.5mg/kg was selected for further assessment as the system 
appeared saturated with both 5mg/kg and 10mg/kg. This dose was administered to mice 
following PH or sham procedure showing no significant difference between mice 1/3 
hepatectomy and sham but a significantly delayed clearance with 2/3 PH (Figure 4.4). 
 
In C57Bl6 mice (black skin pigment) the liver region is not visible as the fluorescence is 
absorbed by skin pigment. However using Balb/c (white) mice a region of interest can 
be placed over the liver region to assess change in fluorescent signal over time (Figure 
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Figure 4.1: In vivo fluorescence following indocyanine green injection 
 a)         Fluorescent image of the Balb/c mouse before and 15 minute following 
indocyanine green injection. b) Ex vivo viscera demonstrating ICG uptake by liver and 
passage into gut 15 minutes following ICG injection.  
 
a b 
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Figure 4.2: Fluorescent intensity following indocyanine green in the C57Bl/6 mouse 
a) Representative fluorescent image following ICG administration. Immediately 
following injection, at 5 minutes and 10 minutes. b) Fluorescent intensity following ICG 
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Figure 4.3. Indocyanine green dose comparison following partial hepatectomy 
ICG clearance assessed immediately following partial hepatectomy, n=2/group 
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Figure 4.4: Effect of extent of partial hepatectomy (1/3, 2/3 or sham) on ICG clearance 
(2.5mg/kg) in C57Bl/6 mice. 
a) Peripheral disappearance of indocyanine green immediately following 2/3 PH, 1/3 PH 
or sham (n=3/group, mean +/- std error). b) 5 minute peripheral disappearance rate ICG. 
Clearance rate significantly reduced following 2/3 PH compared to 1/3 PH or sham 
(n=3/group, mean +/- std error, one-way ANOVA with Bonferroni post hoc). 
 
a b **** 
**** 
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Figure 4.5: Fluorescent intensity following indocyanine green in the Balb/c mouse 
a) Representative fluorescent image following ICG administration to Balb/c mouse. 
Immediately following injection, at 5 minutes and 10 minutes. Blue rectangles show 
regions of interest over liver region, left and right hind paws. b) Fluorescent intensity 
following ICG administration according to region of interest placed over left and right 
paw. c) Fluorescent intensity over liver region of interest corrected according to 
fluorescent signal in lower abdomen (region of interest in lower abdomen subtracted 
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Discussion 
In this experiment I have demonstrated that indocyanine green clearance can be 
assessed using fluorescence imaging in mice in vivo. This novel, non-invasive procedure 
could be performed at repeat time points enabling serial assessment of regeneration in 
the same animal.  
 
The dose of indocyanine green seems crucial to optimise its discriminative capacity, with 
a low dose cleared rapidly even with considerable tissue loss. Finding a dose near the 
saturating level may be key to differentiating between degrees of liver injury. In the 
clinical setting a dose of 0.5mg/kg is well established to discriminate the most severe 
forms of chronic liver disease and is used to assess eligibility for liver surgery179,183. It 
may be that a higher dose of indocyanine green would aid discrimination between 
patients with less severe degrees of liver injury. This measure could potentially form a 
clinical trial outcome measure, given assessment of liver function in the clinical setting 
is currently limited. The current low dose that is used for preoperative assessment is 
unlikely to be beneficial in the trial setting as only severe deficiencies could be noted.  
 
Conclusion  
Indocyanine green clearance can be measured via in vivo fluorescent imaging, which may 
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4.2 Assessment of hepatic phagocytic function 
Background 
Following acute liver injury or major hepatic resection in humans, hepatic innate 
immune capacity is markedly reduced, with sepsis complicating acute liver failure in 
over 30% of cases64,76,77. Hepatic macrophages are crucial for innate immune integrity 
and are necessary for effective hepatocyte proliferation during regeneration. Indeed the 
innate immune system plays a critical role in liver regeneration as macrophages are 
required to phagocytose necrotic liver tissue and pathogens. I therefore wanted to 
develop a technique to assess hepatic phagocytic capacity in mice. 
 
In humans, clearance of radiolabelled albumin microspheres has been used to 
demonstrate impaired hepatic phagocytic capacity following acute liver injury and also 
following partial hepatectomy76,77. However this technique was not feasible in the local 
animal facility given safety issues and site licences required for working with radioactive 
agents. Given the experience I developed with fluorescence imaging I investigated 
whether there was a fluorescent imaging approach which could be used to assess hepatic 
phagocytic capacity.   
 
Aims 
1. Develop an assessment method for hepatic phagocytic capacity.  
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Results 
I found that following injection of fluorescent latex microbeads into the inferior vena 
cava there was rapid uptake by the liver as evidenced by hepatic fluorescent signal 
(Figure 4.6a). Uptake by hepatic phagocytes was rapid, with marked hepatic 
fluorescence detected just one minute following injection. There was minimal uptake of 
fluorescent beads by phagocytes in the spleen, lung, kidney or brain. 
 
Multiphoton imaging of the exvivo liver from the MacGreen mouse one minute following 
bead injection showed that there was considerable phagocytosis by hepatic 
macrophages (Figure 4.6b).   
 
By performing flow cytometry of the blood I was able to assess whether phagocytic 
cellular populations in the blood also took up fluorescent beads following injection. 
While there were some beads within gated cellular populations, overall this was minimal 
and over a period of 15 minutes, as beads were removed from the circulation, this did 
not increase (Figure 4.7).  
 
By performing flow cytometry of blood sampled at timepoints following injection of 
fluorescent microbeads I have shown that fluorescent bead clearance is markedly 
impaired following partial hepatectomy (Figure 4.8).   
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Figure 4.6: Assessment of hepatic phagocytic capacity 
a) Assessment of fluorescent signal in ex vivo organs following injection of fluorescent 
microbeads into the inferior vena cava. Organs were flushed and removed 1 minute 
following bead injection. b) Multiphoton image of exvivo liver MacGreen mouse 1 minute 
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Figure 4.7: Assessment of the blood cellular population following fluorescent bead 
injection. (PTO for details)  
a 
b 
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Representative flow plots of blood sampled from the inferior vena cava at 1 minute (a) 
and 15 minutes (b) following injection of fluorescent microbeads into the circulation. 
Gating strategies including total fluorescent bead count (“Total beads”) and bead count 
within blood cellular populations (“Cells+beads”). 
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Figure 4.8: Fluorescent bead clearance following partial hepatectomy or sham surgery 
Fluorescent bead clearance assessed by flow cytometry of blood samples at Day 2 
following 2/3 partial hepatectomy and sham surgery with injection of fluorescent 
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Discussion 
I have shown that by using a combination of flow cytometry of blood samples to identify 
fluorescent bead clearance from the circulation and also ex vivo fluorescent imaging of 
viscera to indicate fluorescent bead uptake, I am able to assess hepatic phagocytic 
capacity. 
 
It is interesting to note that although the spleen is recognised as possessing considerable 
phagocytic capacity there is minimal uptake at the one minute timepoint following 
injection. On the other hand the liver shows marked phagocytic capacity with rapid 
uptake of fluorescent beads by hepatic macrophages. This discrepancy is discussed in 
more detail in the section “6.4 Focus on the spleen”, p147. 
 
Some fluorescent microbeads were taken up by circulating cellular populations although 
this was minimal. A fluorescent bead technique has been used by others to label 
monocyte populations in vivo to study their subsequent trafficking184. In this study the 
number of labelled circulating cells decreases at later time points rather than increases, 
suggesting that these cells are being cleared from the circulation. Based on the ex vivo 
fluorescent imaging I would hypothesise that these cells are being cleared by the liver. 
This is not an angle that I have explored further.  
 
Conclusion 
Phagocytic capacity can be assessed in vivo by injection of fluorescent microbeads and 
subsequent assessment of bead clearance by flow cytometry and quantification of 
fluorescent signal via ex vivo fluorescent imaging. 
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Aims 
1. Optimise administration of macrophages to mice following chronic liver injury and 
partial hepatectomy 
2. Trial macrophage administration to mice following chronic liver injury and partial 
hepatectomy.  
 
5.1 Macrophage generation and limitations 
I followed protocols used extensively by my supervisor’s laboratory to generate 
macrophages derived from mouse bone marrow by culture in L929 conditioned media 
(see Materials and Methods section, “Macrophage generation for direct administration”, 
p52). Following these protocols I generated cells that were consistent with the purity 
generated by previous researchers in the laboratory (Figure 5.1a). I found that 
approximately 90% of cells were positive for the macrophage marker F4/80 following 7 
days culture (Figure 5.1). Cells also highly expressed CDllb (indicative of myeloid 
lineage), showed low expression of Ly6-C (monocyte lineage marker) and CD209 
(macrophage and dendritic cell marker). Immunohistochemistry showed high 
expression of CD68 (macrophage marker) and mannose receptor (macrophage marker 
unpolarised and “M2” type phenotype), without evidence of INOS expression (“M1” type 
phenotype) (Figure 5.1b). (see section entitled Regulation of cells of the monocyte 
macrophage lineage, p43). 
 
Chapter 5. Macrophage administration in 
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This macrophage generation technique is limited by use of L929 media which although 
contains macrophages colony stimulating factor, which is required for macrophage 
generation, also contains a multitude of other factors (VEGF, MCP-1, KC, and MIG, and 
low amounts of FGF-beta, Eotaxin, IL-10, IL-9, and IL-12) which have the potential to 
alter macrophage phenotype185. As with any conditioned media there is likely to be batch 
to batch variation in the constituent cytokines of L929 conditioned media which could 
then influence macrophage generation. Rather than altering protocols (ie changing to 
pure macrophage colony stimulating factor) at this stage I decided to acknowledge the 
limitations of the technique and continue with the established protocol.   
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Figure 5.1: Characterisation of bone marrow derived cells cultured in L929 media 
a) Flow cytometry dot plot showing representative F4/80 and CD11b expression with 
histogram showing percentage F4/80, CD209, Ly6C and CD11b expression (n=2 per 
surface marker). b) Immunohistochemsitry of generated macrophages for CD68, MR 
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5.2 Optimising route of cellular injection 
Intraportal injection 
The planned route of cellular injection was via the portal vein. However it became 
apparent that portal vein application of cells was poorly tolerated, with issues occurring 
either at the time of injection, prior to terminating the anaesthetic and following 
recovery from anaesthetic. These issues were exacerbated by partial hepatectomy and 
chronic liver injury 
 
At the time of surgery, I injected cells into the portal vein using a 30G needle with clear 
visualisation using a microscope. I used a cotton bud with haemostatic agent (Surgicel®) 
to apply pressure and achieve haemostasis following intraportal injection. This 
technique was previously performed by others in this group87. While this was often 
effective at controlling the bleeding it was often difficult resulting in mice being needing 
to be culled. After seeking technical assistance from experienced animal surgeons both 
in this centre and in other centres, it became apparent that this is generally the case and 
not an issue unique to me. I tried a number of methods in an attempt to optimise portal 
vein injection.  
 
Tachosil® (an alternative haemostatic agent) was trialled as an alternative haemostatic 
agent which in clinical practice is one of the most effective agents around. However in 
this group, livers appeared markedly pale, indicating impaired blood flow. This 
suggested that portal vein thrombosis may have occurred potentially related to the 
effectiveness of thrombotic agent. I trialled slinging the portal vein upstream and 
downstream of the injection site with suture material at the time of injection, but this 
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was time consuming and introduced further risk given manipulation of the vein. I trialled 
needles from a different manufacturer but this did not improve the situation.  
 
After discussion with supervisors I decided that to continue to pursue the strategy of 
portal vein injection in this context was not appropriate. I considered moving to surgery 
in rats where the greater size of the portal vein might enable more effective haemostasis. 
However given the more limited number of reagents available for rats and lack of 
genetically modified animals for elucidation of potential mechanism I decided in 
discussion with my supervisors that continuing with investigations in mice would be the 
best option. I therefore considered alternative routes of injection.  
 
Selecting the intrasplenic route 
Injection routes used by others have included direct hepatic injection, tail vein (or other 
peripheral vein) or intrasplenic (venous drainage of spleen passes straight to liver). 
Direct hepatic injection is limited as it only affects a small portion of the liver and is of 
limited translational relevance as no therapies are currently delivered via this route.  
Unpublished data from the Forbes lab (undertaken by C. Pope, A Mackinnon and others) 
suggests that peripheral administration of macrophages via the portal vein does not 
reduce fibrosis (as opposed to the intraportal injection route used in the Thomas et al.87 
paper).  
 
As proof of principle therefore I worked with A Mackinnon (Senior Post Doc, Forbes lab) 
who labelled murine bone marrow derived macrophage with CSFE (this provides a 
stable nuclear stain which can be detected by flow cytometry).  I then injected these cells 
into the spleen at doses of 1x106 and 5x106. We performed flow cytometry of the liver 
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staining for macrophage marker F4/80 and also gating on CFSE positive cells (488nm) 
to assess if injected macrophages were trafficking to the liver.  
 
Intrasplenic injection was well tolerated with infusion of both 1x106 and 5x106 
macrophages. There was evidence of cells passing to the liver following intrasplenic 
injection as assessed by flow cytometry of hepatic cellular populations (Figure 5.2). 
Following this proof of principle experiment I selected the intrasplenic route for further 
experimentation.  
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Figure 5.2: Hepatic macrophage populations following intrasplenic injection of CSFE 
labelled macrophages 
a) Quantification of number of F4/80 positive, CFSE negative cells (the recipient’s native 
macrophages) and number of F4/80 positive, CFSE positive cells (donor derived 
macrophages). b) Representative flow plots showing F480 populations and F4/80, CFSE 
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Limitations of the intrasplenic route 
While I selected the intrasplenic route for further experimentation I was aware of a 
number of potential issues with this method of cell administration.  
 
Firstly many of the injected cells may remain intrasplenic. There may be a high rate of 
phagocytosis by macrophages in the spleen. The phenotype of injected macrophages 
could be altered during transit through the spleen and this may influence subsequent 
effects on the liver.  I decided that first I would investigate the effect of administration of 
these cells and if this approach were to be successful I planned to then go on and further 
characterise the phenotype of these cells. All experiments were performed using the 
same batch of L929 conditioned media with cells pooled prior to administration to limit 
effects of variation within the batch.  
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5.3 Administration of macrophages following partial 
hepatectomy and chronic liver injury 
 
Results 
Following macrophage administration (5x106) by intrasplenic injection, I found no effect 
on survival (Figure 5.3) and no effect on liver weight to body weight ratio (Figure 5.4). 
Intrasplenic injection did not increase spleen weight to body weight ratio at this Day 4 
time point (Figure 5.5). I used Sirius red stain and image quantification to assess degree 
of fibrosis but there was no reduction in fibrosis following intrasplenic injection of 
macrophages (Figure 5.6).  
I planned on first assessing if macrophage administration via the intrasplenic route 
would influence regeneration. I did not want to label macrophages in this experiment to 
assess effect as there was a possibility that labelled cells might behave differently to 
unlabelled macrophages. If I had found a difference between groups I then planned on 
assessing macrophage dynamics in detail. This would have included location of the 
administered macrophages assessed by immunohistochemistry of labelled cells within 
the liver and also macrophage phenotype assessed by flow cytometry and 
immunohistochemistry. 
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Figure 5.3: Kaplein Meir survival analysis following chronic liver injury, partial 
hepatectomy and intrasplenic macrophage injection. 
(treatment n=7, control n=9) 
 
 
Figure 5.4: Liver weight to body weight ratio at Day 4 following chronic liver injury, 
partial hepatectomy and intrasplenic macrophage injection 
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Figure 5.5: Spleen weight to body weight ratio at Day 4 following chronic liver injury, 
partial hepatectomy and intrasplenic macrophage injection 
 
 
Figure 5.6: Sirius red quantification of fibrosis at Day 4 following chronic liver injury, 
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Discussion 
Based on these outcome measures I did not find benefit with intrasplenic administration 
of macrophages. This contrasts with previous work from this group which found a single 
injection of macrophages via the intraportal route 4 weeks following injection improved 
fibrosis is a mouse model of chronic liver injury87. The mechanism of effect of this 
previous study was based on recruiting host macrophages to the liver by increased 
hepatic chemokine expression. The administered macrophages engrafted transiently.   
 
There are a number of differences between this previous study and my work, including 
model, route of administration and number of cells which could account for the 
difference. Certainly remodelling of the fibrotic matrix is markedly upregulated 
following partial hepatectomy without further intervention (Figure 3.6). It may be that 
any potential effect of additional bone marrow derived macrophages is overwhelmed by 
the endogenous response to partial hepatectomy. In order to assess this would require 
an additional control group of sham surgery to assess the rate of remodelling. However 
due to time constraints (it was not feasible to run a further contemporaneous group) 
 
Given the extensive optimisation I had already performed for this experiment and while 
there were other options for further optimisation (ie. alter macrophage administration 
technique, increase cell number (although others in the group report mortality with 
injection of greater cell numbers), alter macrophages culture conditions, alter model) I 
decided the most appropriate next step would be to examine alternative intervention 
options.  
 
There was an opportunity to work with a novel compound to stimulate macrophages in 
the host. A CSF1-Fc conjugate had been developed by D Gow and D Hume (Roslin 
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Institute, University of Edinburgh) and Zoetis. When administered to mice they found 
that liver size was significantly increased and there was extensive hepatocyte 
proliferation.  This appeared an ideal candidate to test in models of liver regeneration.  
 
Conclusion 
In this model of partial hepatectomy on a background of chronic liver injury intrasplenic 
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6.1 Background 
Macrophage colony stimulating factor (CSF1) is the principal macrophage growth factor. 
It has a central role in macrophage development and homeostasis from bone marrow 
stem cell to tissue resident macrophage. Clinical trials of recombinant CSF1 were first 
conducted in the late 1980’s / early 1990’s following antitumour effects of CSF1 seen in 
preclinical models relating to macrophage mediated phagocytosis of tumour cells186. 
Recombinant CSF1 administration was found to be safe, although the dose limiting 
toxicity related to thrombocytopenia in some patients186-189. These early phase I / II 
studies were not followed up by further trials. There is no clear reason for this in the 
literature. CSF1 facilitates macrophage mediated tissue growth190. This finding led to the 
hypothesis that supplementation of CSF1 could be used to enhance neonatal growth of 
livestock for commercial benefit.  
 
Fc conjugation of CSF1 
However serum CSF1 has a short half-life (several hours) and undergoes rapid receptor 
mediated endocytosis, principally by hepatic macrophages but it is also eliminated via 
renal excretion84. Given these rapid pharmacokinetics, in the clinical setting, trials 
involve repeated infusions of CSF1. CSF1-Fc was developed with the aim of enhancing 
CSF1 half-life so facilitating administration to test potential growth promoting effects in 
weaner pigs.  CSF1-Fc was generated by D. Hume and D. Gow in collaboration with Pfizer 
animal health (now Zoetis).  
 
Chapter 6. Macrophage stimulation in mouse 
models of regeneration 
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Fc conjugation is a well-recognised strategy to increase the pharmacokinetics of a 
protein. It is thought to increase half-life both through an increase in the size of the 
protein, which can limit renal excretion and also through its effects on endosomal 
recycling191. Regarding the latter point, under normal circumstances immunoglobulins 
can be recycled after cellular uptake by first binding to the “neonatal Fc receptor”xxii 
(FcRn). The immunoglobulin-FcRn complex then passes to the cell surface where the 
immunoglobulin is released, so preventing lysosomal degradation192. By fusing a protein 
to an Fc fragment, the resulting conjugate may be treated in the same way as an 
immunoglobulin. Therefore the protein-Fc conjugate is released back into the circulation 
after activating the relevant receptor mediated pathways191. A number of Fc-fusion 
based drugs are in clinical use, including etanercept (TNF receptor – Fc fragment of IgG1 
fusion) and rilonacept (Il-1R –Fc fragment of IgG1 fusion)193,194. 
 
This compound consists of porcine CSF1 protein bound to a porcine Fc fragment. This Fc 
modification substantially increased half-life of CSF1 and exhibits considerable potency 
in terms of stimulating monocyte / macrophage populations in vivo165. In weaner pigs 
CSF1-Fc did not enhance rate of growth, however profound effects were noted on cells 
of monocyte macrophages lineage. Porcine CSF1 is equally active in mice164. When 
administered to mice it was noted that marked hepatosplenomegaly occurred. This was 
associated with extensive proliferation of hepatocytes after 4 days of daily treatment. 
These findings raised the prospect that CSF1-Fc could be used to enhance liver 
regeneration in mouse models of liver injury.  
                                                             
xxii The neonatal Fc receptor (FcRc) was first discovered due to its role in transporting 
IgG derived from the mother’s milk across the gut and into the newborns blood 
stream192. Jones, E.A. & Waldmann, T.A. The mechanism of intestinal uptake and 
transcellular transport of IgG in the neonatal rat. J Clin Invest 51, 2916-2927 (1972). 
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6.2 CSF1 receptor stimulation in the steady state 
Aims 
1. Assess hepatic effects of CSF1R stimulation on the steady state 
2. Assess extrahepatic effects of CSF1R stimulation on the steady state 
 
Results 
CSF1R stimulation induces hepatic macrophage accumulation 
I used the Macgreen mouse Tg(Csf1r-GFP)Hume to assess CSF1 receptor expression under 
physiological conditions. Figure 6.1a shows that CSF1 receptor expression was restricted 
to cells of macrophage morphology in the liver using multiphoton microscopy. I 
collaborated with Professor J Pollard who had generated the Csf1r-Mer2iCreJWP crossed 
with the rosa floxed stop tomato red. In this mouse CSF1R positive cells are then labelled 
with the tomato reporter following tamoxifen induction. Review of liver sections from 
this mouse shows complete co-localisation with the macrophage marker F4/80 in the 
steady state (Figure 6.1b). 
 
I then administered CSF1-Fc to mice without injury, to test hepatic effects of CSF1R 
signalling in the steady state. Six hours following CSF1-Fc administration there was a 
greater than 4-fold upregulation in gene expression of CCR2 ligands- CCl2, CCl7 and 
CCl12 (Figure 6.2a). Marked macrophage accumulation was seen within the liver over 
four days of CSF1-Fc administration (Figure 6.2b). I performed FACS analysis of hepatic 
macrophages which revealed extensive macrophage infiltration (F480lo/CD11b/hi, 
Ly6C/hi) accompanied by expression of markers associated with proliferation (ki67 and 
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BRDU) in both resident (F4/80hi;red) and infiltrating macrophages (F4/80lo; blue) 
(Figure 6.3a-c).  
 
This macrophage accumulation increased hepatic size in wild type (WT) mice after just 
2 days of administration (Figure 6.4a). Given the marked infiltrating macrophage 
phenotype and upregulation of CCR2 ligands, we explored the effects of CSF1-Fc 
administration in CCR2-/- mice. Liver weight to body weight ratio was not increased in 
CCR2-/- mice given CSF1-Fc (Figure 6.4a) and infiltrating macrophage accumulation 
(F480lo/CD11bhi/Ly6Chi) was reduced compared to WT mice (Figure 6.4b). While CCR2-
/- mice have markedly reduced circulating numbers of Ly6C high monocytes in the 
steady state (Figure 6.4c) and this deficit was overcome by CSF1-Fc treatment, with 
resulting Ly6C profile similar to CSF1-Fc treated WT mice (Figure 6.4d). This marked 
monocytosis following CSF1-Fc treatment is likely driving the extensive macrophage 
infiltration occurring in both WT and CCR2-/- (Figure 6.4d). 
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Figure 6.1: Hepatic CSF1 receptor expression 
a)  Representative multiphoton image of ex vivo liver (MacGreen mouse Tg(CSF1r-
GFP)Hume); b) Representative immunofluorescence images of Csf1r-Mer2iCreJWP x Rosa 
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Figure 6.2: Effects of CSF1-Fc on hepatic macrophages 
a) Cytokine/Chemokine array of liver tissue 6 hours following CSF1-Fc treatment versus 
control (n=4/group). (see Appendix 1, p231 for gene list). Quantification of hepatic 
F4/80 immunohistochemistry in PBS control treated (n=8) and mice treated with CSF1-
Fc for 2 or 4 days (n=4/group). 
a 
b 
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Figure 6.3: Hepatic macrophage characteristics following CSF1-Fc administration 
a) Relative number of hepatic macrophage populations (F480hi/CD11blo and 
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Fc= solid circles; control= hollow circles) and representative Ly6C profile of F480hi (red) 
and F480lo (blue) populations (two way ANOVA with Bonferroni post hoc). b) 
Representative dot plots of Ki67 expression and BRDU incorporation of F480hi and 
F480lo hepatic macrophage populations day 2 following CSF1-Fc (solid circles) or Control 
(hollow circles). Quantitative analysis of BRDU and Ki67 dual positive cell populations 
(n=4/group) (two way ANOVA with Bonferroni post hoc). c) Representative dual 
immunohistochemistry F4/80 (green) and BRDU or Ki67 (red) Day 2 following CSF1-Fc 
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Figure 6.4: CSF1-Fc and the CCR2-/- mouse 
a) Liver weight to body weight ratio following 2 days control (black) or CSF1-Fc 
administration (grey) in wild type and CCR2-/- mice. b) Number of F480lo/CD11bhi 
macrophages following CSF1-Fc administration in WT and CCR2-/- mice (n=4/group). 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. c) Blood monocyte Ly6C profile in PBS 
treated controls in WT (clear bars) and CCR2-/- mice (shaded bars) (monocytes 
identified by flow cytometry for CSF1R positivity) (2-way ANOVA with Bonferroni post 
hoc). d) Blood monocyte Ly6C profile in WT (clear bars) and CCR2-/- (shaded bars) 






Manipulating macrophages to enhance liver regeneration 
123 
Macrophage stimulation in mouse models of regeneration 
CSF1R stimulation indirectly induces hepatocyte proliferation 
I then examined the effects of CSF1-Fc induced macrophage accumulation on hepatocyte 
activity. Continued CSF1-Fc administration led to extensive hepatocyte proliferation by 
day 4 (Figure 6.5a and Figure 6.5b). Given early upregulation of Il6 following CSF1-Fc 
administration (Figure 6.2), and its recognised role in inducing hepatocyte 
proliferation26,28, I examined the impact of Il6-deficiency on hepatocyte proliferation 
following CSF1-Fc administration. Following four days of CSF1-Fc administration liver 
weight increased equally in WT and Il6-/- mice. Hepatocyte proliferation was not 
inhibited but impaired with Il6 deficiency (Figure 6.6a and Figure 6.6b). 
 
 Given this I examined other factors previously implicated in hepatocyte proliferation by 
analysis of Affymetrix gene arrayxxiii data of livers following CSF1-Fc or PBS control in 
WT mice20,21. Factors including TNF, matrix remodelling (MMP9) and growth factor 
activation (urokinase activity) were elevated (Figure 6.7a and Figure 6.7b)17,195. Growth 
factor expression remained relatively unchanged although notably Tgfb1 gene 
expression was elevated (Figure 6.7b). This was not accompanied by an increase in TGF 
beta receptor expression and there was no evidence of apoptosis assessed by TUNEL 
staining (Figure 6.8a and Figure 6.8b). This was accompanied by a reduction in classic 
markers of hepatocyte injury (ALT and Alk phos) (Figure 6.8c).  
 
Based on whole liver gene expression CSF1-Fc induces a mixed macrophage phenotype, 
with elevation of genes associated with “M1” type and “M2” type macrophages196 (Figure 
6.9).   
 
                                                             
xxiii:  This Affymet rix ge ne  arra y wa s complete d by col la borat ors D. Hume a nd D Gow a nd  publ ishe d 
onl ine . I  downloa de d t he  ra w dat a a nd a nalyse d this  a ccordingly . 
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Figure 6.5: Hepatocyte proliferation following CSF1-Fc administration 
a) Quantification of hepatocyte proliferation at Day 2 and Day 4 following CSF1-Fc 
administration (20 HPF/mouse). b) Representative images of HE stain and Ki67 
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Figure 6.6: CSF1-Fc and the Il6-/- mouse 
a) Liver weight to body weight ratio in wild type and Il6-/- mice following PBS control 
(n=4/group) or CSF1-Fc treatment in WT or Il6-/- mice (n=5/group) 2-way ANOVA with 
Bonferroni post hoc. b) Hepatocytes proliferation in WT or Il6-/- mice at Day 4 following 
CSF1-Fc administration (n=5/group). 
 
a b 
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Figure 6.7: Gene array analysis whole liver 
a) Cytokine and chemokine profile extracted from Affymetrix gene array20 showing 
expression of genes significantly elevated following CSF1-Fc administration (number of 
genes assessed n=73; Gene list Supplementary Fig. 9b). b) Growth factors and matrix 
metalloproteinases extracted from Affymetrix gene array20 showing expression of genes 
significantly elevated following CSF1-Fc administration (number of genes assessed 
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Figure 6.8: TGF beta pathway and markers of hepatic injury 
a) Funnel plot showing TGF beta related gene expression extracted from Affymetrix gene 
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administration (positive control DNAse treated section). c) Serum liver associated 
biochemistry tests following PBS control or CSF1-Fc treatment for 4 days (n=4/group) 
2-way ANOVA (Control= solid black dots; CSF1-Fc treatment= hollow grey dots) 
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Figure 6.9: Macrophage polarisation markers 
Macrophage markers and markers of macrophage polarisation extracted from 
Affymetrix gene array20 showing expression of genes significantly elevated following 
CSF1-Fc administration compared to PBS control (number of genes assessed n=61; 
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Effect on extrahepatic organs 
I also examined spleen, lung, kidney and brain following CSF1-Fc injection. Most notably 
spleen size increased following CSF1-Fc administration associated with increase in red 
pulp macrophages and BRDU incorporation (Figure 6.10).  
 
There is evidence of increased macrophage numbers and BRDU incorporation in the lung 
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Figure 6.10: Effect of CSF1-Fc administration on the spleen 
a) Spleen weight to body weight ratio 2 days following CSF1-Fc or PBS control to WT 
mice (n=4/group; t test). b) Indicative immunofluorescence of WT spleen showing F4/80 
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Figure 6.11: BRDU and F4/80 immunohistochemistry lung, kidney and brain 
Indicative immunofluorescence of WT lung, kidney and brain showing F4/80 (green) and 
BRDU incorporation (red) following 2 days PBS control or CSF1-Fc administration. 
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Discussion 
I have shown that CSF1-Fc administration to uninjured mice led to an early upregulation 
of hepatic CCR2 ligand gene expression. This supports previous work showing CSF1 
induced CCR2 dependent monocyte trafficking during placental growth197.  Although 
hepatic macrophage infiltration was reduced in CCR2 -/- mice following CSF1-Fc 
compared to control, the infiltrate was still considerable demonstrating the functionality 
of other chemokine receptors. Interestingly CSF1-Fc can overcome the blood Ly6C high 
monocyte deficit in the CCR2-/- mouse and this warrants further investigation.  
 
Macrophage accumulation is recognised as an important feature of hepatic regeneration 
following injury28,49. Here we show that even in the absence of injury, hepatocyte 
proliferation was induced following macrophage accumulation. Indeed serum injury 
markers (ALT and Alk phos) were actually reduced in this setting, supporting a role for 
the clearance of these enzymes by hepatic macrophages28,198. I targeted the IL6 pathway 
as a potential mechanism for hepatocyte proliferation based on early gene changes and 
published work indicating the role of Il6 in hepatocyte proliferation26. Hepatocyte 
proliferation was not prevented but was impaired in Il6-/-, indicating a multifactorial 
mechanism supported by the multitude of other regeneration associated hepatic gene 
changes. Given the different dynamics of macrophage accumulation and hepatocyte 
proliferation (rapid and early versus late) it is likely that the former is the main 
contributor to hepatic size increase. Supporting this is the finding that despite reduced 
hepatocyte proliferation hepatic size increase was similar to WT controls following 
CSF1-Fc.  
 
The array analyses shows that both TGF-beta and Il-10 are both elevated at the gene level 
following CSF1-Fc administration. These cytokines can have immunosuppressive 
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functions, acting in particular through T regulatory cells199. Effect on T cell phenotype 
has not been explored during this thesis but certainly warrants further investigation. 
Kupffer cells responding to fulminant hepatitis are also known to upregulate Il-10 and 
TGF-beta, which plays an important role in attenuating the inflammatory injurious 
process200.  
 
Hepatic gene expression revealed no clear macrophage “M1” or “M2” activation bias 
following CSF1R stimulation, rather a spectrum of pro and anti-inflammatory 
macrophage markers. Relating whole liver analysis to a specific cell is clearly limited but 
the alternative of extracting macrophages for gene analysis is limited by the effect of the 
extraction process on cell function. While macrophage accumulation was also seen in the 
kidney and lung, there was no evidence of deleterious effects. Indeed this may be 
beneficial in injury given CSF1 administration in mouse models can support renal 
regeneration and CSF1-deficiency in sepsis leads to early death associated with 
phagocytic impairment148,201,202.  
 
Conclusion 
CSF1 receptor stimulation with CSF1-Fc induces marked hepatic macrophage 
accumulation involving both infiltration and proliferation, which increases hepatic size. 
After continued administration there is evidence of hepatocyte proliferation which is 
likely due to macrophages.  
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6.3 CSF1 receptor stimulation following partial 
hepatectomy 
Aims 
1. Assess effects of CSF1R stimulation on hepatocellular regeneration following PH 
2. Assess effects of CSF1R stimulation on macrophage phagocytic function following PH 
 
Results 
Following PH I found that effects of CSF1-Fc were similar to the uninjured mouse with 
an increase in liver size and overall enhanced hepatocyte proliferation (Figure 6.12a and 
Figure 6.12b). Peak hepatocyte proliferation (Day 2) was not increased by CSF1-Fc 
treatment. However CSF1 dependence was supported by the inhibitory actions of CSF1R 
kinase inhibition (GW2580) and antibody against the CSF1 receptor (AFS98) (Figure 
6.12c).  
 
The liver is the dominant clearance site for insoluble material, as demonstrated earlier 
(“4.2 Assessment of hepatic phagocytic function”, p94). CSF1-Fc treatment increased 
hepatic macrophage density following PH (Figure 6.13a) with corresponding elevation 
in phagocytic genes MARCO (macrophage receptor with collagenous structure) and 
MSR1 (macrophage scavenger receptor 1) (Figure 6.13b). PH leads to a marked 
impairment in fluorescent microbead clearance from the circulation and I found that this 
deficit was substantially improved by CSF1-Fc treatment (Figure 6.14a). By assessing 
whole liver fluorescence I show that CSF1-Fc treatment also augmented hepatic 
phagocytic capacity (Figure 6.14b). 
 
Manipulating macrophages to enhance liver regeneration 
136 
Macrophage stimulation in mouse models of regeneration 
Elevation in genes associated with matrix remodelling and cytokine gene profiles are 
similar to that seen in uninjured mice with reciprocal change given CSF1R inhibition 
(Figure 6.15a and Figure 6.15b). Serum cytokine multiplex showed increased circulating 
Il5, CXCl9 and CXCL10 (Figure 6.15c) 
 
Immunohistochemistry for hepatocyte marker CYPD2 showed a reduction at day 4 
(Figure 6.16a) suggestive of non-parenchymal cell accumulation. Extracted 
macrophages show a predominance of F480lo/CD11bhi/Ly6Chi macrophages (Figure 
6.16b and Figure 6.16c).  Macrophage proliferation was seen in both infiltrating and 
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Figure 6.12: Effects of CSF1-Fc on regenerative parameters following partial 
hepatectomy  
a) Liver weight to body weight ratio following partial hepatectomy (PH) with CSF1-Fc or 
control (2 way ANOVA; n=8/group). b) Ki67positive hepatocytes per HPF following PH 
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hepatocytes per HPF following CSF1 receptor inhibitor (GW2580, red, n=8), CSF1R 
antibody blockade (AFS98, blue, n=7) or CSF1-Fc (grey, n=8). Compared to vehicle 
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Figure 6.13: Hepatic macrophage density and markers of phagocytosis 
a) Whole liver gene expression of phagocytic markers MARCO (macrophage receptor 
with collagenous structure), MSR1 (macrophage scavenger receptor 1) and MR 
(mannose receptor) versus relevant control (2-way ANOVA, Bonferroni post-test). b) 
Hepatic macrophage accumulation by F4/80 immunohistochemistry at Day 2 (t test) and 
representative F4/80 immunohistochemistry 
a 
b 
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Figure 6.14: Phagocytosis assay following partial hepatectomy and CSF1-Fc 
a) Clearance of microbeads from the circulation following sham or 2/3 PH with control 
or CSF1-Fc (n=6/group/timepoint) with area under the curve (one-way ANOVA, 
Bonferroni post-hoc, n=6/group). b) Net fluorescence liver, spleen, lung, kidney and 
brain Day 2 following PH and CSF1-Fc or control. (2 way repeated measures ANOVA with 
Bonferroni post test, n=6 per group). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
a 
b 
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Figure 6.15: Hepatic gene and serum cytokine expression profiles following partial 
hepatectomy and CSF1-Fc administration 
a) Hepatic gene cytokine expression at Day 2 following partial hepatectomy and either 
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PBS; n=8/group; 2-way ANOVA comparing intervention with relevant control, 
Bonferroni post hoc).  b) Hepatic MMP and UPAR (urokinase plasminogen activator 
receptor) gene expression Day 2 following partial hepatectomy and either GW2580, 
AFS98 or CSF1-Fc administration versus control (vehicle gavage, rat IgG2a, CSF1-Fc; 
n=8/group; 2-way ANOVA comparing intervention with relevant control, Bonferroni 
post hoc). c) Serum cytokine array Day 4 following partial hepatectomy and either PBS 
control or CSF1-Fc treatment (2-way ANOVA and Bonferroni post hoc). 
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Figure 6.16: Macrophage accumulation following partial hepatectomy and CSF1-Fc. 
a) Quantification CYPD2 immunofluorescence (red) per 20x HPF/mouse (control n=8; 
CSF1-Fc n=7; t test). b) Hepatic macrophage populations at Day 4 following partial 
hepatectomy and either PBS control or CSF1-Fc administration with quantification of 
F4/80++ and F4/80+ populations (2-way ANOVA). c) Ly6C profile of F4/80 + and ++ 
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Figure 6.17: Macrophage proliferation following partial hepatectomy and CSF1-Fc 
BRDU and Ki67 quantification F4/80 ++ and F4/80 + populations at Day 4 following 
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Discussion 
I have found that following PH, CSF1-induced macrophage accumulation led to an overall 
increase in hepatocyte proliferation. However at the peak proliferative time point (Day 
2) hepatocyte proliferation was not increased over control. This early stage of 
regeneration is the most clinically relevant time period, aiming to restore hepatic volume 
as rapidly as possible. As regeneration in mice is rapid, improving hepatocyte 
proliferation over and above what is already highly effective may not necessarily be 
advantageous. The requirement for CSF1 signalling to enable effective regeneration is 
demonstrated by the impaired regeneration following CSF1R blockade. This is consistent 
with findings in the CSF1 deficient mouse162. Liver weight to body weight was increased 
at later time points (Day 4 and Day 7) following CSF1-Fc administration, however this 
most likely relates, at least in part, to the marked macrophage accumulation.   
 
Comparing both CSF1 receptor stimulation and inhibition there is an elevation and 
reciprocal reduction respectively in cytokines associated with liver regeneration and 
matrix remodelling. This supports a multifactorial mechanism by which macrophage 
exert their proregenerative effects.  
 
I have shown that the impairment in hepatic phagocytic capacity following PH is 
considerable. This is consistent with work in humans where clearance of circulating 
radiolabelled albumin microbeads was impaired following partial hepatectomy to a 
similar extent as patients with severe chronic liver disease76. The liver represents the 
first line of defence from gut derived pathogens, receiving around 75% of its blood from 
the portal system203. Infection rate is increased following major PH204 therefore 
enhancing hepatic innate capacity is desirable. CSF1-induced macrophage accumulation 
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markedly improved both rate of phagocytosis assessed by clearance of beads from the 
circulation and phagocytic capacity assessed by hepatic fluorescent bead uptake.  
 
Conclusion 
CSF1R signalling is crucial for effective regeneration. Partial hepatectomy results in a 
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6.4 Focus on the spleen 
Aims 
1. Assess splenic dynamics following partial hepatectomy and CSF1R stimulation 





In the spleen, macrophages reside predominantly in the splenic red pulp. I assessed 
splenic macrophage morphology using multiphoton imaging of the MacGreen mouse 
spleen ex vivo. Macrophages are abundant in the splenic red pulp with distinct 
morphology as compared to hepatic macrophages (Figure 6.18a and Figure 6.18b). 
 
I found that spleen size increased following partial hepatectomy in control treated mice 
and this was significantly increased further by CSF1-Fc treatment (Figure 6.19a and 
Figure 6.19b). Following PH, enhanced red pulp Ki67 expression co-stains with 
macrophage marker F4/80 and this was further increased following CSF1-Fc 
administration indicating macrophage proliferation (Figure 6.19c).  
 
I considered whether, given this increase in size, there would be an effect on splenic 
cytokine and chemokine gene expression. However, I found that splenic cytokine gene 
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Given the abundance of macrophages in the spleen, I analysed the effects of the 
fluorescent microbead assay on the spleen and compared this to the liver. I found that 
microbead uptake of the spleen was markedly inferior to the liver both overall and per 
unit area (Figure 6.21).  
 
Given the increase in splenic macrophage populations, I considered whether there was 
evidence of trafficking of these cells between the liver and spleen in addition to bone 
marrow production. I therefore analysed the number and percentage of monocytes in 
the portal blood (which directly drains the spleen and also gut) and compared this to the 
inferior vena cava (which is down-stream of the femoral bone marrow- a major blood 
monocyte producer) and tail vein (a site upstream of the major monocyte producing 
regions). I found an increase in monocytes in the portal blood, immediately downstream 
of the spleen, greatly enhanced by CSF1-Fc treatment (Figure 6.22). This suggests that 
the spleen is also a site of monocyte production with trafficking of 
monocyte/macrophages between spleen and liver. This is likely to occur in addition to 
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Figure 6.18: Comparison of splenic and hepatic macrophage morphology 
a) Multiphoton image MacGreen mouse spleen in the steady state; b) Multiphoton image 
MacGreen mouse liver in the steady state (Note: this liver image is also shown in “Figure 
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Figure 6.19: Splenic size following partial hepatectomy +/- CSF1-Fc 
a) Representative image demonstrating change in spleen size following partial 
hepatectomy and partial hepatectomy with CSF1-Fc treatment. b) Change in spleen 
weight to body weight ratio following partial hepatectomy with PBS control (dotted line) 
and CSF1-Fc treatment (solid line). Compared using two way ANOVA with Bonferroni 
post-hoc analysis. *p<0.05, ****p<0.0001. c) Dual immunohistochemistry for 





Day 4: PH + control Day 4: PH + CSF1-Fc 
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Figure 6.20: Pooled sample cytokine/chemokine array whole spleen 
Comparison between partial hepatectomy plus CSF1-Fc and partial hepatectomy plus 
PBS control. (n=4 per group, samples pooled following RNA extraction)  
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Figure 6.21: Fluorescence of spleen compared to liver following fluorescent microbead 
injection 
Explanation: Here I injected mice with fluorescent microbeads via the inferior vena cava 
at Day 2 following partial hepatectomy with PBS control (white bar) or CSF1-Fc 
treatment (grey bar) as per analysis shown in “Figure 6.14: Phagocytosis assay following 
partial hepatectomy and CSF1-Fc”. I then compared the relative fluorescence of the 
spleen compared to the liver for each mouse ([liver fluorescence] / [splenic 
fluorescence]; n=6 per group). This includes both the total fluorescence of each organ 
(Total fluor.) and fluorescence per area (Fluor. / area).  
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Figure 6.22: Splenic monocyte trafficking 
a) Diagram illustrating sampling sites for assessment of blood monocyte content (tail 
vein= green; inferior vena cava (blue) and portal vein (red). b) Total monocyte number 
at each sampling site in untreated/uninjured mice (Norm), PBS control treated mice at 
Day 2 following partial hepatectomy (Control) and CSF1-Fc treated mice at Day 2 
following partial hepatectomy. c) Percentage monocytes out of total cellular blood 
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Discussion 
I have shown that the spleen increases in size following partial hepatectomy in mice and 
that spleen size is increased further by CSF1-Fc treatment. In the clinical setting an 
increase in spleen size is noted following partial hepatectomy for colorectal liver 
metastasis with a greater than 40% increase in splenic size evident 6 months following 
surgery205. Portal pressure does increase transiently following partial hepatectomy of 
greater 30% (as assessed using an indirect ultrasonography method)206,207 and this may 
be in part responsible for the increase in spleen size, but as this pressure increase is 
short-lived it might be that circulating growth factors contribute to splenic size increase.   
 
Despite the spleen’s reputation as the “body’s largest filter of blood”208, microbead 
uptake was markedly inferior to the liver. Anatomically the liver’s far superior 
phagocytic capacity makes sense given that it is situated immediately downstream from 
the gut. The percentage cardiac output that the liver receives is also far superior to the 
spleen, with the spleen receiving approximately 2.2% and the liver (via its dual supply 
of portal vein and hepatic artery) receiving approximately 27.3%209.  The functional 
reason behind splenic size increase does not appear to be to increase phagocytic 
capacity. 
 
It has been shown that in other injury models, such as cardiac ischemia, that 
splenomegaly also occurs. In these models the spleen can act as a monocyte reservoir, 
supporting trafficking of monocytes to sites of distant injury210. I assessed blood 
monocyte content of the portal vein, directly downstream from the spleen and found that 
blood monocyte content was markedly increased compared to blood sampled from 
either the tail vein or inferior vena cava. This finding indicates that there is likely to be a 
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degree of monocyte trafficking from the spleen to the liver. This may serve to provide 
sufficient monocyte numbers during repair and regeneration.   
 
The literature on effects of splenectomy on regeneration following partial hepatectomy 
is mixed with some investigators finding that splenectomy impaired regeneration in 
mice via its effects on t cells and Il17 production (monocyte/macrophage dynamics not 
assessed)211, with others finding that splenectomy enhanced liver regeneration in rats 
by removing the splenic source of TGF beta212. Studying the effects of splenectomy on 
monocyte and macrophage dynamics following partial hepatectomy is required.  
 
Conclusion 
Spleen size increases following partial hepatectomy with further increase following 
CSF1-Fc treatment. Macrophage populations within the splenic red pulp expand and 
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6.5 CSF1 receptor stimulation, partial hepatectomy and 
chronic liver injury  
Aims 
Assess the effects of CSF1R stimulation on outcomes following partial hepatectomy and 




Following partial hepatectomy and chronic liver injury CSF1-Fc treatment led to a non-
significant trend to improved survival (p=0.08) (Figure 6.23). Subsequent results reflect 
analysis of survivors (Day 4: control n=5, treatment n=7; Day 7: control n=6, treatment 
n=7). Liver weight to body weight ratio was significantly increased from Day 3 onwards 
(Figure 6.24). Hepatocyte proliferation was not enhanced at the Day 4 time point but was 
significantly increased at Day 7 (Figure 6.26). I used indocyanine green (ICG) as an 
indicator of hepatocyte function. I found no difference in ICG clearance between CSF1-Fc 
and control treated mice although both these groups had significantly impaired ICG 
clearance compared to control at postoperative day 4 (Figure 6.27) (n=8 per group at 
each time point). These ICG data are the almagmation of two sets of experiments; n= 4 
per group randomly selected from the mice prior to cull; and n=4 per group at day 4 of 
mice that were then recovered and continued to the Day 7 time point).  
 
Figure 6.28 shows Ki67 and F4/80 dual immunohistochemistry of mouse liver from the 
Day 4 timepoint, with macrophage clustering around the scar area. I did not find a 
reduction in degree of fibrosis following CSF1-Fc treatment by quantification of Sirius 
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red staining (Figure 6.29). There was a significant reduction in serum ALT and serum 
bilirubin at Day 4 postoperatively (Figure 6.30; Figure 6.31). Serum albumin was 
decreased at both Day 4 and Day 7 time points (Figure 6.32). There was no significant 
difference in serum creatinine at either day 4 or day 7 (Figure 6.33). 
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Figure 6.23: Kaplan-Meier survival plot following partial hepatectomy and chronic liver 
injury with CSF1-Fc or control 
Log rank test p=0.08 
 
 
Figure 6.24: Mouse body weight following partial hepatectomy and chronic liver injury 
with CSF1-Fc or control 
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Figure 6.25: Liver weight to body weight ratio following partial hepatectomy and chronic 
liver injury with control (solid circles) or CSF1-Fc (hollow circles) assessed by 
hepatocyte Ki67 expression. 2 way ANOVA with Bonferroni post hoc. *p<0.05, 
***p<0.001 
 
Figure 6.26: Hepatocyte proliferation following partial hepatectomy and chronic liver 
injury with control (solid circles) or CSF1-Fc (hollow circles) assessed by hepatocyte 
Ki67 expression. 2 way ANOVA with Bonferroni post hoc. *p<0.05 
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Figure 6.27: Indocyanine green clearance following partial hepatectomy and chronic 
liver injury with CSF1-Fc or control 
a) Indicative ICG clearance images including fluorescent images taken prior to ICG 
injection (Pre ICG), at 0 mins (immediately following injection), at 5 and 10 minutes post 
injection. b) ICG plasma disappearance rate in control (PH + chronic liver injury with PBS 
control, dotted line, n=8), treatment (PH+ chronic liver injury with CSF1-Fc, solid black 
line, n=8) and normal (uninjured untreated mice, solid grey line n=6). c) Area under ICG 
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Figure 6.28: Ki67 and F4/80 immunohistochemistry following partial hepatectomy and 
chronic liver injury with CSF1-Fc or control 
Pink= F4/80; brown (DAB) = Ki67 
 
 
Figure 6.29: Fibrosis quantification via Sirius red image analysis following partial 
hepatectomy and chronic liver injury with control (solid circles) or CSF1-Fc (hollow 
circles). (NB. n=1 from day 4 timepoint 0 was not suitable for Sirius red analysis (despite 
repeated attempts) and so was discarded)2-way ANOVA; p=0.35 
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Figure 6.30: Serum ALT following partial hepatectomy and chronic liver injury with 
control (solid circles) or CSF1-Fc (hollow circles).  
2 way ANOVA with Bonferroni post hoc. ***p<0.001 
 
  
Figure 6.31: Serum bilirubin following partial hepatectomy and chronic liver injury with 
control (solid circles) or CSF1-Fc (hollow circles). 
2 way ANOVA with Bonferroni post hoc. *p<0.05 
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Figure 6.32: Serum albumin following partial hepatectomy and chronic liver injury with 
control (solid circles) or CSF1-Fc (hollow circles). 




Figure 6.33: Serum creatinine following partial hepatectomy and chronic liver injury 
control (solid circles) or CSF1-Fc (hollow circles). 2 way ANOVA with Bonferroni post 
hoc. ns 
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Discussion 
While survival was not significantly enhanced with CSF1-Fc treatment there was a 
significant increase in body weight suggestive of improved postoperative course. Liver 
weight to body weight was increased but as in the partial hepatectomy model (without 
chronic liver injury) this was not accompanied by a significant increase in hepatocyte 
proliferation indicating that macrophage accumulation accounted for much of this size 
increase. I used the ICG clearance assay to provide a dynamic assessment of hepatocyte 
function. The lack of difference between groups despite the increased liver size further 
indicates that this increase in liver size is likely to be due to macrophage accumulation. 
It should also be noted that ICG clearance was not impaired by the macrophage 
accumulation in this model.  
 
Fibrosis as assessed by Sirius red was reduced by CSF1 therapy. As shown previously 
(“Figure 3.6: Comparison in fibrosis resolution between mice undergoing partial 
hepatectomy and mice undergoing sham surgery.” p 72) fibrosis remodelling following 
partial hepatectomy on a background of chronic liver injury is already rapid. 
 
Serum analyses show some differences between control and CSF1-Fc treated groups 
including a lower bilirubin and ALT at Day 4, although serum albumin is also reduced. 
(this is discussed in more detail in the following section (“6.6 CSF1 receptor stimulation 
and Paracetamol toxicity ”; p 176) 
 
Conclusion 
CSF1-Fc treatment in this model led to a trend to improved survival, increased body 
weight and increased liver weight to body weight ratio, likely due to hepatic macrophage 
accumulation.  
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6.6 CSF1 receptor stimulation and Paracetamol toxicity  
Aims 
1. Assess effects of CSF1R stimulation on hepatocyte mediated regeneration following 
paracetamol intoxication 




Treatment post injury 
I treated male C57/Bl6 mice with CSF1-Fc or PBS control 12 hours following 
acetaminophen intoxication (n=8 per group). This delayed treatment time point was 
chosen to enable injury to develop without the effects of CSF1-Fc intervention. Between 
12 and 24 hours are recognised as the time of maximal injury166. I had thought that 
delaying treatment further would limit potential effects of the intervention given the 
rapid regenerative process in mice.  
 
Liver weight to body weight ratio was significantly increased with CSF1-Fc 
administration (Figure 6.34a) although I found that hepatocyte proliferation was not 
enhanced at clinically relevant early time points (Figure 6.34b). There was no significant 
difference in area of necrosis following CSF1-Fc administration (Figure 6.34c).  CSF1-Fc 
treatment resulted in marked hepatic macrophage accumulation at the area of necrosis 
and this accumulation persisted at later timepoints (Figure 6.35a).  Despite profound 
macrophage changes, serum cytokines were unaffected by CSF1-Fc at Day 4 (Figure 
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6.35b). Hepatic cytokine profile following CSF1R stimulation and inhibition is shown in 
Figure 6.36.  
 
This macrophage expansion was paralleled by a reduction in serum injury markers, with 
a reciprocal increase following CSF1R blockade (Figure 6.37). Serum albumin level was 
reduced with CSF1-Fc treatment (Figure 6.37) although hepatic albumin gene expression 
was not reduced by CSF1-Fc treatment (Figure 6.38).  
 
Hepatic phagocytic genes MARCO and MSR1 were elevated with CSF1-Fc administration 
with a reciprocal decrease following CSF1R inhibition (Figure 6.39). Clearance of 
microbeads from the circulation remained effective in both groups likely due to the much 
reduced liver loss compared to PH (Figure 6.40a). Overall liver fluorescence increased 
following microbead injection with CSF1-Fc treatment (Figure 6.40a).  
 
I found that CSF1-Fc increased blood monocyte count following paracetamol 
intoxication, with continued CSF1R stimulation increasing both Ly6C-high and Ly6C-low 
populations (Figure 6.41a and Figure 6.41b; gating strategy: Appendix 3, p233). 
Prolonged stimulation also increased neutrophil count but T cell, B cell and eosinophils 
were unchanged (Figure 6.42). 
 
 
Manipulating macrophages to enhance liver regeneration 
167 
Macrophage stimulation in mouse models of regeneration 
 
Figure 6.34: Regenerative parameters following paracetamol intoxication and CSF1-Fc 
a) Liver weight to body weight ratio with CSF1-Fc or control (2 way ANOVA with Bonferroni post-
test). b) Quantification of Ki67 positive hepatocytes at days 2, 3 and 4 following acetaminophen 
intoxication (one way ANOVA with Bonferroni post hoc). c) Quantification of area of necrosis 
and cellular infiltrate at Day 2, 3 and 4 following acetaminophen intoxication (see Figure 3.12: 
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Figure 6.35: Effects of CSF1-Fc on regeneration following paracetamol intoxication  
a) Representative immunohistochemistry F4/80 (red) and Ki67 (DAB) at Day 2 and Day 
4 following acetaminophen with PBS control or CSF1-Fc. b) Serum cytokine array Day 4 
following partial hepatectomy and either PBS control (white bar) or CSF1-Fc treatment 
(grey bar) (2-way ANOVA and Bonferroni post hoc ns). 
a 
b 
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Figure 6.36: Hepatic cytokine expression 
Hepatic gene cytokine expression at Day 3 following paracetamol intoxication and either 
GW2580, AFS98 or CSF1-Fc administration versus control (vehicle gavage, rat IgG2a, 
PBS; n=8/group; 2-way ANOVA comparing intervention with relevant control, 
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Figure 6.37: Serum biochemistry following CSF1R blockade or stimulation 
Serum liver associated biochemistry tests relative to mean of control group at day 3 
following acetaminophen intoxication and either GW2580 (red), AFS98 (blue) or CSF1-




Figure 6.38: Hepatic albumin gene expression 
Whole liver, n=8/group 
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Figure 6.39: Hepatic phagocytosis related gene expression 
Hepatic phagocytic related gene expression at Day 3 following paracetamol intoxication 
and either GW2580, AFS98 or CSF1-Fc administration versus control (vehicle gavage, rat 
IgG2a, PBS; n=8/group; 2-way ANOVA comparing intervention with relevant control, 
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Figure 6.40: Phagocytosis assay 
a) Bead clearance at Day 2 following acetaminophen intoxication with PBS control or 
CSF1-Fc.  b) Net ex vivo liver fluorescence 15 minutes following injection of fluorescent 
beads at Day 2 following acetaminophen intoxication with PBS control (solid circle) or 
CSF1-Fc (hollow circle) (2-way ANOVA with Bonferroni post-test). 
a b 
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Figure 6.41: Blood monocyte profile following CSF1-Fc administration 
a 
b 
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a) Blood monocyte count (Student t test, *p<0.05) and Ly6C profile (2 way ANOVA with 
Bonferroni post test) day 2 following acetaminophen intoxication and CSF1-Fc or control 
(gating strategy Supplementary Fig. 7a). b) Blood monocyte count (t test) and Ly6C 
profile (2 way ANOVA with Bonferroni post-test) day 4 following paracetamol 
intoxication and CSF1-Fc or control. 
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Figure 6.42: Blood cellular populations following paracetamol intoxication 
Quantification of T cells, B cells, neutrophils and eosinophils Day 2 (a) and 4 (b) following 
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Discussion 
The effects seen in the PH model with enhanced phagocytosis prompted me to 
investigate the effects of CSF1-induced macrophage expansion in a mouse model of 
paracetamol intoxication where liver tissue loss is characterised by hepatocyte death 
through both necrotic and apoptotic mechanisms48. 
 
Mice do not develop the same protracted clinical deterioration as humans and at high 
paracetamol doses death in mice is rapid, limiting study of the regenerative process168. I 
therefore used a mouse model leading to marked injury but not associated with death so 
enabling study of regeneration and resolution. CSF1R stimulation or inhibition was 
commenced at 12 hours after injury to limit effects on the injurious process.  
 
Liver size increased with CSF1-Fc treatment and in the absence of increased hepatocyte 
proliferation this likely relates to enhanced macrophage accumulation. Extent of tissue 
loss by necrosis was much less than 2/3PH and microbead clearance from the circulation 
remained effective. Nevertheless, overall liver fluorescence was increased by CSF1-Fc 
consistent with increase in phagocytosis associated genes. In the clinical setting a 
marked impairment in microbead clearance occurs, consistent with degree of injury77. A 
higher dose of paracetamol would have led to a greater extent of liver injury in this 
mouse model but this is associated with high mortality (up to 50%168), which was not 
feasible given Home Office Animal Welfare restrictions.  
 
Following prolonged CSF1-Fc administration (4days), macrophages continued to 
accumulate in the area of previous necrosis whereas in control mice macrophage 
accumulation reduced in line with a fall in hepatic CSF1 gene expression. It is evident 
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that hepatic CSF1 production drives macrophage accumulation during the early post 
injury phase when phagocytosis is essential to clear dying hepatocytes.  
 
Treatment with CSF1-Fc reduced traditional injury markers, with a reciprocal increase 
following CSF1R blockade. Since CSF1-Fc was administered after peak injury this likely 
indicates enhanced macrophage related clearance of these enzymes198. Serum albumin 
level was reduced following 4 days of CSF1-Fc treatment. This is likely a reflection of the 
pro-inflammatory state given hepatic albumin gene expression was unchanged from 
control. Despite profound changes in macrophage trafficking serum cytokines were 
unaffected by CSF1-Fc, indicating that the context rather than simply the presence of 
macrophages drives systemic inflammatory cytokine expression. 
 
CSF1-Fc increased blood monocyte count, with continued CSF1R stimulation increasing 
both Ly6C-high and Ly6C-low populations. As is well documented in the literature CSF1 
administration boosted blood monocyte levels, but also increased neutrophil count at 
the later time point (Day 4). This is consistent with reports of CSF1 responsive 
granulocyte progenitors within bone marrow213. 
 
Conclusion 
CSF1-Fc administration enhances hepatic macrophage accumulation and markers of 
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7.1 Partial hepatectomy in humans 
Aims 
1. Identify cohort of patients where serum has been collected prior to and following 
partial hepatectomy 
2. Assess serum CSF1 level in these patients 
 
Results 
Relating these findings to the clinical setting I assessed serum CSF1 level in patients 
undergoing PH. Following ethical approval I collaborated with a surgical colleague (M. 
Hughes, Surgical Registrar, Royal Infirmary of Edinburgh) who was collecting serum 
samples from patients prior to and at days 1 and 3 following partial hepatectomyxxiv. 
Figure 7.1 details the characteristics of this group. Two patients developed postoperative 
liver failure and their details are provided in Figure 7.2. Healthy control data was 
provided by D. Antoine, University of Liverpool (Appendix 4, p234). 
 
I trialled several methods of serum CSF1 assessment including ELISA and cytometric 
bead array technology however these attempts were unsuccessful. Serum CSF1 level is 
                                                             
xxiv Sa mple s we re  colle cte d by M.  Hughe s (a  col la borat or ) a nd I  a me nde d a nd submitte d t he  e t hical 
docume ntat ion t o e na ble CSF1 a nalysis  on t he se sa mple s 
Chapter 7. Serum macrophage colony 
stimulating factor in humans following liver 
injury 
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apparently notoriously difficult to analyse. I then collaborated with D. Antoine (Principal 
Investigator, Centre for Translational Medicine, Liverpool) who has extensive experience 
of biomarker usage and development. D. Antoine analysed the samples using the 
Mesoscale Discovery platformxxv blinded to patient and time point and then sent results 
back to me for analysis. This was successful.  
 
I found that preoperative serum CSF1 in this patient cohort was higher than healthy 
volunteers (Figure 7.3a). Initial reduction in serum CSF1 following partial hepatectomy 
was followed by a marked increase at postoperative Day 3 (Figure 7.3a). The two 
patients who developed postoperative liver failure (Figure 7.2) had serum CSF1 levels 
below the 25th percentile (Figure 7.3c).  
 
Although more extensive resection may increase blood loss there was no correlation 
between serum CSF1 and blood loss at either time point (Figure 7.4a and Figure 7.4b). 
Monocyte count increased proportionate to extent of resection, although there was no 
direct correlation between monocyte count and serum CSF1 level (Figure 7.6).  
 
Given the increase in serum CSF1 level we looked to assess hepatic CSF1 gene expression 
during regeneration.  Liver biopsy following PH in humans carries significant clinical risk 
so we therefore analysed mouse liver following PH. CSF1 gene expression in total liver 




                                                             
xxv This plat form use s e le ctroche milumine sce nce de tect ion t o dete ct binding e ve nt s on patt erne d 
a rra ys 
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Figure 7.1: Details of patients undergoing partial hepatectomy categorised according to 




Figure 7.2: Details of patients developing postoperative liver failure  
(n=2) 
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Figure 7.3: Serum CSF1 increases following partial hepatectomy in humans proportional 
to extent of resection. 
a) Serum CSF1 in healthy volunteers and patients undergoing partial hepatectomy to 
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(One-way repeated measures ANOVA with Bonferroni post hoc). b) Mean serum CSF1 
categorised according to extent of resection (<3 liver segments, 3-5 liver segments and 
>5 liver segments resected; Two-way RM ANOVA with Tukey’s post hoc). c) Box and 
whisker plots showing minimum to maximum values per time point with patients 
developing postoperative liver failure overlaid with red dots. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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Figure 7.4: Serum CSF1 level versus blood loss 
a) Blood loss according to extent of resection. b) Dot plot showing blood loss versus 
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Figure 7.6: Correlation between serum CSF1 and monocyte count on Day 3 post op. 
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Discussion 
In humans, I found a marked increase in CSF1 level following PH, proportionate with the 
extent of resection. It has previously been reported that hepatic macrophages are the 
main clearance source of CSF1 from the circulation84. I therefore considered whether this 
postoperative rise related to extent of resection was either due to reduced clearance of 
serum CSF1 given the smaller liver remnant or whether the liver remnant was producing 
a greater quantity of CSF1 following surgery. I considered whether obtaining liver 
biopsies following surgery in humans would be appropriate. However, given the high 
risks associated with liver biopsy this would not be ethical in the postoperative period. I 
therefore analysed hepatic CSF1 gene expression in mice following partial hepatectomy. 
I found that hepatic CSF1 gene expression was not increased in mice following PH, 
indicating that the rise in serum CSF1 likely relates to reduced CSF1 clearance capacity.  
 
In my analysis two patients with low serum CSF1 levels developed postoperative liver 
failure. Recent work in living liver donors undergoing PH showed that a higher serum 
CSF1 level was associated with more rapid liver regrowth126. Together, this could suggest 
a potential role for supplementary CSF1 to enhance liver regeneration in humans but the 
numbers in my study are too low to draw clear conclusions. 
 
In my series the serum CSF1 level was higher preoperatively than normal controls, and 
actually reduced Day 1 following surgery. This is consistent with the production of CSF1 
by the malignant process. The majority of these patients were undergoing surgery for 
metastatic colorectal cancer. The production of CSF1 has been linked with 
aggressiveness of cancers, metastasis and poor outcome214,215. Indeed the link between 
CSF1 and tumour growth has led to work inhibiting this pathway215. Following this 
patient cohort up so as to identify those patients whose cancer recurs may enable 
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prediction of those patients with particularly aggressive cancer that are at high risk of 
subsequently recurring. If this was the case, a patient group could be targeted for 
subsequent chemotherapy.  
 
Although blood monocyte count rise follows a similar pattern at Day 3 following partial 
hepatectomy as that of serum CSF1, the lack of association between these two variables 
likely reflects the multifactorial nature of inflammatory response stimuli. 
 
In the mouse model CSF1-Fc was administered following PH when the cancer in humans 
would have been resected. While theoretically the patient may be cancer free, up to 50% 
of patients may recur within 2 years216. Therefore it is crucial that any potential effects 
of CSF1 therapy on recurrence are thoroughly explored. Routine use of a CSF1 based 
therapy following partial hepatectomy might seem inappropriate. However perhaps in 
the context of a patient with low serum CSF1 level and a failing liver postoperatively, a 
CSF1 based therapy could have a therapeutic role, by boosting hepatic macrophage 
accumulation, facilitating regeneration and phagocytic capacity.  
 
Conclusion 
Serum CSF1 is raised in patients prior to partial hepatectomy to remove liver cancer. 
Following an initial reduction, CSF1 level rebounds most likely related to reduced CSF1 
clearance by the liver.  
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7.2 Paracetamol intoxication in humans 
Aims 
1. Identify cohort of patients where serum has been collected following paracetamol 
intoxication 
2. Assess serum CSF1 level in these patients 
 
I collaborated with K. Simpson (Senior lecturer, Liver Transplantation, University of 
Edinburgh) who has an established collaboration with D. Antoine (Principal Investigator, 
Centre for Translational Medicine, University of Liverpool). Together they have 
established a series of 84 patients who presented to a specialist liver centre with acute 
liver failure induced by paracetamol intoxication. This cohort has been well 
characterised and previous work assessing markers of injury has been published on this 
series97. A second group of patients where serum samples were collected from first 
presentation to hospital was also analysed. 
 
D. Antoine analysed the samples using the Mesoscale Discovery platformxxvi blinded to 
patient and time point and then sent results back to me for analysis.  
 
  
                                                             
xxvi This  plat form use s e lect roche milumine sce nce  de tect ion to detect  binding eve nt s on pat terne d 
a rra ys 
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Results 
Patient cohort characteristics are shown in Figure 7.8 and Figure 7.9. Serum CSF1 level 
was significantly elevated in survivors compared with patients who subsequently died 
or required liver transplantation (Figure 7.10a). The receiver operator characteristic 
curve indicates biomarker potential, with area under the curve of 0.84 (Figure 7.10b). 
Serial samples in a further cohort of patients (patient characteristics in Figure 7.9), this 
time from first presentation to hospital, showed serum CSF1 level continued to increase 
after presentation in survivors (Figure 7.10c). Due to the prohibitive risks of liver biopsy 
hepatic CSF1 gene expression was assessed in mice, revealing increased expression 
following acetaminophen intoxication, peaking at Day 2 (Figure 7.11). 
 
Given previously published work demonstrating the prognostic value of the injury 
marker acetyl-HMGB197, I considered whether combining CSF1 and acetyl-HMGB1 could 
enhance prognostic ability using logistic regression analysis. For this section I 
collaborated with B. Francis (Statistician, Centre for Translational Medicine, University 
of Liverpool). B. Francis undertook the logistic regression analysis using the software 
package R169. 
 
Analysis of acetyl-HMGB1 levels from serial samples from admission to hospital showed 
a marked increase in patients who subsequently died or required liver transplantation 
(Figure 7.12a). We then reviewed the patient cohort from admission to the specialist 
liver unit again.  Many acetyl-HMGB1 values in this cohort were close to zero so a log 
transformation was performed (Appendix 5).  A high inverse correlation existed between 
serum acetyl-HMGB1 and serum CSF1, with a similar relationship shown in both the 
survivors of acute liver failure and those who died or subsequently required liver 
transplantation (Figure 7.12b).   
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When combined in a logistic regression model, only CSF1 showed significance (Figure 
7.14a; Details of the logistic regression modelling are provided in Appendix 6 (p236), 
Appendix 7 (p236), Appendix 8 (p236)). Analysis of deviance showed no significant 
difference between the combined model and CSF1 alone indicating that the addition of 
acetyl-HMGB1 did not further enhance the model (Figure 7.14b). This can be visually 
represented by receiver operator characteristic curves (Figure 7.13c). Figure 7.14 
provides example CSF1 values with risk of death based on the ‘CSF1 alone’ logistic 
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Figure 7.8: Details of acetaminophen intoxication patients presenting to the specialist 
liver unit with acute liver failure grouped according to survivors versus those who 
subsequently required liver transplantation or died. 
Patient cohort and acetyl-HMGB1 values as per Antoine et al.24 
 
 
Figure 7.9: Details of patients from first presentation to hospital following 
acetaminophen intoxication 
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Figure 7.10: Serum CSF1 level is associated with survival in acute liver failure in humans. 
a) Serum CSF1 level in healthy volunteers and in patients following paracetamol 
intoxication on arrival to a specialist liver unit grouped according to outcome (mean and 
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Bonferroni post-hoc). b) Receiver operator characteristic based on serum CSF1 level in 
patients who subsequently survived or died/required liver transplantation 
corresponding to cohort shown in (a). c) Serial CSF1 samples of patients on first 
presentation to hospital following acetaminophen intoxication categorised into survived 
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Figure 7.11: Hepatic CSF1 gene expression in mice following paracetamol intoxication at 
time points including normal (uninjured mice, (n=8)), Day 1 (n=4), Day 2, (n=4), Day 3 
(n=4) and Day 4 (n=4)   
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Figure 7.12: Serum CSF1 versus acetyl-HMGB1  
a) Serial acetyl-HMGB1 samples of patients first presenting to hospital following 
acetaminophen intoxication categorised into survived or died/required liver 
transplantation (n=10/group). b) Dot plots of serum CSF1 level versus log(serum acetyl-
HMGB1) on presentation to the specialist liver centre (survived= black; died/required 
liver transplantation=red) with line of best fit (survived: r2 0.22, p=0.0008; Died/liver 
transplantation: r2 0.52, p<0.0001; slope difference: F=0.15, p=0.70; Intercept difference: 
F=8.03, p=0.006). 
a b 
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Figure 7.13: Details of the combined logistic regression model involving Log(serum 
acetyl-HMGB1) + serum CSF1. b) Analysis of deviance comparing combined Log(acetyl-
HMGB1) + CSF1 model (Model 1) and CSF1 alone (Model 2). c) Receiver operator 
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Figure 7.14: Logistic regression model 
a) Example serum values and predicted chance of death based on logistic regression 
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I then sought to examine the serum level levels of the other main regulator of 
macrophage phenotype, GMCSF. As discussed in “Regulation of cells of the monocyte 
macrophage lineage”, (p43), GMCSF can influence macrophage phenotype to generate a 
more pro inflammatory cell and in the presence of lipopolysaccharide (found in the outer 
membrane of gram negative bacteria) GMCSF predominance can lead to wide spread 
hepatocyte apoptosis130,144. In this cohort of patients, GMCSF was significantly elevated 
in patients with acute liver failure who either died or required liver transplantation 
(Figure 7.15a). The receiver operator characteristic curve indicates that serum GMCSF 
has more limited discriminative ability than serum CSF1 (Figure 7.15b). There was no 
relationship between serum CSF1 and GMCSF levels (Figure 7.16).  
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Figure 7.15: Serum GMCSF in acute liver failure 
a) Serum GMCSF in patients presenting with acute liver failure due to paracetamol 
intoxication who either survived or died following admission to liver unit with acute liver 
failure (median; Mann-Whitney test). b) Receiver operator characteristic based on 
serum GMCSF level in patients who subsequently survived or died/required liver 
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Figure 7.16: Relating serum GMCSF and CSF1 in acute liver failure 
Serum GMCSF versus serum CSF1 in patients who either survived or died due to acute 
liver failure following paracetamol intoxication (survivors (black): r2=0.038, p=0.19; 
died/LT (red): r2=0.029, p=0.36).  
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Discussion 
In humans, I found that serum CSF1 level was elevated in all patients with acute liver 
failure induced by paracetamol intoxication. However serum CSF1 level was highest in 
those who survived compared with those who died or required liver transplantation. 
Given the ethical concerns regarding liver biopsy in humans I turned to the mouse model 
to assess hepatic CSF1 production. Here hepatic CSF1 gene expression increased 
following hepatic injury, peaking at Day 2. It is evident that hepatic CSF1 production drives 
macrophage accumulation during the early post injury phase when phagocytosis is essential to 
clear dying hepatocytes. Falling CSF1 levels in the non-survivor group therefore indicates 
worsening hepatic function.  Falling CSF1 levels may also influence tissue macrophage 
phenotype51, reduce monocyte survival217 and potentially contributing to organ 
dysfunction at extrahepatic sites.  The serum CSF1 reduction is consistent with the 
monocytopenia described in acute liver failure51,52 particularly given the persistence of 
bone marrow monocyte precursors52.  
 
Others have shown that remaining monocytes express low levels of HLA-DR which can 
impair response to sepsis51. Supplementary CSF1 therapy in this setting might facilitate 
regeneration by increasing monocyte numbers, facilitate a proregenerative macrophage 
phenotype, increase monocyte HLA-DR expression217 and enhance phagocytic capacity. 
  
We tested whether the combination of serum CSF1 level, with the previous best 
biomarker of injury (acetyl-HMGB197) could improve prognostic capacity. However, 
within the combined logistic regression model only serum CSF1 was significant, with no 
significant difference between the combined model and CSF1 alone. Given there is no 
clear advantage of combining CSF1 and acetyl-HMGB1 it would suggest that serum CSF1 
is the maximal predictor of eventual death in this cohort.  
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The ability to stratify patients on admission to the specialist liver centre would be highly 
advantageous, potentially enabling earlier listing for transplantation in those predicted 
to die and even avoiding transplantation in those with a high chance of survival. This 
data provides a platform on which to power prospective studies and develop a validation 
cohort for the current observations.  
 
The finding that serum GMCSF was significantly elevated in patients who died or 
required liver transplantation might reflect the more polarised inflammatory 
environment in patients with the severest liver injury. Animal models that demonstrate 
hepatocyte apoptosis in the presence of raised GMCSF indicate the potentially negative 
consequences of this situation130. The presence of competition between CSF1 and GMCSF 
for resulting cell phenotype may indicate that supplementary CSF1 could alter the 
cellular effects of this in a favourable direction.  
 
Conclusion 
Serum CSF1 level is raised in patients with acute liver failure induced by paracetamol 
intoxication and demonstrates discriminative capacity in identifying those at the 
greatest risk of requirement for liver transplantation or death.  
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The objective of this project was to explore whether macrophages could be manipulated 
to enhance liver regeneration following acute injury. Hepatic macrophages perform a 
multitude of functions critical to maintaining homeostasis. Following hepatic injury, 
macrophage mediated innate immunity is compromised, associated with a high risk of 
sepsis. Given the role of hepatic macrophages in inducing hepatocyte proliferation, the 
link between innate immunity and regeneration is clear. The ability to enhance hepatic 
macrophage function could offer a therapeutic strategy to improve outcomes following 
liver injury. 
 
I found that, following partial hepatectomy, macrophage number in the liver increases 
markedly, mainly via infiltration in the early stages and then subsequent proliferation. I 
trialled direct administration of macrophages in a clinically relevant model of chronic 
liver injury and partial hepatectomy. Experiments were hampered initially by technical 
difficulties with the fibrosis induction regimen and safe administration of the cells. After 
extensive optimisation I did not find a benefit with macrophage administration in this 
model. 
 
I went on to explore the effects of macrophage stimulation in vivo. Here I used a potent 
CSF1 receptor stimulator, CSF1-Fc.  CSF1-Fc resulted in marked upregulation of 
chemokines within the liver, via direct hepatic macrophage signalling. In particular the 
CCR2 ligands, CCl2, CCl7 and CCl12, were elevated. In the CCR2 -/- mouse there was a 
reduction in monocyte trafficking to the liver and liver size increase was less marked 
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following CSF1-Fc administration. As has been previously well characterised, CSF1 
receptor stimulation can induce macrophage proliferation. I found that CSF1-Fc 
administration caused both a marked monocytosis and also stimulated tissue resident 
macrophages in the liver and spleen to proliferate. After 4 days of CSF1-Fc 
administration liver size had increased markedly. By assessment of F4/80 staining it was 
apparent that this was mainly due to macrophage accumulation, however there was 
evidence of hepatocyte proliferation. With an early increase in Il6 and evidence that Il6 
can induce hepatocyte proliferation I found that this proliferation was reduced in the Il6 
-/- mouse potentially implicating Il6 in this mechanism. A multitude of other factors 
changed based on analysis of gene array data, in particular matrix remodelling genes 
which are likely to also influence hepatocyte proliferation. The mechanism of hepatocyte 
proliferation is likely multifactorial, but given this occurs late and at a time of massive 
macrophage accumulation, this enhanced hepatocyte proliferation is likely to be of little 
clinical relevance. 
 
 It was interesting to note that the marked macrophage accumulation induced by CSF1-
Fc did not appear detrimental to the mice, indeed injury markers were not elevated and 
systemic cytokine profile showed minimal disruption. Together these data indicate that 
it is the context which these inflammatory cells are in, rather than the simply the 
presence of these inflammatory cells, that drives the injurious response. 
 
In the models of liver regeneration, the overwhelming phenotype following CSF1-Fc 
administration was that of macrophage accumulation involving both proliferation of 
resident macrophages and infiltration of circulating monocytes. There was an effect on 
hepatocyte proliferation at later time points, however this occurred at a timepoint when 
regeneration in the control treated mouse was effectively complete. The most clinically 
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relevant effect of CSF1-Fc on hepatic injury models was the enhanced innate immune 
capacity of the liver. This was as a direct consequence of the increased macrophage 
density within the liver. The fluorescent microbead assay that I developed demonstrated 
just how effective the liver macrophage is at clearing insoluble material.  
 
Relating these preclinical findings to the clinical setting I have shown that serum CSF1 
level rises following partial hepatectomy in humans. Given hepatic gene expression of 
CSF1 did not rise in mice following partial hepatectomy it is most likely that this increase 
in serum CSF1 related to extent of liver resection is due, at least in part, to impaired 
clearance by the reduced liver remnant size. Following paracetamol intoxication in 
humans a high CSF1 level was associated with survival in acute liver failure. I went on to 
examine biomarker potential using logistic regression models and show that serum CSF1 
outperforms the previous best indicator of outcome in this model. These findings require 
validation in a prospective cohort of patients to assess potential use as a biomarker. 
 
My work has identified a number of potential future studies, with both therapeutic and 
prognostic opportunities.  
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8.2 Therapeutic opportunities 
The ability to enhance the innate immune capacity of the liver with CSF1-Fc could have 
number of possible applications in liver disease. Certainly the enhanced clearance of 
necrotic material following paracetamol intoxication and support for innate immune 
capacity could improve outcomes in the most severe liver injury. Of course the profound 
immune stimulation caused by CSF1-Fc could have deleterious effects. Therefore 
studying the effects of CSF1-Fc in a more clinically relevant model of acute liver injury 
would be an appropriate next step. The pig may offer an appropriate intermediary to the 
clinic given similarities between the pig and human mononuclear-phagocytic systems218. 
A porcine model of paracetamol intoxication has been established in Edinburgh and 
discussions are underway to trial CSF1-Fc in this model219.  
 
CSF1-Fc could have a role in boosting hepatic innate immune function following partial 
hepatectomy in humans. However, the effects of CSF1 on any residual cancer (given 
partial hepatectomy is mainly performed for malignant disease) are unclear. Concerns 
over the growth promoting effects of CSF1-Fc on cancer require further investigation. 
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8.3 Prognostic opportunities 
The ability to stratify patients according to predicted outcome prior to clinical 
deterioration would be highly advantageous. My results suggest that serum CSF1 could 
serve as a prognostic marker in acute liver failure, which could indicate which patients 
would benefit from supplementary CSF1 therapy. However this prognostic finding in 
retrospective cohort requires validation in a second cohort. If this validation reveals 
similar results then testing the prognostic capacity of CSF1 against current clinical 
criteria in a prospective trial will be required. This is an avenue that I am currently 
exploring. 
 
Serum CSF1 level was raised in patients prior to partial hepatectomy and subsequently 
reduced when the cancer had been resected. In other cancers there has been an 
association between raised serum CSF1 and more aggressive malignancy. Therefore 
following this patient cohort over the next 5 years and relating perioperative CSF1 level 
to incidence of cancer recurrence may provide a tool to predict which cancers are most 
likely to recur. Stratifying patients in this way at an early stage could facilitate the 
administration of chemotherapeutics to patients with the greatest clinical need.  
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8.4 Conclusions 
Macrophages have a central role in regeneration and manipulating macrophages can 
enhance regeneration of the injured liver. Providing a cellular therapy by stimulating a 
specific effector cell in vivo can induce profound effects, offering an alternative to direct 
cellular administration. The immune and regenerative responses are highly evolved to 
facilitate rapid recovery and identifying those factors which govern the response at a 













1. Lombard, M. Liver disease and primary care: a briefing paper. Vol. 2014 (2011). 
2. Schindl, M.J., Redhead, D.N., Fearon, K.C., Garden, O.J. & Wigmore, S.J. The value of 
residual liver volume as a predictor of hepatic dysfunction and infection after major liver 
resection. Gut 54, 289-296 (2005). 
3. UK, C.R. Liver cancer rates by age, UK 1975-2010. Vol. 2014 (2013). 
4. Capocaccia, R., et al. Hepatocellular carcinoma: trends of incidence and survival 
in Europe and the United States at the end of the 20th century. Am J Gastroenterol 102, 
1661-1670; quiz 1660, 1671 (2007). 
5. Altekruse, S.F., McGlynn, K.A. & Reichman, M.E. Hepatocellular carcinoma 
incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin 
Oncol 27, 1485-1491 (2009). 
6. Takamoto, T., et al. Recovery of liver function after the cessation of preoperative 
chemotherapy for colorectal liver metastasis. Ann Surg Oncol 17, 2747-2755 (2010). 
7. Berry, P.A., et al. Admission levels and early changes in serum interleukin-10 are 
predictive of poor outcome in acute liver failure and decompensated cirrhosis. Liver Int 
30, 733-740 (2010). 
8. Khuroo, M.S. & Kamili, S. Aetiology and prognostic factors in acute liver failure in 
India. J Viral Hepat 10, 224-231 (2003). 
9. Rantala, M. & van de Laar, M.J. Surveillance and epidemiology of hepatitis B and 
C in Europe - a review. Euro surveillance : bulletin Europeen sur les maladies 
transmissibles = European communicable disease bulletin 13(2008). 
10. Hawton, K., et al. UK legislation on analgesic packs: before and after study of long 
term effect on poisonings. BMJ 329, 1076 (2004). 
Manipulating macrophages to enhance liver regeneration 
210 
References 
11. Bretherick, A.D., et al. Acute liver failure in Scotland between 1992 and 2009; 
incidence, aetiology and outcome. QJM : monthly journal of the Association of Physicians 
104, 945-956 (2011). 
12. Bernal, W., Auzinger, G., Dhawan, A. & Wendon, J. Acute liver failure. Lancet 376, 
190-201 (2010). 
13. Zamora Nava, L.E., Aguirre Valadez, J., Chavez-Tapia, N.C. & Torre, A. Acute-on-
chronic liver failure: a review. Therapeutics and clinical risk management 10, 295-303 
(2014). 
14. Kohler, J.J., et al. Approaches to hepatitis C treatment and cure using NS5A 
inhibitors. Infection and drug resistance 7, 41-56 (2014). 
15. Pellicoro, A., Ramachandran, P. & Iredale, J.P. Reversibility of liver fibrosis. 
Fibrogenesis & tissue repair 5, S26 (2012). 
16. Godwin, J.W., Pinto, A.R. & Rosenthal, N.A. Macrophages are required for adult 
salamander limb regeneration. Proc Natl Acad Sci U S A 110, 9415-9420 (2013). 
17. Michalopoulos, G.K. Liver regeneration after partial hepatectomy: critical 
analysis of mechanistic dilemmas. Am J Pathol 176, 2-13 (2010). 
18. Mars, W.M., et al. Immediate early detection of urokinase receptor after partial 
hepatectomy and its implications for initiation of liver regeneration. Hepatology 21, 
1695-1701 (1995). 
19. Sokabe, T., et al. Differential regulation of urokinase-type plasminogen activator 
expression by fluid shear stress in human coronary artery endothelial cells. Am J Physiol 
Heart Circ Physiol 287, H2027-2034 (2004). 
20. Michalopoulos, G.K. Liver regeneration. J Cell Physiol 213, 286-300 (2007). 
21. Yeh, C.C., et al. Shear stress modulates macrophage-induced urokinase 
plasminogen activator expression in human chondrocytes. Arthritis research & therapy 
15, R53 (2013). 
Manipulating macrophages to enhance liver regeneration 
211 
References 
22. Gu, J.M., et al. Urokinase plasminogen activator receptor promotes macrophage 
infiltration into the vascular wall of ApoE deficient mice. J Cell Physiol 204, 73-82 (2005). 
23. Kim, T.H., Mars, W.M., Stolz, D.B. & Michalopoulos, G.K. Expression and activation 
of pro-MMP-2 and pro-MMP-9 during rat liver regeneration. Hepatology 31, 75-82 
(2000). 
24. LaMarre, J., et al. An alpha 2-macroglobulin receptor-dependent mechanism for 
the plasma clearance of transforming growth factor-beta 1 in mice. J Clin Invest 87, 39-
44 (1991). 
25. Yamada, Y., Kirillova, I., Peschon, J.J. & Fausto, N. Initiation of liver growth by 
tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis 
factor receptor. Proc Natl Acad Sci U S A 94, 1441-1446 (1997). 
26. Cressman, D.E., et al. Liver failure and defective hepatocyte regeneration in 
interleukin-6-deficient mice. Science 274, 1379-1383 (1996). 
27. Huang, W., et al. Nuclear receptor-dependent bile acid signaling is required for 
normal liver regeneration. Science 312, 233-236 (2006). 
28. Selzner, N., et al. ICAM-1 triggers liver regeneration through leukocyte 
recruitment and Kupffer cell-dependent release of TNF-alpha/IL-6 in mice. 
Gastroenterology 124, 692-700 (2003). 
29. Abshagen, K., Eipel, C., Kalff, J.C., Menger, M.D. & Vollmar, B. Loss of NF-kappaB 
activation in Kupffer cell-depleted mice impairs liver regeneration after partial 
hepatectomy. Am J Physiol Gastrointest Liver Physiol 292, G1570-1577 (2007). 
30. Tiberio, G.A., et al. IL-6 Promotes compensatory liver regeneration in cirrhotic 
rat after partial hepatectomy. Cytokine 42, 372-378 (2008). 
31. Lesurtel, M., et al. Platelet-derived serotonin mediates liver regeneration. Science 
312, 104-107 (2006). 
Manipulating macrophages to enhance liver regeneration 
212 
References 
32. Borude, P., et al. Hepatocyte-specific deletion of farnesoid X receptor delays but 
does not inhibit liver regeneration after partial hepatectomy in mice. Hepatology 56, 
2344-2352 (2012). 
33. Goh, Y.P., et al. Eosinophils secrete IL-4 to facilitate liver regeneration. Proc Natl 
Acad Sci U S A 110, 9914-9919 (2013). 
34. DeAngelis, R.A., et al. A complement-IL-4 regulatory circuit controls liver 
regeneration. J Immunol 188, 641-648 (2012). 
35. Oben, J.A. & Diehl, A.M. Sympathetic nervous system regulation of liver repair. 
The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology 
280, 874-883 (2004). 
36. Wang, L., et al. Liver sinusoidal endothelial cell progenitor cells promote liver 
regeneration in rats. J Clin Invest 122, 1567-1573 (2012). 
37. Olsen, P.S., Poulsen, S.S. & Kirkegaard, P. Adrenergic effects on secretion of 
epidermal growth factor from Brunner's glands. Gut 26, 920-927 (1985). 
38. Ochoa, B., et al. Hedgehog signaling is critical for normal liver regeneration after 
partial hepatectomy in mice. Hepatology 51, 1712-1723 (2010). 
39. Dong, J., et al. Elucidation of a universal size-control mechanism in Drosophila 
and mammals. Cell 130, 1120-1133 (2007). 
40. Sakamoto, T., et al. Mitosis and apoptosis in the liver of interleukin-6-deficient 
mice after partial hepatectomy. Hepatology 29, 403-411 (1999). 
41. Braun, L., et al. Transforming growth factor beta mRNA increases during liver 
regeneration: a possible paracrine mechanism of growth regulation. Proc Natl Acad Sci U 
S A 85, 1539-1543 (1988). 
42. Sanderson, N., et al. Hepatic expression of mature transforming growth factor 
beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A 92, 
2572-2576 (1995). 
Manipulating macrophages to enhance liver regeneration 
213 
References 
43. Apte, U., et al. Enhanced liver regeneration following changes induced by 
hepatocyte-specific genetic ablation of integrin-linked kinase. Hepatology 50, 844-851 
(2009). 
44. Rahman, T.M. & Hodgson, H.J. Animal models of acute hepatic failure. Int J Exp 
Pathol 81, 145-157 (2000). 
45. Lee, W.M. & Seremba, E. Etiologies of acute liver failure. Current opinion in critical 
care 14, 198-201 (2008). 
46. Nelson, S.D. Molecular mechanisms of the hepatotoxicity caused by 
acetaminophen. Semin Liver Dis 10, 267-278 (1990). 
47. Zakowski, J.J. & Tappel, A.L. Purification and properties of rat liver mitochondrial 
glutathione peroxidase. Biochim Biophys Acta 526, 65-76 (1978). 
48. Antoine, D.J., Williams, D.P., Kipar, A., Laverty, H. & Park, B.K. Diet restriction 
inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment 
during acetaminophen hepatotoxicity. Molecular medicine 16, 479-490 (2010). 
49. Dambach, D.M., Watson, L.M., Gray, K.R., Durham, S.K. & Laskin, D.L. Role of CCR2 
in macrophage migration into the liver during acetaminophen-induced hepatotoxicity in 
the mouse. Hepatology 35, 1093-1103 (2002). 
50. Hogaboam, C.M., et al. Exaggerated Hepatic Injury Due to Acetaminophen 
Challenge in Mice Lacking C-C Chemokine Receptor 2. The American Journal of Pathology 
156, 1245-1252 (2000). 
51. Antoniades, C.G., et al. Reduced monocyte HLA-DR expression: a novel biomarker 
of disease severity and outcome in acetaminophen-induced acute liver failure. 
Hepatology 44, 34-43 (2006). 
52. Antoniades, C.G., et al. Source and characterization of hepatic macrophages in 
acetaminophen-induced acute liver failure in humans. Hepatology 56, 735-746 (2012). 
Manipulating macrophages to enhance liver regeneration 
214 
References 
53. Brattin, W.J., Glende, E.A., Jr. & Recknagel, R.O. Pathological mechanisms in 
carbon tetrachloride hepatotoxicity. Journal of free radicals in biology & medicine 1, 27-
38 (1985). 
54. Clawson, G.A. Mechanisms of carbon tetrachloride hepatotoxicity. Pathology and 
immunopathology research 8, 104-112 (1989). 
55. Chieli, E. & Malvaldi, G. Role of the microsomal FAD-containing monooxygenase 
in the liver toxicity of thioacetamide S-oxide. Toxicology 31, 41-52 (1984). 
56. Xie, G., et al. Role of differentiation of liver sinusoidal endothelial cells in 
progression and regression of hepatic fibrosis in rats. Gastroenterology 142, 918-927 
e916 (2012). 
57. Pellicoro, A., Ramachandran, P., Iredale, J.P. & Fallowfield, J.A. Liver fibrosis and 
repair: immune regulation of wound healing in a solid organ. Nature reviews. 
Immunology 14, 181-194 (2014). 
58. Ruddell, R.G., et al. A role for serotonin (5-HT) in hepatic stellate cell function and 
liver fibrosis. Am J Pathol 169, 861-876 (2006). 
59. Duffield, J.S., et al. Selective depletion of macrophages reveals distinct, opposing 
roles during liver injury and repair. J Clin Invest 115, 56-65 (2005). 
60. Bourbonnais, E., et al. Liver fibrosis protects mice from acute hepatocellular 
injury. Gastroenterology 142, 130-139 e134 (2012). 
61. Suarez-Cuenca, J.A., et al. Partial hepatectomy-induced regeneration accelerates 
reversion of liver fibrosis involving participation of hepatic stellate cells. Exp Biol Med 
(Maywood) 233, 827-839 (2008). 
62. Moreau, R., et al. Acute-on-chronic liver failure is a distinct syndrome that 
develops in patients with acute decompensation of cirrhosis. Gastroenterology 144, 
1426-1437, 1437 e1421-1429 (2013). 
Manipulating macrophages to enhance liver regeneration 
215 
References 
63. Arvaniti, V., et al. Infections in patients with cirrhosis increase mortality four-fold 
and should be used in determining prognosis. Gastroenterology 139, 1246-1256, 1256 
e1241-1245 (2010). 
64. Vaquero, J., et al. Infection and the progression of hepatic encephalopathy in 
acute liver failure. Gastroenterology 125, 755-764 (2003). 
65. Rolando, N., et al. The systemic inflammatory response syndrome in acute liver 
failure. Hepatology 32, 734-739 (2000). 
66. Bjerring, P.N., Eefsen, M., Hansen, B.A. & Larsen, F.S. The brain in acute liver 
failure. A tortuous path from hyperammonemia to cerebral edema. Metabolic brain 
disease 24, 5-14 (2009). 
67. Stravitz, R.T. & Larsen, F.S. Therapeutic hypothermia for acute liver failure. 
Critical care medicine 37, S258-264 (2009). 
68. Gao, B., Jeong, W.I. & Tian, Z. Liver: An organ with predominant innate immunity. 
Hepatology 47, 729-736 (2008). 
69. Mogensen, T.H. Pathogen recognition and inflammatory signaling in innate 
immune defenses. Clinical microbiology reviews 22, 240-273, Table of Contents (2009). 
70. Krueger, P.D., Lassen, M.G., Qiao, H. & Hahn, Y.S. Regulation of NK cell repertoire 
and function in the liver. Critical reviews in immunology 31, 43-52 (2011). 
71. Balmer, M.L., et al. The liver may act as a firewall mediating mutualism between 
the host and its gut commensal microbiota. Science translational medicine 6, 237ra266 
(2014). 
72. Wiest, R., Lawson, M. & Geuking, M. Pathological bacterial translocation in liver 
cirrhosis. J Hepatol 60, 197-209 (2014). 
73. Tuomisto, S., et al. Changes in gut bacterial populations and their translocation 
into liver and ascites in alcoholic liver cirrhotics. BMC Gastroenterol 14, 40 (2014). 
Manipulating macrophages to enhance liver regeneration 
216 
References 
74. Verbeke, L., Nevens, F. & Laleman, W. Bench-to-beside review: acute-on-chronic 
liver failure - linking the gut, liver and systemic circulation. Crit Care 15, 233 (2011). 
75. Wang, X.D., Soltesz, V., Andersson, R. & Bengmark, S. Bacterial translocation in 
acute liver failure induced by 90 per cent hepatectomy in the rat. Br J Surg 80, 66-71 
(1993). 
76. Schindl, M.J., et al. The adaptive response of the reticuloendothelial system to 
major liver resection in humans. Ann Surg 243, 507-514 (2006). 
77. Canalese, J., et al. Reticuloendothelial system and hepatocytic function in 
fulminant hepatic failure. Gut 23, 265-269 (1982). 
78. Stutchfield, B.M. & Forbes, S.J. Liver sinusoidal endothelial cells in disease - And 
for therapy? J Hepatol 58, 178-180 (2013). 
79. Corbitt, N., et al. Gut bacteria drive Kupffer cell expansion via MAMP-mediated 
ICAM-1 induction on sinusoidal endothelium and influence preservation-reperfusion 
injury after orthotopic liver transplantation. Am J Pathol 182, 180-191 (2013). 
80. MacDonald, K.P., et al. An antibody against the colony-stimulating factor 1 
receptor depletes the resident subset of monocytes and tissue- and tumor-associated 
macrophages but does not inhibit inflammation. Blood 116, 3955-3963 (2010). 
81. Hume, D.A., Pavli, P., Donahue, R.E. & Fidler, I.J. The effect of human recombinant 
macrophage colony-stimulating factor (CSF-1) on the murine mononuclear phagocyte 
system in vivo. J Immunol 141, 3405-3409 (1988). 
82. Wiktor-Jedrzejczak, W., et al. Total absence of colony-stimulating factor 1 in the 
macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U S A 87, 4828-
4832 (1990). 
83. Stanley, E.R., et al. Biology and action of colony--stimulating factor-1. Molecular 
reproduction and development 46, 4-10 (1997). 
Manipulating macrophages to enhance liver regeneration 
217 
References 
84. Bartocci, A., et al. Macrophages specifically regulate the concentration of their 
own growth factor in the circulation. Proc Natl Acad Sci U S A 84, 6179-6183 (1987). 
85. Sauter, K.A., et al. Pleiotropic effects of extended blockade of CSF1R signaling in 
adult mice. J Leukoc Biol (2014). 
86. Devey, L., et al. Tissue-resident macrophages protect the liver from ischemia 
reperfusion injury via a heme oxygenase-1-dependent mechanism. Mol Ther 17, 65-72 
(2009). 
87. Thomas, J.A., et al. Macrophage therapy for murine liver fibrosis recruits host 
effector cells improving fibrosis, regeneration and function. Hepatology (2011). 
88. Abu-Tair, L., et al. Natural killer cell-dependent anti-fibrotic pathway in liver 
injury via Toll-like receptor-9. PLoS One 8, e82571 (2013). 
89. Gao, B. Natural killer group 2 member D, its ligands, and liver disease: good or 
bad? Hepatology 51, 8-11 (2010). 
90. Proctor, W.R., et al. Eosinophils mediate the pathogenesis of halothane-induced 
liver injury in mice. Hepatology 57, 2026-2036 (2013). 
91. Bjornsson, E., Kalaitzakis, E. & Olsson, R. The impact of eosinophilia and hepatic 
necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 
25, 1411-1421 (2007). 
92. Chan, A.C., et al. Liver transplantation for acute-on-chronic liver failure. Hepatol 
Int 3, 571-581 (2009). 
93. O'Grady, J. Liver transplantation for acute liver failure. Best practice & research. 
Clinical gastroenterology 26, 27-33 (2012). 
94. O'Grady, J.G., Alexander, G.J., Hayllar, K.M. & Williams, R. Early indicators of 
prognosis in fulminant hepatic failure. Gastroenterology 97, 439-445 (1989). 
Manipulating macrophages to enhance liver regeneration 
218 
References 
95. Avery, R.K. Recipient screening prior to solid-organ transplantation. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of America 35, 
1513-1519 (2002). 
96. O'Grady, J. Timing and benefit of liver transplantation in acute liver failure. J 
Hepatol 60, 663-670 (2014). 
97. Antoine, D.J., et al. Molecular forms of HMGB1 and keratin-18 as mechanistic 
biomarkers for mode of cell death and prognosis during clinical acetaminophen 
hepatotoxicity. J Hepatol 56, 1070-1079 (2012). 
98. Antoine, D.J., et al. Mechanistic biomarkers provide early and sensitive detection 
of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 
(2013). 
99. Xue, F., et al. Hepatocyte growth factor gene therapy accelerates regeneration in 
cirrhotic mouse livers after hepatectomy. Gut 52, 694-700 (2003). 
100. Ozawa, S., et al. Combination gene therapy of HGF and truncated type II TGF-beta 
receptor for rat liver cirrhosis after partial hepatectomy. Surgery 139, 563-573 (2006). 
101. Ido, A., et al. Safety and pharmacokinetics of recombinant human hepatocyte 
growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, 
following preclinical studies to ensure safety. Journal of translational medicine 9, 55 
(2011). 
102. Harrison, P.M., et al. Failure of insulin and glucagon infusion to stimulate liver 
regeneration in fulminant hepatic failure. J Hepatol 10, 332-336 (1990). 
103. Luo, S.M., Liang, L.J. & Lai, J.M. Effects of recombinant human growth hormone on 
remnant liver after hepatectomy in hepatocellular carcinoma with cirrhosis. World J 
Gastroenterol 10, 1292-1296 (2004). 
104. Stutchfield, B.M., Simpson, K. & Wigmore, S.J. Systematic review and meta-
analysis of survival following extracorporeal liver support. Br J Surg 98, 623-631 (2011). 
Manipulating macrophages to enhance liver regeneration 
219 
References 
105. Stutchfield, B.M., Forbes, S.J. & Wigmore, S.J. Prospects for stem cell 
transplantation in the treatment of hepatic disease. Liver Transpl 16, 827-836 (2010). 
106. Stutchfield, B.M., Rashid, S., Forbes, S.J. & Wigmore, S.J. Practical barriers to 
delivering autologous bone marrow stem cell therapy as an adjunct to liver resection. 
Stem Cells Dev 19, 155-162 (2010). 
107. Thorgeirsson, S.S. & Grisham, J.W. Hematopoietic cells as hepatocyte stem cells: 
a critical review of the evidence. Hepatology 43, 2-8 (2006). 
108. Wang, L., Wang, X., Xie, G., Hill, C.K. & Deleve, L.D. Liver sinusoidal endothelial cell 
progenitor cells promote liver regeneration in rats. J Clin Invest 122, 1567-1573 (2012). 
109. Theise, N.D., et al. Derivation of hepatocytes from bone marrow cells in mice after 
radiation-induced myeloablation. Hepatology 31, 235-240 (2000). 
110. Lagasse, E., et al. Purified hematopoietic stem cells can differentiate into 
hepatocytes in vivo. Nat Med 6, 1229-1234 (2000). 
111. Pittenger, M.F., et al. Multilineage potential of adult human mesenchymal stem 
cells. Science 284, 143-147 (1999). 
112. Moore, J.K., Stutchfield, B.M. & Forbes, S.J. Systematic review: the effects of 
autologous stem cell therapy for patients with liver disease. Aliment Pharmacol Ther 39, 
673-685 (2014). 
113. Zocco, M.A., et al. CD133+ stem cell mobilization after partial hepatectomy 
depends on resection extent and underlying disease. Digestive and Liver Disease 43, 147-
154 (2011). 
114. Garg, V., et al. Granulocyte-Colony Stimulating Factor Mobilizes CD34+ Cells and 
improves Survival of Patients with Acute-On-Chronic Liver Failure. Gastroenterology 
(2011). 
115. Furst, G., et al. Portal vein embolization and autologous CD133+ bone marrow 
stem cells for liver regeneration: initial experience. Radiology 243, 171-179 (2007). 
Manipulating macrophages to enhance liver regeneration 
220 
References 
116. am Esch, J.S., 2nd, et al. Portal application of autologous CD133+ bone marrow 
cells to the liver: a novel concept to support hepatic regeneration. Stem Cells 23, 463-470 
(2005). 
117. Lorenzini, S., et al. Characterisation of a stereotypical cellular and extracellular 
adult liver progenitor cell niche in rodents and diseased human liver. Gut 59, 645-654 
(2010). 
118. Aldeguer, X., et al. Interleukin-6 from intrahepatic cells of bone marrow origin is 
required for normal murine liver regeneration. Hepatology 35, 40-48 (2002). 
119. Klein, I., et al. Kupffer cell heterogeneity: functional properties of bone marrow 
derived and sessile hepatic macrophages. Blood 110, 4077-4085 (2007). 
120. Meijer, C., et al. Kupffer cell depletion by CI2MDP-liposomes alters hepatic 
cytokine expression and delays liver regeneration after partial hepatectomy. Liver 20, 
66-77 (2000). 
121. Prins, H.A., et al. Kupffer cell-depleted rats have a diminished acute-phase 
response following major liver resection. Shock 21, 561-565 (2004). 
122. Prins, H.A., et al. The role of Kupffer cells after major liver surgery. JPEN J Parenter 
Enteral Nutr 29, 48-55 (2005). 
123. Abshagen, K., Eipel, C., Kalff, J.C., Menger, M.D. & Vollmar, B. Kupffer cells are 
mandatory for adequate liver regeneration by mediating hyperperfusion via modulation 
of vasoactive proteins. Microcirculation 15, 37-47 (2008). 
124. Luo, J., et al. Colony-stimulating factor 1 receptor (CSF1R) signaling in injured 
neurons facilitates protection and survival. J Exp Med 210, 157-172 (2013). 
125. Alikhan, M.A., et al. Colony-stimulating factor-1 promotes kidney growth and 
repair via alteration of macrophage responses. Am J Pathol 179, 1243-1256 (2011). 
Manipulating macrophages to enhance liver regeneration 
221 
References 
126. Matsumoto, K., et al. Serial changes of serum growth factor levels and liver 
regeneration after partial hepatectomy in healthy humans. International journal of 
molecular sciences 14, 20877-20889 (2013). 
127. Meng, F., et al. Role of stem cell factor and granulocyte colony-stimulating factor 
in remodeling during liver regeneration. Hepatology 55, 209-221 (2012). 
128. Vassiliou, I., et al. The combined effect of erythropoietin and granulocyte 
macrophage colony stimulating factor on liver regeneration after major hepatectomy in 
rats. World J Surg Oncol 8, 57 (2010). 
129. Eroglu, A., et al. Effect of granulocyte-macrophage colony-stimulating factor on 
hepatic regeneration after 70% hepatectomy in normal and cirrhotic rats. HPB (Oxford) 
4, 67-73 (2002). 
130. Hirano, K., et al. Overexpression of granulocyte-macrophage colony-stimulating 
factor in mouse liver enhances the susceptibility of lipopolysaccharide leading to 
massive apoptosis of hepatocytes. Liver Int 25, 1027-1035 (2005). 
131. Crofton, R.W., Diesselhoff-den Dulk, M.M. & van Furth, R. The origin, kinetics, and 
characteristics of the Kupffer cells in the normal steady state. J Exp Med 148, 1-17 (1978). 
132. Volkman, A. Disparity in origin of mononuclear phagocyte populations. J 
Reticuloendothel Soc 19, 249-268 (1976). 
133. Yamamoto, T., et al. Repopulation of murine Kupffer cells after intravenous 
administration of liposome-encapsulated dichloromethylene diphosphonate. Am J 
Pathol 149, 1271-1286 (1996). 
134. Lehenkari, P.P., et al. Further insight into mechanism of action of clodronate: 
inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-
containing metabolite. Molecular pharmacology 61, 1255-1262 (2002). 
Manipulating macrophages to enhance liver regeneration 
222 
References 
135. Auffray, C., Sieweke, M.H. & Geissmann, F. Blood monocytes: development, 
heterogeneity, and relationship with dendritic cells. Annual review of immunology 27, 
669-692 (2009). 
136. Jenkins, S.J., et al. Local macrophage proliferation, rather than recruitment from 
the blood, is a signature of TH2 inflammation. Science 332, 1284-1288 (2011). 
137. Davies, L.C., et al. Distinct bone marrow-derived and tissue-resident macrophage 
lineages proliferate at key stages during inflammation. Nature communications 4, 1886 
(2013). 
138. Schulz, C., et al. A lineage of myeloid cells independent of Myb and hematopoietic 
stem cells. Science 336, 86-90 (2012). 
139. Yona, S., et al. Fate mapping reveals origins and dynamics of monocytes and 
tissue macrophages under homeostasis. Immunity 38, 79-91 (2013). 
140. Rosas, M., et al. The transcription factor Gata6 links tissue macrophage 
phenotype and proliferative renewal. Science 344, 645-648 (2014). 
141. Ezure, T., Ishiwata, T., Asano, G., Tanaka, S. & Yokomuro, K. Production of 
macrophage colony-stimulating factor by murine liver in vivo. Cytokine 9, 53-58 (1997). 
142. Stanley, E.R., Berg, K.L., Einstein, D.B., Lee, P.S. & Yeung, Y.G. The biology and 
action of colony stimulating factor-1. Stem Cells 12 Suppl 1, 15-24; discussion 25 (1994). 
143. Chitu, V. & Stanley, E.R. Colony-stimulating factor-1 in immunity and 
inflammation. Current opinion in immunology 18, 39-48 (2006). 
144. Hamilton, J.A. Colony-stimulating factors in inflammation and autoimmunity. 
Nature reviews. Immunology 8, 533-544 (2008). 
145. Li, Y., et al. Induction of functional human macrophages from bone marrow 
promonocytes by M-CSF in humanized mice. J Immunol 191, 3192-3199 (2013). 
146. Phillips, W.A. & Hamilton, J.A. Colony stimulating factor-1 is a negative regulator 
of the macrophage respiratory burst. J Cell Physiol 144, 190-196 (1990). 
Manipulating macrophages to enhance liver regeneration 
223 
References 
147. Martinez, F.O., Sica, A., Mantovani, A. & Locati, M. Macrophage activation and 
polarization. Frontiers in bioscience : a journal and virtual library 13, 453-461 (2008). 
148. Zhang, M.Z., et al. CSF-1 signaling mediates recovery from acute kidney injury. J 
Clin Invest 122, 4519-4532 (2012). 
149. Nandi, S., et al. The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct 
developmental brain expression patterns and regulate neural progenitor cell 
maintenance and maturation. Developmental biology 367, 100-113 (2012). 
150. Menke, J., et al. CSF-1 signals directly to renal tubular epithelial cells to mediate 
repair in mice. J Clin Invest 119, 2330-2342 (2009). 
151. Dai, X.M., et al. Targeted disruption of the mouse colony-stimulating factor 1 
receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased 
primitive progenitor cell frequencies, and reproductive defects. Blood 99, 111-120 
(2002). 
152. Lin, H., et al. Discovery of a cytokine and its receptor by functional screening of 
the extracellular proteome. Science 320, 807-811 (2008). 
153. Wang, Y., et al. IL-34 is a tissue-restricted ligand of CSF1R required for the 
development of Langerhans cells and microglia. Nature immunology 13, 753-760 (2012). 
154. Ferenbach, D. & Hughes, J. Macrophages and dendritic cells: what is the 
difference? Kidney Int 74, 5-7 (2008). 
155. Hume, D.A. Macrophages as APC and the dendritic cell myth. J Immunol 181, 
5829-5835 (2008). 
156. Itoh, Y., et al. Serum levels of macrophage colony stimulating factor (M-CSF) in 
liver disease. J Hepatol 21, 527-535 (1994). 
157. Duffield, J.S., et al. Conditional ablation of macrophages halts progression of 
crescentic glomerulonephritis. Am J Pathol 167, 1207-1219 (2005). 
Manipulating macrophages to enhance liver regeneration 
224 
References 
158. Ramachandran, P., et al. Differential Ly-6C expression identifies the recruited 
macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc 
Natl Acad Sci U S A 109, E3186-3195 (2012). 
159. Dhaliwal, K., et al. Monocytes control second-phase neutrophil emigration in 
established lipopolysaccharide-induced murine lung injury. American journal of 
respiratory and critical care medicine 186, 514-524 (2012). 
160. Medoff, B.D., et al. CD11b+ Myeloid Cells Are the Key Mediators of Th2 Cell 
Homing into the Airway in Allergic Inflammation. The Journal of Immunology 182, 623-
635 (2008). 
161. Movita, D., et al. Kupffer cells express a unique combination of phenotypic and 
functional characteristics compared with splenic and peritoneal macrophages. J Leukoc 
Biol 92, 723-733 (2012). 
162. Amemiya, H., Kono, H. & Fujii, H. Liver Regeneration is Impaired in Macrophage 
Colony Stimulating Factor Deficient Mice After Partial Hepatectomy: The Role of M-CSF-
Induced Macrophages. J Surg Res (2009). 
163. Sasmono, R.T., et al. A macrophage colony-stimulating factor receptor-green 
fluorescent protein transgene is expressed throughout the mononuclear phagocyte 
system of the mouse. Blood 101, 1155-1163 (2003). 
164. Gow, D.J., et al. Cloning and expression of porcine Colony Stimulating Factor-1 
(CSF-1) and Colony Stimulating Factor-1 Receptor (CSF-1R) and analysis of the species 
specificity of stimulation by CSF-1 and Interleukin 34. Cytokine 60, 793-805 (2012). 
165. Jenkins, S.J., et al. IL-4 directly signals tissue-resident macrophages to proliferate 
beyond homeostatic levels controlled by CSF-1. J Exp Med 210, 2477-2491 (2013). 
166. McGill, M.R., et al. The mechanism underlying acetaminophen-induced 
hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA 
fragmentation. J Clin Invest 122, 1574-1583 (2012). 
Manipulating macrophages to enhance liver regeneration 
225 
References 
167. Mitchell, C. & Willenbring, H. A reproducible and well-tolerated method for 2/3 
partial hepatectomy in mice. Nature protocols 3, 1167-1170 (2008). 
168. Henderson, N.C., et al. Critical role of c-jun (NH2) terminal kinase in paracetamol- 
induced acute liver failure. Gut 56, 982-990 (2007). 
169. R Development Core Team. R: A language and environment for statistical 
computing.  (R Foundation for Statistical Computing, Vienna, Austria, 2010). 
170. Starkel, P. & Leclercq, I.A. Animal models for the study of hepatic fibrosis. Best 
practice & research. Clinical gastroenterology 25, 319-333 (2011). 
171. Colakoglu, T., Keskek, M., Colakoglu, S., Can, B. & Sayek, I. Serum endostatin levels 
and regenerative capacities of normal and cirrhotic livers following partial hepatectomy 
in mice: the response to different resection sizes. J Surg Res 143, 337-343 (2007). 
172. Fujii, T., et al. Mouse model of carbon tetrachloride induced liver fibrosis: 
Histopathological changes and expression of CD133 and epidermal growth factor. BMC 
Gastroenterol 10, 79 (2010). 
173. Espanol-Suner, R., et al. Liver progenitor cells yield functional hepatocytes in 
response to chronic liver injury in mice. Gastroenterology 143, 1564-1575 e1567 (2012). 
174. Kuramitsu, K., et al. Failure of fibrotic liver regeneration in mice is linked to a 
severe fibrogenic response driven by hepatic progenitor cell activation. Am J Pathol 183, 
182-194 (2013). 
175. de Graaf, W., et al. Quantitative assessment of hepatic function during liver 
regeneration in a standardized rat model. J Nucl Med 52, 294-302 (2011). 
176. de Graaf, W., et al. Transporters involved in the hepatic uptake of (99m)Tc-
mebrofenin and indocyanine green. J Hepatol 54, 738-745 (2011). 
177. de Graaf, W., Bennink, R.J., Vetelainen, R. & van Gulik, T.M. Nuclear imaging 
techniques for the assessment of hepatic function in liver surgery and transplantation. J 
Nucl Med 51, 742-752 (2010). 
Manipulating macrophages to enhance liver regeneration 
226 
References 
178. de Graaf, W., et al. Assessment of future remnant liver function using 
hepatobiliary scintigraphy in patients undergoing major liver resection. J Gastrointest 
Surg 14, 369-378 (2010). 
179. Fan, S.T. Liver functional reserve estimation: state of the art and relevance for 
local treatments: the Eastern perspective. J Hepatobiliary Pancreat Sci 17, 380-384 
(2010). 
180. Lam, C.M., Fan, S.T., Lo, C.M. & Wong, J. Major hepatectomy for hepatocellular 
carcinoma in patients with an unsatisfactory indocyanine green clearance test. Br J Surg 
86, 1012-1017 (1999). 
181. Faybik, P., et al. Comparison of invasive and noninvasive measurement of plasma 
disappearance rate of indocyanine green in patients undergoing liver transplantation: a 
prospective investigator-blinded study. Liver Transpl 10, 1060-1064 (2004). 
182. Yuan, L., Lin, W., Zheng, K., He, L. & Huang, W. Far-red to near infrared analyte-
responsive fluorescent probes based on organic fluorophore platforms for fluorescence 
imaging. Chemical Society reviews 42, 622-661 (2013). 
183. Manizate, F., Hiotis, S.P., Labow, D., Roayaie, S. & Schwartz, M. Liver functional 
reserve estimation: state of the art and relevance to local treatments. Oncology 78 Suppl 
1, 131-134 (2010). 
184. Potteaux, S., et al. Suppressed monocyte recruitment drives macrophage removal 
from atherosclerotic plaques of Apoe-/- mice during disease regression. J Clin Invest 121, 
2025-2036 (2011). 
185. Gersuk, G.M., Razai, L.W. & Marr, K.A. Methods of in vitro macrophage maturation 
confer variable inflammatory responses in association with altered expression of cell 
surface dectin-1. J Immunol Methods 329, 157-166 (2008). 
Manipulating macrophages to enhance liver regeneration 
227 
References 
186. Bukowski, R.M., et al. Phase I trial of subcutaneous recombinant macrophage 
colony-stimulating factor: clinical and immunomodulatory effects. J Clin Oncol 12, 97-
106 (1994). 
187. Weiner, L.M., et al. Phase I trial of recombinant macrophage colony-stimulating 
factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects. 
Cancer Res 54, 4084-4090 (1994). 
188. Momin, F.A., et al. Phase II trial of recombinant human macrophage colony-
stimulating factor in metastatic soft tissue sarcoma. Journal of immunotherapy with 
emphasis on tumor immunology : official journal of the Society for Biological Therapy 16, 
224-228 (1994). 
189. Cole, D.J., et al. Phase I trial of recombinant human macrophage colony-
stimulating factor administered by continuous intravenous infusion in patients with 
metastatic cancer. Journal of the National Cancer Institute 86, 39-45 (1994). 
190. Pollard, J.W. Role of colony-stimulating factor-1 in reproduction and 
development. Molecular reproduction and development 46, 54-60; discussion 60-51 
(1997). 
191. Marshall, S.A., Lazar, G.A., Chirino, A.J. & Desjarlais, J.R. Rational design and 
engineering of therapeutic proteins. Drug discovery today 8, 212-221 (2003). 
192. Jones, E.A. & Waldmann, T.A. The mechanism of intestinal uptake and 
transcellular transport of IgG in the neonatal rat. J Clin Invest 51, 2916-2927 (1972). 
193. Goldenberg, M.M. Etanercept, a novel drug for the treatment of patients with 
severe, active rheumatoid arthritis. Clin Ther 21, 75-87; discussion 71-72 (1999). 
194. Hoffman, H.M., et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in 
patients with cryopyrin-associated periodic syndromes: results from two sequential 
placebo-controlled studies. Arthritis Rheum 58, 2443-2452 (2008). 
Manipulating macrophages to enhance liver regeneration 
228 
References 
195. Gow DJ, S.K., Hume DA. NCBI GEO database, accession: PRJNA229512 ID:229512. 
(2013). 
196. Murray, P.J. & Wynn, T.A. Protective and pathogenic functions of macrophage 
subsets. Nature reviews. Immunology 11, 723-737 (2011). 
197. Tagliani, E., et al. Coordinate regulation of tissue macrophage and dendritic cell 
population dynamics by CSF-1. J Exp Med 208, 1901-1916 (2011). 
198. Radi, Z.A., et al. Increased serum enzyme levels associated with kupffer cell 
reduction with no signs of hepatic or skeletal muscle injury. Am J Pathol 179, 240-247 
(2011). 
199. Sakaguchi, S., Wing, K., Onishi, Y., Prieto-Martin, P. & Yamaguchi, T. Regulatory T 
cells: how do they suppress immune responses? International immunology 21, 1105-
1111 (2009). 
200. Zhang, M., Xu, S., Han, Y. & Cao, X. Apoptotic cells attenuate fulminant hepatitis by 
priming Kupffer cells to produce interleukin-10 through membrane-bound TGF-beta. 
Hepatology 53, 306-316 (2011). 
201. Ogiku, M., Kono, H., Ishii, K., Hosomura, N. & Fujii, H. Role of macrophage colony-
stimulating factor in polymicrobial sepsis according to studies using osteopetrotic 
(op/op) mice. J Surg Res 169, 106-116 (2011). 
202. Feltis, B.A., Jechorek, R.P., Erlandsen, S.L. & Wells, C.L. Bacterial translocation and 
lipopolysaccharide-induced mortality in genetically macrophage-deficient op/op mice. 
Shock 2, 29-33 (1994). 
203. Leevy, C.M., Smith, F., Longueville, J., Paumgartner, G. & Howard, M.M. 
Indocyanine green clearance as a test for hepatic function. Evaluation by dichromatic ear 
densitometry. JAMA 200, 236-240 (1967). 
204. Schindl, M.J., et al. The value of residual liver volume as a predictor of hepatic 
dysfunction and infection after major liver resection. Gut 54, 289-296 (2005). 
Manipulating macrophages to enhance liver regeneration 
229 
References 
205. Jacobs, K.E., Visser, B.C. & Gayer, G. Changes in spleen volume after resection of 
hepatic colorectal metastases. Clinical radiology 67, 982-987 (2012). 
206. Nagasue, N., Yukaya, H., Ogawa, Y. & Higashi, T. Portal pressure following partial 
to extensive hepatic resection in patients with and without cirrhosis of the liver. Annales 
chirurgiae et gynaecologiae 72, 18-22 (1983). 
207. Zoli, M., Melli, A., Viti, G., Marra, A. & Marchesini, G. Sonographic evaluation of 
liver, spleen, and splanchnic vessels following partial liver resection. Journal of 
ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine 
5, 563-567 (1986). 
208. Mebius, R.E. & Kraal, G. Structure and function of the spleen. Nature reviews. 
Immunology 5, 606-616 (2005). 
209. McDevitt, D.G. & Nies, A.S. Simultaneous measurement of cardiac output and its 
distribution with microspheres in the rat. Cardiovasc Res 10, 494-498 (1976). 
210. Swirski, F.K., et al. Identification of splenic reservoir monocytes and their 
deployment to inflammatory sites. Science 325, 612-616 (2009). 
211. Furuya, S., et al. Interleukin-17A plays a pivotal role after partial hepatectomy in 
mice. J Surg Res 184, 838-846 (2013). 
212. Ueda, S., et al. Transforming growth factor-beta1 released from the spleen exerts 
a growth inhibitory effect on liver regeneration in rats. Lab Invest 83, 1595-1603 (2003). 
213. Rothstein, G., et al. Stimulation of neutrophil production in CSF-1-responsive 
clones. Blood 72, 898-902 (1988). 
214. Aharinejad, S., et al. Elevated CSF1 serum concentration predicts poor overall 
survival in women with early breast cancer. Endocrine-related cancer 20, 777-783 
(2013). 
215. Webster, J.A., et al. Variations in stromal signatures in breast and colorectal 
cancer metastases. J Pathol 222, 158-165 (2010). 
Manipulating macrophages to enhance liver regeneration 
230 
References 
216. de Jong, M.C., et al. Rates and patterns of recurrence following curative intent 
surgery for colorectal liver metastasis: an international multi-institutional analysis of 
1669 patients. Ann Surg 250, 440-448 (2009). 
217. Becker, S., Warren, M.K. & Haskill, S. Colony-stimulating factor-induced 
monocyte survival and differentiation into macrophages in serum-free cultures. J 
Immunol 139, 3703-3709 (1987). 
218. Bode, G., et al. The utility of the minipig as an animal model in regulatory 
toxicology. J Pharmacol Toxicol Methods 62, 196-220 (2010). 
219. Newsome, P.N., et al. Development of an invasively monitored porcine model of 










Appendix 1: Gene array data 
a) Array data 6 hours following CSF1-Fc administration in uninjured mice (n=4/group). 
b) Cytokine / chemokine gene data extracted from Affymetrix gene array comparing 
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CSF1-Fc treatment (n=3) or PBS control at day 4. c) Growth factor and matrix 
remodelling associated gene data extracted from Affymetrix gene array comparing CSF1-
Fc treatment (n=3) or PBS control at day 4. d) Macrophage phenotype data extracted 
from Affymetrix gene array comparing CSF1-Fc treatment (n=3) or PBS control at day 4 
(blue= M1 associated genes; red=M2 associated genes). 
 
  

























Appendix 4: Healthy control details 
  




Appendix 5: Dot plots showing acetyl-HMG1 level in entire cohort and log(acetyl-
HMGB1) in entire cohort. 
 
  













Appendix 8: Deviance residuals for logistic regression models. 
